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Synopsis
Diabetes is a leading cause of peripheral neuropathy. It is the main initiating factor for foot 
ulceration and amputation resulting in considerable morbidity and remarkable consumption 
of scarce medical resources. Relatively little is known about the pathophysiology underlying 
DPN. Research into DPN has focused mainly on the peripheral nervous system (PNS) with 
central nervous system (CNS) involvement relatively overlooked. The studies undertaken 
have been designed to investigate CNS involvement in DPN.
1. Before embarking on spinal cord studies, I reviewed and modified the techniques 
employed in the pilot study to improve the precision and accuracy of cord cross sectional 
area measurements. These modifications were patiented to quality control studies, which are 
reported in Chapter 2.
2. I performed in-vivo cross-sectional magnetic resonance imaging of the cervical spine and 
reported evidence of spinal cord shrinkage (atrophy) in Painless DPN (Chapter 3). This 
study showed spinal cord atrophy to be an early phenomenon, present even in subclinical 
DPN. As the spinal cord is the caudal portion of the CNS, its involvement made us question 
whether the brain too may be involved.
3. Using MR spectroscopy I examined thalamic involvement in Painless DPN (Chapter 4). 
This deep brain nucleus is considered the gateway to all somatosensory information entering 
the brain, and responsible for modulation of sensory information prior to presentation to the 
cerebral cortex. I demonstrated thalamic biochemical abnormalities consistent with possible 
neuronal dysfunction in patients with Painless DPN.
4. The demonstration of thalamic neuronal dysfunction in DPN suggests that CNS 
involvement is not limited to the spinal cord but other important areas, responsible for 
somatosensory perception, may also be involved. Although the pathogenesis of thalamic 
involvement is unknown, it is likely that both vascular and metabolic factors that have been 
implicated in the pathogenesis of DPN are involved. In Chapter 4, I examined the possible
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role of metabolic factors in the pathogenesis of thalamic neuronal dysfunction in DPN. Using 
MR spectroscopy, I demonstrated a significant elevation in thalamic glutamine/glutamate in 
patients with diabetes. Glutamate is the most abundant excitatory neurotransmitter and 
implicated in various models of neuronal cell death. Astrocytes, which play an important role 
in glutamate/glutamine metabolism, were impaired in the thalamus of diabetic patients in this 
study. The combination of elevated glutamate and impaired thalamic astrocytes may provide 
a pathophysiological explanation for thalamic dysfunction in DPN.
5. In Chapter 5, an alternative hypothesis for thalamic neuronal dysfunction in DPN was 
tested. Using dynamic contrast enhanced MR perfusion imaging, I demonstrated that Painful 
DPN is associated with unique thalamic perfusion abnormalities. Intriguingly, these 
abnormalities were present in patients with Painful but not Painless DPN.
6. Finally, in Chapter 6, I conducted a randomised, double blind and placebo-control trial 
(RCT) comparing the efficacy and tolerability of sativex, a cannabis based medicinal extract 
(CBME), with placebo in the symptomatic treatment of painful DPN. This is the first ever 
RCT using a CBME in painful DPN. We report no significant difference in the primary 
outcome measure due to a massive placebo effect and that depression is a potential major 
confounder in such clinical trials.
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1 INTRODUCTION
1.1 Diabetes Mellitus and Nervous System Complications
The worldwide prevalence of diabetes is Increasing at an alarming rate. The number of 
cases worldwide in 2000 among adults over 20 years of age was estimated to be about 171 
million (Wild, Roglic et al. 2004). With increasing population growth, aging, urbanisation and 
increased prevalence of obesity and physical inactivity, conservative estimates predict that 
the number of people with diabetes will more than double. The human and economic costs 
of this growing public health burden are enormous (Ward 1995). This increasing prevalence 
will inevitably result in increased mortality and morbidity from associated complications of 
diabetes. Microvascular complications of neuropathy, retinopathy and nephropathy occur in 
patients with type 1 and 2 diabetes.
1.1.1 Diabetic Neuropathy
Diabetes mellitus is one of the commonest diseases to affect the nervous system. Distal 
symmetrical diabetic sensorymotor polyneuropathy (DPN) is the main initiating factor for foot 
ulceration and is the commonest cause of non-traumatic lower limb amputation in the 
western world (Hollingshead 1991). It can severely affect an individuals social functioning 
and occupational productivity.
1.1.2 Epidemiology
Epidemiological reports on the prevalence of DPN have been confounded by the lack of a 
consensus over diagnostic criteria, the wide variety of measurement techniques used and 
the patient selection for study (Shaw and Zimmet 2000). As a result the prevalence of DPN 
has been shown in clinical and population based studies to vary from 8% to 63% depending 
on the criteria used to diagnose neuropathy (Shaw, Hodge et al. 1998) (Dyck, Kratz et al. 
1993). The EURODIAB complications study showed the prevalence in 16 European 
countries to be 28% (Tesfaye, Stevens et al. 1996). In this study, DPN was diagnosed if
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there were more than two abnormalities amongst symptoms, signs, vibration perception 
threshold and autonomic function tests. This prevalence was related to age, duration of 
diabetes and the quality of metabolic control. The presence of severe neuropathy is often 
accompanied by the other microvascular diabetic complications of retinopathy and 
nephropathy (Pirart, Lauvaux et al. 1978). It has also been shown more recently that 
traditional cardiovascular risk factors of smoking, hyperlipidaemia and hypertension are also 
independent risk factors for the development of DPN (Tesfaye, Chaturvedi et al. 2005). 
Patients with type 1 and 2 diabetes of similar disease duration have equal prevalence of 
DPN (Shaw, Hodge et al. 1998).
As mentioned above DPN plays a central role in the pathophysiological pathway 
leading to foot ulceration and amputation. In fact the presence of DPN increases the risk of 
amputation 1.7 fold, 12 fold if there is deformity and 36 fold if there is a history of previous 
foot ulceration (Armstrong, Lavery et al. 1998).
1.1.3 Pathogenesis of DPN
As early as 1890, Charcot opined that vascular factors could be of significance in the 
development of neurological complications in diabetes. Woltman and Wilder in 1929 were 
the first to describe marked thickening of the intraneural blood vessels in three autopsy 
cases and seven amputated lower limbs from patients with diabetes (Woltman H.W 1929). 
But it was not until 1959 when Fagerberg first observed the microvascular changes in an 
autopsy study of cases exhibiting clinical signs of neuropathy (Fagerberg 1959). He 
demonstrated thickening and occlusion of intraneural vessel walls by materials staining 
positive with Periodic Acid Schiff. Other morphological changes such as closed capillaries, 
microvascular thrombosis, basement membrane thickening, endothelial cell reduplication 
and multifocal loss of myelinated fibres have also been described in DPN (Malik, Tesfaye et 
al. 1994; Theriault, Dort et al. 1997). Tesfaye et al. demonstrated impairment of blood flow 
and the presence of epineural arterio-venous shunts in human DPN using sural nerve
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photography and fluorescein angiography (Tesfaye, Harris et al. 1993). Newrick et al have 
shown that sural nerve oxygen tension measured by microelectrode polarography, is 
reduced in diabetic patients with neuropathy (Newrick, Wilson et al. 1986). Similarly reduced 
microvascular oxygen saturation and raised fluorescein rise time, which are suggestive of 
ischaemia, have been shown in the sural nerve by Ibrahim et al, in patients with DPN 
(Ibrahim, Harris et al. 1999). Morphometric studies on human sural nerve have 
demonstrated increased perineurial capillary endothelial cell hyperplasia and reduced 
luminal area. A significant relationship was observed between endothelial cell hyperplasia 
and measures of neuropathic severity, providing further insight into the pathogenesis of DPN 
(Malik, Tesfaye et al. 1994).
The Diabetes Control and Complications Trial (DCCT), a large scale prospective 
study, showed a causal relationship between hyperglycaemia and the microvascular 
complications of diabetes mellitus (DCCT research group 1993). However, other factors are 
likely to contribute to an individual’s susceptibility to hyperglycaemia and these may be 
governed by genetic factors such as gene polymorphisms.
It is clear that a complex cascade of vascular and metabolic factors are involved 
eventually resulting in end-organ damage. The ultimate challenge is to identify the crucial 
initiating or perpetuating factors; particularly those that may have the potential for 
manipulation and therapeutic gain.
1.1.4 Classification
Peripheral nerve damage in diabetes mellitus can be broadly separated into its effects on the 
somatic and autonomic nervous systems, although the two frequently co-exist. Clinical 
classification of the various syndromes of diabetic somatic neuropathy has proved very 
difficult. The variation and overlap in aetiology, clinical features, natural history and 
prognosis have meant that most classifications are necessarily oversimplified and none has 
proved capable of accounting for all of these factors. In 1998, during the American Diabetes
24
Association (ADA) Scientific Congress in San Antonio (Texas, USA), a working group 
consisting of representatives from both the ADA and the American Academy of Neurology 
was convened to classify DPN. Based on this consensus, there are four main groups of 
neurological disturbance in diabetes (ADA 1988).
These were:
1. Subclinical neuropathy
This group consists of asymptomatic individuals with abnormalities on formal testing of their 
nervous system with quantitative sensory testing and nerve conduction studies.
2. Distal symmetrical sensorymotor polyneuropathy (DPN)
This is the most common form of diabetic somatic neuropathy. It is characterised by a length 
dependent, distal distribution involvement of sensory and motor nerves (otherwise known as 
distal symmetrical polyneuropathy) and autonomic involvement, which together form part of 
this clinical complex.
3. Focal and multifocal neuropathies
This sub-group of neuropathies often occur in the context of DPN. Both vascular and 
compressive aetiologies can be involved. They can present either with a rapid, self-limiting 
onset or a slowly progressive persistent (without intervention) nature
4. Hyperglycaemic neuropathy
Pain, paraesthesia and hyperalgesia predominantly in the feet associated with poor 
glycaemic control occur in this subset of diabetic somatic neuropathy. Symptoms and signs 
are rapidly reversed with improvement of glycaemic control.
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1.1.5 Sub-clinical neuropathy
As mentioned above, patients in this category are frequently asymptomatic with the 
presence of neuropathy diagnosed based on quantitative sensory testing and nerve 
conduction studies. Nerve conduction velocities of the most distal sensory nerves (plantar 
and sural), typically provide the first evidence of neuropathy. As the disease progresses, 
nerve conduction studies show loss of distal nerve sensory and motor amplitudes. This is a 
reflection of axonal loss, which is the hallmark of this form of DPN.
Abnormal quantitative sensory testing for vibration, cooling and thermal perception 
thresholds assessed using specialised equipment (CASE IV, Minnesota, USA) is also seen. 
Quantitative autonomic function tests also show abnormalities with heart rate variation with 
deep breathing, valsalva manoeuvre and postural testing. The early identification of the 
neuropathic process offers the patient an opportunity to alter its course by correcting or at 
least improving the risk factors ultimately reducing the morbidity associated with neuropathy 
(Boulton 1998).
1.1.6 Distal symmetrical sensorimotor polyneuropathy (DPN)
This is the most common and widely recognised form of diabetic somatic neuropathy. There 
is often long duration of diabetes, which precedes its diagnosis. If present at the diagnosis of 
type 2 diabetes, it suggests a long period of pre-existing abnormal glucose metabolism, 
usually of many years duration. Often the onset is insidious and it is not uncommon for DPN 
or even diabetes mellitus itself, to present initially as foot ulceration (Ward 1982). As foot 
ulcerations are wholly preventable this represents a failure somewhere along the pathway of 
care. This length-dependent, “glove and stocking," neurological deficit affects both sensory 
and motor nerves. Sensory loss predominate the early stages, starting at the toes and 
gradually progressing into the feet and legs. The fingers and hands become involved when 
the neuropathy has extended above the mid calf. In the worst cases the deficit may extend 
into the buttocks and trunk, although spreading beyond this is exceptionally rare. Some
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patients, however, have “positive neuropathic symptoms” which can range from mild 
paraesthesia and numbness to more severe burning, allodynia and lancinating pains. These 
symptoms are often but not always symmetrical in distribution and nocturnal exacerbation is 
a common feature.
Motor nerve involvement is usually sub-clinical although it Is easily detectable on 
neurophysiological testing (Andersen 1999). Non-invasive Imaging techniques have revealed 
atrophy of the musculature of the foot and this may be visible clinically in severe cases 
(Andreassen, Jakobsen et al. 2009). However, early and predominantly motor involvement 
should raise the possibility of alternative diagnoses.
1.1.6.1 Clinical signs
On inspection of the feet, deformities or calluses should be noted. The presence of any one 
of these in the context of DPN highlights regions in the feet that are patient to abnormal 
pressure loading and prone to developing foot ulceration. One should inspect for fissures 
and ulcers in obvious pressure bearing regions (e.g. heels and toes). Frequently there is 
wasting of the small muscles of the feet resulting in clawing of the toes. A shiny, dry 
appearance of the foot (decreased sweating) with prominent veins (arterio-venous shunting) 
suggests accompanying autonomic neuropathy. While a dusky appearance with venous 
guttering and atrophic skin and nails Is the result of peripheral vascular disease.
The methods available for the detection and quantification of DPN are numerous and 
varied. The clinical setting usually governs the technique used to assess DPN (Eaton and 
Tesfaye 2000). In a busy annual review diabetic clinic, where the main concern is identifying 
individuals at risk for foot ulceration, a careful clinical examination, inspection of footwear 
and simple clinical instruments such as the 10g monofilament and a pinprick will suffice 
(Boulton 1998). For epidemiological studies, techniques such as vibration perception 
threshold (VPT) are usually a minimum requirement. On the other hand, when greater 
diagnostic accuracy is required (e.g. randomised control trials) expensive, computer-assisted
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quantitative sensory testing and laboratory based techniques (e.g. nerve conduction studies) 
are employed.
Testing of all sensory modalities will reveal abnormalities in a “glove and stocking” 
distribution. Individual modalities tested will provide clues to the type of nerve fibres affected. 
For example impairment of vibration perception (128Hz tuning fork) and joint position sense 
reflect large fibre neuropathy. Whereas, defective warm and cold thermal discrimination is in 
keeping with small nerve fibre involvement. The use of ankle reflexes and vibration testing 
has been advocated in guidelines for screening for DPN (ADA 2001). There is, however, 
greater evidence in the literature for the use of the Semmes-Weinstein 5.07 (10g) 
monofilament (Perkins, Olaleye et al. 2001). It is a cheap, simple, rapid, reproducible 
screening tool for DPN, which can be used in a busy diabetic clinic (Perkins, Olaleye et al. 
2001). An abnormal monofilament test is associated with a three year relative risk as high as 
15 for the development of ulceration or amputation. The 10g monofilament is applied to a 
non-callused site on the dorsum of the first toe just proximal to the nail bed. This is repeated 
four times on both feet in an arrhythmic manner. Five or greater insensate stimuli is 
associated with a very high probability of DPN (Perkins, Ngo et al. 2002).
If there is upper limb sensory loss in a glove distribution then the level of impairment 
in the legs has to have reached mid thigh. If not, look for another explanation for the upper 
limb sensory loss. Motor weakness is usually mild and confined to the feet. As the disease 
progresses severe distal weakness limits a patient’s ability to stand/walk on the heels or 
toes.
1.1.6.2 Complications and Sequelae
• Foot ulceration
The most important consequence of DPN is the development of foot ulceration which affects 
15% of diabetic patients in their lifetime (Mayfield, Reiber et al. 1998). Foot ulcers are the
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commonest reason for admission to hospital in the diabetic patient and precede 80% of non- 
traumatic lower limb amputations, exerting a massive economic burden on health services 
(Ramsey, Newton et al. 1999). In addition and perhaps more importantly, this condition has 
devastating consequence on a social and personal level to the patient (Gries 2003). High 
levels of depression and social isolation are associated with chronic foot ulceration and 
lower limb amputation (Carrington, Mawdsley et al. 1996), (Price and Harding 2000). 
Furthermore the economic consequences of time off work or early retirement are significant,
particularly in younger patients.
Even in the presence of DPN, foot ulceration is wholly preventable. Simple, but 
effective interventions, such as education, podiatry, footwear and orthoses are capable of 
reducing ulceration rates by up to 80% (Boulton 1995).
• Charcot Neuroarthropathy
Charcot neuroarthropathy (CN) is a chronic and progressive disease of the bone and joints, 
characterised by painful bone and joint destruction in limbs that have lost sensory 
innervation (Edmonds 1999). Affected joints exhibit synovitis, instability, subluxation and 
destruction. Trauma is thought to be an important initiating factor which is often not recalled. 
(Rajbhandari, Jenkins et al. 2002). The typical acute presentation is often undiagnosed due 
to a lack of recognition and the often asymptomatic nature of the condition. As a result the 
true prevalence of CN in patients with diabetes mellitus is not known. The main cause of CN 
in the developed world is now DPN with the joints of the foot being most commonly affected 
(Frykberg and Kozak 1978).
A complete understanding of the pathogenesis of CN remains elusive although a 
variety of simultaneous occurring factors are likely to be involved (Rajbhandari, Jenkins et al. 
2002). Diabetic peripheral neuropathy is present in all cases and may contribute by 
permitting minor repetitive traumatic events, which trigger a reparative response within the 
bone. In the presence of autonomic neuropathy, blood flow increases dramatically and
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causes over compensated osteoclastic activity and bone resorption. This in turn may 
exacerbate the trauma site, cause fracture and subluxation, and ultimately leads to the gross 
deformity characteristically seen. The presence of foot deformity leads to an increase in the 
risk of foot ulceration, which can be very difficult to prevent and treat. Hence, the main aim of 
treatment should be the early identification and treatment in the acute phase. With the 
advent of non-invasive techniques, such as isotope bone scans and magnetic resonance 
(MR) imaging, and the use of non-weight bearing treatments, and bisphosphonates, this may 
become a more realistic aim (Rajbhandari, Jenkins et al. 2002).
• Mortality and premature death
There is an increase in mortality associated with DPN, mainly from cardiovascular causes, 
especially in the presence of cardiac autonomic neuropathy (Boyko, Ahroni et al. 1996, 
Forsblom, Sane et al. 1998; Faglia, Favales et al. 2001). As mentioned previously, traditional 
artherosclerotic risk factors play an important role in the pathogenesis of DPN. Hence, it is 
likely that a combination of the nerve damage itself and associated artherosclerotic co­
morbidities explain this increase in mortality and premature death. Thus, the management of 
DPN should not only focus on cardiovascular risk factors but also strategies for its 
prevention.
1.1.6.3 Management of DPN
The mainstay of treatment for neuropathy currently is prevention, mainly by delaying its 
onset. Once DPN is established, it is usually irreversible and slowly progressive. Aims of 
treatment should then be directed at reducing symptoms and slowing the progression of 
neuropathy.
• Correction of the risk factors for neuropathy
There is now overwhelming evidence that strict glycaemic control from the time of 
diagnosis of diabetes reduces the prevalence rates of DPN. In type 1 diabetes, the DCCT
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showed that intensive insulin treatment reduced the prevalence rates for DPN by as much as 
50% in both the primary and secondary prevention cohorts (DCCT research group 1995). in 
type 2 diabetes, strict control of blood glucose was associated with an improvement in 
vibration perception threshold (UK Prospective Diabetes Study group 1998; 2002). This 
benefit was however, far less than that observed in the DCCT (DCCT research group 2002).
A possible explanation for this is proposed by the outcome of the STENO 2 study. In this 
study, patients with type 2 diabetes were divided into two treatment cohorts (Gaede, Lund- 
Andersen et al. 2008). One cohort received conventional treatment and the other intensive 
treatment to tackle multiple other risk factors for DPN. This included antihypertensive drugs 
e.g. angiotensin converting enzyme inhibitors and calcium channel antagonist, 
hypoglycaemic agents, aspirin, lipid lowering agents and anti-oxidants. There was a 0.32 
reduction in the odds ratio for developing autonomic neuropathy as a result. Notably, this 
study did not show a reduction in the risk of developing DPN.
• Treatments aimed at pathogenetic mechanisms of DPN
Numerous treatments directed at the pathogenetic mechanisms of DPN have been 
though rigours clinical trials. Despite early promising results many of these compounds have 
failed to make sufficient impact and hence are not widely prescribed. There are however, a 
few treatments that have been granted licenses for use in certain countries (e.g. a-lipoic acid 
in Germany and the aldose reductase inhibitor (epalerestat in Japan) and this provides us 
with more experience of their use. A summary of these compounds can be found in the 
Table 1.1 below.
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Table 1.1 : Treatments aimed at pathogenetic mechanisms of distal symmetrical neuropathy. 
Aldose reductase inhibitors
Method o f action
Reduces glucose flux through the polyol pathway, Lowers accumulation of toxic sorbitol, Prevents reduction of redox potentials 
C linical Trials
19 trials, testing four different aldose reductase inhibitors between 4 -  208 weeks duration (median 24 weeks) were patiented to a meta­
analysis (Airey, Bennett et al. 2000). The reviewers concluded that although aldose reductase inhibitors treatment diminished the reduction 
in motor nerve conduction velocity, the clinical relevance of such a change in this outcome measure is uncertain. There was no effect in 
terms of this outcome measure in small sensory nerve fibres, degeneration of which is primarily responsible for DPN.
Aminoguanidine
Method of action
Inhibitor of the formation of advanced glycation end products 
Clinical Trials
Administration in diabetic animals prevents the development of microvascular complications (Miyauchi, Shikama et al. 1996). 
Human trials discontinued because of toxicity.
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a -lip o ic  acid
Method o f action
Alpha-lipoic acid is an endogenous, sulphur-containing, free radical scavenger found in mitochondria. Free radicals can reduce nitric-oxide- 
mediated vasodilation and damage to the vascular endothelium (Cameron and Cotter 1997). Alpha-lipoic acid also recycles other 
antioxidants, such as vitamins E and C.
Clinical Trials
Treatment with a-lipoic acid improves nerve blood flow and distal nerve conduction and increases endoneurial glucose uptake and energy 
metabolism in animals.
A systemic review of 15 randomised clinical trials concluded that a-lipoic should be considered as a treatment option for diabetic patients 
with mild to moderate neuropathy. It has a limited side effect profile and patients should be warned of possible side effects which include 
headache, skin rash, stomach upset at high doses (>600 mg/d) and possible hypoglycaemia (Halat and Dennehy 2003).
Nerve Growth Factor
Method o f action
Have trophic effects on sensory neurons in the dorsal root ganglion and sympathetic postganglionic neurons. Nerve injury impairs release. 
C linical Trials
Two large worldwide multicentre studies showed that recombinant human nerve growth factor had no beneficial effects over placebo 
(Pittenger and Vinik 2003).
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1.1.7 Diabetic Autonomic Neuropathy
Although clinically significant autonomic neuropathy is uncommon, formal autonomic 
function testing will be abnormal in 90% of patients with DPN (Vinik 1999). When present 
the variety of symptoms reflects the diversity of organ systems involved. Morta ty 
associated with autonomic neuropathy is placed at between 20-50 /o within five to ten years 
(Rathmann, Ziegler et al. 1993). The major manifestations are cardiovascular, 
gastrointestinal and genitourinary dysfunction. Frequent complaints include symptomatic 
postural hypotension, gustatory sweating, nocturnal diarrhoea, incontinence, heat 
intolerance, erectile dysfunction and poor hypoglycaemic awareness. Methods of testing the 
autonomic nervous system range from simple blood pressure estimation with postural 
change to monitoring R-R variation (using ECG monitoring software) with deep breathing, 
valsalva manoeuvre and postural changes. There is however a wide variability with repeat 
testing, which can be minimised by standardizing the methodology and using a central 
testing facility (Low 1993). In addition it is not clear whether these are useful indicators of 
autonomic problems elsewhere.
1.1.8 Painful Diabetic Neuropathies
In some patients pain is an unwanted component of diabetic neuropathy. It can accompany 
DPN or other comparatively less common varieties of acute or chronic diabetic neurologic 
syndromes. Pain is also a feature of certain focal and multifocal neuropathies, which will be 
discussed later in this chapter. The underlying pathogenesis of painful neuropathy remains 
poorly understood and as a result there are currently not effective, rational treatments
(Thomas 1999).
1.1.8.1 Chronic Painful Diabetic Neuropathy
The prevalence of chronic painful DPN is not clear. In one study 11/o of insulin treated 
patients under 60 years of age had painful symptoms (Boulton, Knight et al. 1985). Another
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study based in a hospital diabetic clinic population put the prevalence at 25% compared with 
15% in a control population (Chan, Mac Farlane et al. 1990). Painful symptoms can be 
variable but are typical of neuropathic pain. There is a slow but progressive build up of 
neuropathic symptoms starting in the feet marching up the leg to involve the thighs in severe 
cases. Progress occurs over many years and eventually in some cases the upper limbs are 
involved. Typical features of neuropathic pain are paraesthesia (tingling, pins and needles), 
burning, lancinating (shooting), deep aching, allodynia (pain sensation when affected limbs 
are touched by normally non painful stimuli e.g. bed sheets or clothes) and hyperaesthesia. 
Often patients describe a continuous background dull aching or cramping sensation affecting 
the legs and feet with periodic sharp shooting exacerbations, which are superficial. Pain 
accompanies walking which is likened to walking on stones or hot coals. Nocturnal 
exacerbations are commonly experienced but are not unique to DPN. Sleep quality and 
pattern are also frequently affected. Not surprisingly quality of life and social functioning is 
impaired, often leading to depression and unfortunately suicide. Requests for amputations 
of the affect limbs are not uncommon from sufferers. Paradoxically, sensory loss can be 
complete, such that the individual is unable to feel pain of pressure, trauma or temperature, 
whilst continuing to experience constant neuropathic pain.
Chronic painful symptoms may last for many years. Eventually a large proportion of 
patients experience a reduction in symptoms, which in one study occurred after a mean 
follow up of 3.6 years (Mayne 1968; Bischoff 1980; Boulton, Armstrong et al. 1983; Benbow, 
Chan et al. 1994). This was associated with deterioration in peripheral nerve function 
(Benbow, Chan et al. 1994). The reason why some get it and others do not is still unclear 
(Benbow, Cossins et al. 1999).
The aetiology of painful neuropathy is likely multifactorial with vascular, autoimmune 
and biochemical meachanisms playing important roles (Thomas 2003). Limited work has 
explored metabolic or molecular mechanisms of painful diabetic neuropathy. However, 
Llewellyn et al (Llewelyn, Gilbey et al. 1991) and Britland et al (Britland, Young et al. 1992)
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were unable to detect any correlation between painful neuropathy and morphologic 
Indicators of regeneration in sural nerve biopsies.
• Management
The treatment options we have available for this condition are often unsatisfactory, as they 
are poorly tolerated and frequently ineffective (Tesfaye 1997, Benbow, Cossins et al. 1999, 
Thomas 1999). The first step in managing painful DPN should be optimising glycaemic 
control, with insulin in type 2 diabetes if necessary (Boulton, Drury et al. 1982).
Tricyclic antidepressants
These compounds are the first line treatment option for neuropathic pain. Numerous 
crossover and parallel placebo control trials have shown the effectiveness of these 
compounds in reducing both background pain (dull ache) and shooting pains (Davis, Lewis 
et al. 1977; Kvinesdal, Molin et al. 1984; Gomez-Perez, Rull et al. 1985; Mendel, Klein et al. 
1986; Sindrup, Ejlertsen et al. 1989; Max, Lynch et al. 1992). Amitriptyline and imipramine 
are the common drugs of choice from this class. They are usually prescribed at low doses 
taken at bedtime, which is the gradually titrated if necessary to overcome painful symptoms 
at the same time keeping a watchful eye out for their side effects. In fact optimum use of 
these drugs are limited by their troublesome side effects. These include drowsiness, 
dizziness, dry mouth and urinary retention. Particular caution is advised when prescribing 
these drugs to elderly patients. If the side effects limits the use of amitriptyline, imipramine 
could be tried and vice versa.
Anticonvulsants
These compounds have a role as second line agents in treating painful DPN. The 
anticonvulsants carbamazepine (Rull, Quibrera et al. 1969; Wilton 1974, Badran, Aly et al. 
1975), phenytoin (Ellenberg 1968; Saudek, Werns et al. 1977), clonazepam, gabapentin 
(Backonja, Beydoun et al. 1998; Gorson, Schott et al. 1999; Hemstreet and Lapointe 2001)
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and more recently pregabalin (Rosenstock, Tuchman et al. 2004) have been evaluated in 
various diabetic painful neuropathy trials. Uses of these compounds are also limited by their 
side effect profiles which include drowsiness, ataxia and dizziness. Treatment should be 
started at a low dose and gradually increases to an appropriate maintenance dose for these 
drugs.
Capsaicin
Derived from capsicum peppers, this topically applied compound works by depleting 
substance P from nociceptors at the end of unmyelinated C fibres (Buck and Burks 1986). 
Nociceptive nerve transmissions is blocked as a result. It is applied sparingly 3-4 times a 
day to affected areas with a warning that neuropathic symptoms could worsen in the first 2-4 
weeks before relief occurs (Halat and Dennehy 2003).
Local anaesthetic agents
Both intravenous lignocaine (Boas, Covino et al. 1982; Kastrup, Petersen et al. 1987) and 
oral mexiletine (Dejgard, Petersen et al. 1988; Oskarsson, Ljunggren et al. 1997) (a 
lignocaine analogue) are used to treat patients with severe pain not responding to the 
agents above. Intravenous lignocaine has to be administered slowly over 30 minutes with 
continuous cardiac monitoring. If successful, treatment can be continued with oral 
mexiletine. A review of clinical trials evaluating these agents is beyond the scope of this 
chapter and can be found in the following reference (Ziegler 2008).
Pain clinics
The management of chronic pain is full of challenges which specialised pain clinics are well 
adapted to address. The availability of different therapeutic options and accompanying 
expertise available in these clinics, help patients cope better with their pain through their 
holistic approach. Among the therapeutic options available include psychological 
counselling, alternative therapies (e.g. acupuncture), spinal blocks or even spinal cord
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stimulation. In a limited number of patients with severe painful neuropathy, unresponsive to 
other treatments, electrical spinal cord stimulation has been used with some benefit
(Tesfaye, W attetal. 1996).
1.1.8.2 Acute painful neuropathy
Acute painful neuropathy is an uncommon painful syndrome associated with diabetes that 
should be distinguished from chronic painful neuropathy described above. It is characterised 
by a rapid onset of severe pain in a glove and stoking distribution similar to that of chronic 
painful neuropathy. Despite the intensity of accompanying symptoms, there is often little 
objective abnormality found on neurophysiological assessments. Clinical tests of sensory 
function are often normal and nerve conduction velocities are usually only mildly reduced. 
The most consistent abnormality is loss of small fibre function with reduced temperature 
discrimination on quantitative sensory testing. Fortunately patients can be reassured that 
their symptoms will resolve within ten months. However this can still be an utterly disabling 
condition for some patients. This form of neuropathy can be categorised into two different 
clinical syndromes, differentiated on whether they present in the context of poor glycaemic 
control or periods of rapid improvement of glycaemic control. In the former scenario, there is 
accompanying precipitous weight loss and was initially described by Ellenberg as 
“neuropathic cachexia" (Ellenberg 1974). A further description of the natural history of this 
syndrome illustrated that pain improved as tight gylcaemic control was initiated and weight 
started to increase (Archer, Watkins et al. 1983). Paradoxically, acute painful neuropathy 
has also been described following rapid improvements in glycaemic control. This was often 
in the context of insulin use and was originally called “insulin neuritis”. This term is 
misleading, however, as acute painful neuropathy has also been reported after 
improvements in control associated with oral hypoglycaemic agents (Ellenberg 1958).
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1.1.8.3 Proximal Motor Neuropathy
Initially described by Bruns (Bruns 1890) and then by Garland (Garland 1955), this 
syndrome has been reported under many names including diabetic amyotrophy, femoral 
neuropathy and proximal diabetic neuropathy. This entity of diabetic neuropathy tends to 
affect type 2 diabetic patients more frequently that type 1 diabetes (Sander and Chokroverty 
1996). Males are also more frequently affected compared to females. Pain, typically 
burning and aching in nature, affects anterior thighs, lower back and buttocks with nocturnal 
exacerbations. Symptoms usually begin unilaterally and then progresses to become 
bilateral. After a period of a few days weakness of the affected muscle groups develops and 
progresses slowly over several weeks. This weakness manifests as difficulty climbing stairs 
or rising from a low chair and examination reveals wasting of the quadriceps muscle. 
Occasionally other muscle groups may be involved, including some not supplied by the 
femoral nerve. There may be associated weight loss of between 10-20 kg over the course of 
this disease. Prognosis is reasonable, with recovery commences with stabilisation of body 
weight and optimising glycaemic control. Muscle strength improves slowly over many 
months, but a number of patients never regain normal lower limb strength (Sander and 
Chokroverty 1996). Agents used to treat painful DPN can be used for symptom control in 
diabetic amyotrophy.
The cause of proximal motor neuropathy is unknown although clinical and 
neurophysiological evidence would suggest femoral nerve dysfunction (Chopra and Hurwitz 
1968; Lamontagne and Buchthal 1970; Subramony and Wilbourn 1982). Histological 
assessment of a cutaneous branch of the femoral nerve has revealed changes of 
microvasculitis (Said, Goulon-Goeau etal. 1994).
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1.1.8.4 Thoracolumbar Radiculopathy
This is another rare manifestation of an acute, painful neuropathic syndrome. A dermatomal 
pattern of pain and sensory loss is experienced, often with muscle weakness causing 
bulging of the abdominal wall (Ellenberg 1978; Boulton, Angus et al. 1984; Chaudhuri, Wren 
et al. 1997). It may again be associated with weight loss and recovery is usually complete 
within 3 -  12 months.
1.1.8.5 Focal and Multifocal Neuropathies
Focal and multifocal neuropathies are part of the clinical spectrum of diabetic neuropathy 
(Malik 2002). These tend to occur among older individuals and DPN is invariably present. A 
list of this subset of neuropathy can be found in Table 1.2.
1.1.8.6 Cranial Nerve Palsies
With an underlying vascular aetiology, cranial nerve palsies often have a rapid onset and a 
good prognosis for recovery. Sixth nerve palsy is the most common variety. Full recovery 
occurs in the vast majority over 3-5 months. Third nerve palsy not as common, are 
occasionally associated with retro orbital pain. Traditionally the pupil is spared as the 
parasympathetic fibres supplying the pupil run on the outer layers of the fasicle and 
ischaemia tends to affect its centre. Nonetheless, a magnetic resonance scan is indicated to 
exclude compression from a posterior communicating artery aneurysm Is recommended. 
While waiting for resolution, troublesome diplopia can be corrected with prisms. Resolution 
is expected to take 3-6 months.
1.1.8.1 Compression Neuropathies
Diabetic nerves are more susceptible to damage from compression. The treatment of 
entrapment neuropathies should follow the same management guidelines as in a non­
diabetic individual. Surgical decompression is indicated when pain is intractable and
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especially when there is associated muscle weakness. Diagnosis can be made using nerve 
conduction studies, where characteristically there is delay in conduction velocities over the 
region of compressed nerve. The results of decompressive surgery are not as good as in 
non-diabetic patients (Dawson 1993). Non-surgical treatments include symptomatic relief 
with non-steroidal anti-inflammatory agents and immobilisation using splints.
Table 1.2: Varieties o f focal and m ultifoca l neuropathies.
Cranial nerve palsies
III nerve palsy 
VI nerve palsy
Compression neuropathies
Median nerve
Ulnar nerve 
Peroneal nerve
Lateral cutaneous nerves of the thigh
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1.2 Central Nervous System Involvement in Diabetes Mellitus
Most research on diabetic complications has focused on the kidney, retina, PNS, small and 
larger blood vessels. The CNS, which is connected structurally and functionally to the PNS, 
has been largely ignored. In recent years, with significant improvements in neuroimaging 
methods, it has become evident that diabetes causes significant CNS complications. These 
result in important cerebrovascular and functional impairments (Mijnhout, Scheltens et al. 
2006). The CNS is affected by both the metabolic and vascular consequences of diabetes.
1.2.1 Central Nervous System Involvement in Diabetic Neuropathy
1.2.1.1 Spinal Cord
Largely considered a disease of the PNS, there is increasing evidence to support 
concomitant involvement of the CNS in DPN. In fact, patho-anatomical studies dating back 
to the 1900’s were the first to report the distribution and character of lesions in the CNS in 
diabetes. Involvement of the spinal cord reported in these postmortem studies, 
demonstrated axonal loss, gliosis, and demyelination within the spinal cord (Leichtentritt 
1893; Pryce 1893; Williamson 1904; Reske-Nielsen and Lundbaek 1968; Reske-Nielsen, 
Lundbaek et al. 1970). Olsson et al. demonstrated in an autopsy study of nine patients with 
diabetes that the predominant spinal cord lesion was degeneration of long tracts (Olsson, 
Save-Soderbergh et al. 1968). When compared with age matched non-diabetic patients, 
there was significant demyelination of the dorsal, ventral and spinocerebellar long tracts in 
diabetic patients. In contrast, there were only slight changes in cord grey matter and minimal 
degeneration of the ventral motor neurons. Degeneration of the dorsal columns was also 
frequently reported in autopsy studies from this era (Woltman H.W 1929). Dolman et al 
demonstrated that the maximum brunt is borne by the lower segments of the cord, where the 
entire posterior column showed significant degeneration, in the upper segments, the lesions 
involved only the medial portions, indicating an ascending degeneration from the lower 
regions (Dolman 1963). Within degenerated areas myelin sheaths were few in number and
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many of the remaining ones were thin. The posterior roots of cords from diabetic patients 
were atrophic, corresponding with that in the posterior columns. The dorsal root ganglia and 
anterior roots were, by contrast, well preserved. Another consistent finding from these early 
autopsy studies was changes to the blood vessels within the CNS. Sclerotic changes in the 
arteries and intraneural arterioles of the brain and spinal cord were frequently reported 
(Fagerberg 1959; Dolman 1963).
The early spinal cord autopsy data, originating mainly from the 1920-30’s (Woltman 
H.W 1929)(ref) are difficult to interpret for a number of reasons: Firstly, the knowledge of 
neuroanatomy and in particular, functional neuroanatomy was limited. Secondly, most 
patients in the pre-insulin or early insulin use era suffered catastrophic systemic disease 
which relates poorly with the vast majority of patients we see now, furthermore, the 
diagnostic aids, and thus the ability to exclude other disease processes such as 
neurosyphillis, were poor. Thirdly, subsequent modern advances in the management of 
diabetes which have resulted in better glycaemic, blood pressure and lipid control have 
resulted in alterations in the current clinicopathological presentation of DPN, and, finally, the 
classifications and syndromes described bear little relation to those we presently use. 
Indeed, they predate Joslin and Root's original characterisation of DPN (Joslin E.P 1939 ). 
Despite these limitations, variable pathological changes were observed within the spinal 
cord. What is fascinating, certainly in the context of this thesis, is that the changes within the 
peripheral nerve were always much more consistent, which in 1929 prompted Woltman and 
Wilder to state that ‘the degenerations noted in the spinal cord are unimportant (Woltman 
H.W 1929).
The 1980’s saw a proliferation of studies conducted to evaluate CNS function in 
diabetes using somatosensory evoked potentials (SEP). SEP provides an indirect measure 
of spinal cord as well as supraspinal (central) conduction velocity. A peripheral nerve is 
stimulated, usually with an electrical current, and the latency measured at various levels 
including the spinal cord, brainstem and cortex. Studies using SEP have had variable
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results, especially in the presence of peripheral nerve dysfunction (Gupta and Dorfman 
1981), although most do suggest some element of central conduction delay in diabetes 
(Collier, Reid et al. 1988; Pozzessere, Rizzo et al. 1988; Pozzessere, Rizzo et al. 1989; 
Nakamura, Noritake et al. 1992). Ziegler et al. conducted the most significant SEP study in 
DPN (Ziegler, Muhien et al. 1993). This study determined proximal, spinal and central nerve 
conduction in different stages of DPN using somatosensory potentials evoked by tibial nerve 
stimulation. One hundred patients with type 1 diabetes (37 No DPN, 37 subclinical DPN and 
36 symptomatic DPN) and 51 healthy volunteers were recruited. Patients with symptomatic 
neuropathy demonstrated the greatest degree of cortical and peripheral sensory conduction 
deficit compared to other study groups. There were also significant correlations between 
SEP components with indices of peripheral and autonomic function tests. Hence, 
dysfunction along the somatosensory afferent pathways in type 1 diabetes is characterized 
by peripheral conduction deficits, absent spinal components and reduced or absent 
amplitudes of the cortical complex. These results indicate a degree of dysfunction within 
both central and peripheral nerves in DPN.
Further evidence for CNS involvement in DPN arose from observations by Tesfaye et al 
in a study assessing electrical spinal cord stimulation in painful DPN. This invasive technique 
is used, albeit infrequently, to alleviate neuropathic pain that is unresponsive to conventional 
drug treatment. However, this technique was ineffective in patients with severe loss of 
vibration and joint position sense. This is possibly due to the inability of electrical stimulation 
of the dorsal columns because of degeneration/atrophy that accompanies DPN. This 
observation led to further studies looking at the extent of involvement of the spinal cord in 
DPN.
In a pilot study, using non-invasive in-vivo MR imaging, Eaton et al measured the 
cord cross-sectional area of 19 patients with DPN, ten diabetic patients with No DPN and ten 
Healthy Volunteers. All patients underwent MR imaging of the spinal cord with 
measurements of cord cross sectional area at three anatomical levels (lower cervical [C4/5],
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upper [T3/4] and lower [T8/9] thoracic regions). They demonstrated a significantly lower cord 
area in the cervical and upper thoracic regions in patients with DPN compared to Healthy 
Volunteers, indicating extensive disease in these areas (Eaton, Harris et al. 2001). Subgroup 
analysis of DPN patients showed no significant difference in cord area to explain the 
presence or absence of painful symptoms. These results suggested that the abnormalities 
previously reported in post mortem studies reflected a neuropathic process affecting the 
spinal cord. One theory postulates that damage to the peripheral nerve causes secondary 
spinal cord “shrinkage “ due to degeneration or atrophy, so called dying back phenomenon. 
And another postulates that the primary insult may be to the CNS, with the well documented 
peripheral changes occurring as secondary phenomenon. It is also conceivable that both 
PNS and CNS involvement o c c u r  concomitantly resulting in the findings described.
1.2.1.2 Brain
Findings from the spinal cord studies described above, suggest that the metabolic insult of 
diabetes has a generalised effect on the whole nervous system, and made us question 
whether the brain too may be involved. Anatomical studies have demonstrated that 
ascending sensory pathways of the spinal cord terminate within the thalamus before higher 
order sensory projections are sent to the somatosensory cortex (Wilson, Kitchener et al. 
1999). Recent studies have shown that the thalamus does not merely act as a sensory relay 
station but also modulates/processes the information that is presented to the cortex 
(McCormick and Bal 1994).
In vivo proton MR spectroscopy (H-MRS) is a non-invasive technique that can provide 
metabolic information from different body tissues, including the brain. It has been used to 
study the classification and pathophysiology of various neurological conditions including 
neoplasms, viral and retroviral infections, ischaemia, demyelination and some forms of 
epilepsy and dementias (Wilkinson, Lunn et al. 1997; Wilkinson, Griffiths et al. 2001, 
Wilkinson, Hadjivassiliou et at. 2005). Conventional MRI and H-MRS rely on the same
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physical principles to collect MR signal, but differ in the way the data is processed, displayed 
and interpreted. H-MRS produces data presented in spectrum form that contains several 
resonances or peaks. Recent MR spectroscopy studies in diabetes have focused on its 
metabolic impact on the developing brain (Sarac, Akinci et al. 2005) and the cerebral 
consequences of hypoglycaemia (Rankins, Wellard et al. 2005) or diabetic ketoacidosis 
(Wootton-Gorges, Buonocore et al. 2005). N-acetyl aspartate (NAA) is a prominent peak that 
is used as a marker of neuronal integrity and function. Observations of cerebral NAA in 
diabetes that have been reported are contradictory and most studies did not quantify the 
presence of DPN in their subgroups with diabetes (Kreis and Ross 1992). Thus, it remains 
unclear if the changes observed are the result of diabetes of the consequences of
neuropathy.
1.2.1.3 Painful DPN and neuroimaging
Painful DPN is a severe disabling chronic condition that affects a significant number of 
patients with diabetes. The exact pathophysiological mechanisms of neuropathic pain 
remain unknown although based on experiments in animal models both peripheral and 
central mechanisms have been postulated (Cervero and Laird 1996). However, there are no 
consistent differences in peripheral nerve morphological parameters between painful DPN 
and painless DPN (Malik, Tesfaye et al. 1994). It is likely that the pathophysiological 
changes resulting in pain may in part, lie elsewhere within the nervous system. Recent 
advances in modern, non-invasive, neuroimaging methods have led to better understanding 
and refinement of pain processing in the brain. Many studies based on positron emission 
tomography (PET) and functional MRI (fMRI) have investigated changes in brain activity in 
response to various experimental stimuli inducing pain. This has led to the characterisation 
of a network of brain areas that consistently activate in response to acute pain, forming the 
“pain matrix” involved in the different dimensions of pain perception (Melzack 1999). These 
areas include: primary and secondary somatosensory cortex, insular, anterior cingulated and 
prefrontal cortices and the thalamus. Other regions such as basal ganglia, cerebellum,
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amygdala, hippocampus and areas within the parietal and temporal cortices can also be 
active dependent upon the particular set of circumstances for that individual (Apkarian, 
Bushnell et al. 2005). Many of these studies, however, have been performed in healthy 
volunteers following acute pain stimulation, and changes in the brain associated with chronic 
pain have been less thoroughly investigated.
Several positron emission tomography studies have investigated changes in basal 
regional cerebral blood flow (CBF) related to spontaneous continuous non-diabetic 
neuropathic pain. These studies mainly report a significant decrease in regional CBF in the 
hemithalamus contralateral to the pain (Laterre, De Voider et al. 1988). In many instances, 
this decrease in thalamic activity was reversed by therapeutic interventions providing 
significant symptomatic relief (Di Piero, Jones et al. 1991). These results, however, appear 
contrary to electrophysiological findings in animal and human studies of chronic pain, which 
have demonstrated abnormal hyperactivity of thalamic neurons (Hua, Garonzik et al. 2000). 
There is no satisfactory explanation for the observed relative decrease in thalamic relative 
CBF in neuropathy pain patients (Moisset and Bouhassira 2007). Some investigators have 
postulated that this decrease may be a compensatory mechanism for inhibiting excessive 
nociceptive inputs or to the uncoupling between blood flow and neuronal activity in patients 
experiencing neuropathic pain (ladarola, Max et al. 1995). The observed decrease in 
thalamic activity appears to be reversible following various types of analgesic procedures 
suggests that this decrease results from functional impairment rather than degenerative 
process.
Increases in relative CBF have been reported in the anterior insula, posterior parietal 
cortex, inferior and lateral prefrontal cortex and the anterior cingulated cortex in several other 
non-diabetic neuropathic pain studies (Hsieh, Belfrage et al. 1995). These data suggest that 
changes in basal brain activity in patients with chronic neuropathic pain involve only a small 
portion of the “pain matrix” (described below) associated with acute pain. Further studies 
with better characterisation of neuropathy are required to confirm the pattern of brain activity
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associated with spontaneous neuropathic pain in diabetes. Given the complex, 
multidimensional clinical entity that is painful DPN, it is likely to be mediated by a number of 
diverse pathophysiological brain mechanisms and possess a unique pain matrix of its own. 
A greater understanding of the specific features of painful DPN will help advance our 
understanding of the mechanisms of this troublesome complication of diabetes and may 
result in the development of more rationale (mechanism-based) treatment approaches.
The pathogenesis of diabetic CNS complications is not limited to the effects of 
neuropathy, but is likely that a multifactorial process involving adverse effects of chronic 
hyperglycaemia, recurrent hypoglycaemia and cerebrovascular disease maybe collectively 
responsible. A comprehensive review of the impact of these factors on the CNS is found in 
Appendix 1.
1.3 Summary
Chronic complications are significant problems in patients with diabetes mellitus and are 
major causes of morbidity and mortality. It has become increasingly clear that the brain and 
spinal cord are also susceptible to diabetic end organ damage. Recognition that diabetes 
results in important complications of the CNS should prompt further research into 
understanding the pathological mechanisms that underpin these effects. Advances in 
neuroimaging will enable us to define at what stage during the course of diabetes pathologic 
changes develop in the brain and will hopefully result in new strategies to prevent or reverse 
the damage caused by diabetes mellitus.
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1.4 Aims of Thesis
• To review and appropriately modify the MR acquisition protocol and spinal cord area 
measurement technique to improve overall precision and accuracy. To patient these 
modifications to stringent quality control studies.
• To assess and confirm involvement of the spinal cord occurs in DPN using non 
invasive MR imaging techniques and investigate if this occurs early in patients with 
subclinical DPN.
• To establish the involvement of the thalamus is DPN using H-MRS.
• To investigate the aetiology of thalamic neuronal dysfunction in DPN by testing a 
metabolic hypothesis using H-MRS.
• To investigate the aetiology of thalamic neuronal dysfunction in DPN by testing a 
vascular hypothesis using MR perfusion imaging.
• To assess the therapeutic efficacy and side effect profile of CBME (sativex) in severe 
intractable painful DPN in a randomised double blind placebo controlled trial.
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2 QUALITY ASSESSMENTS OF METHODOLOGICAL TECHNIQUES
2.1 Introduction
Central nervous system involvement in DPN is increasingly being recognised. As highlighted 
in the previous chapter, early post mortem studies have demonstrated axonal loss, gliosis 
and demyelination of the spinal cord in patients with of long standing duration of diabetes 
(Olsson, Save-Soderbergh et al. 1968). A pilot study was conducted to explore the possible 
involvement of the spinal cord in DPN by using MR imaging and performing spinal cord 
cross sectional area (CSA) measurements. Subsequently a larger study (Study 2) was 
designed to confirm the findings of the pilot study but also to investigate if spinal cord 
involvement occurs in patients with early, sub-clinical DPN. The pilot study used a manual 
outlining method with pixel counting to estimate cord CSA. The advantage of this technique 
is that it is quick and simple to perform, but, it is however operator dependent.
The accuracy and reproducibility of the measurement technique are important factors 
in obtaining high quality spinal cord CSA results in Study 2. The various methods available 
to estimate cord CSA can be broadly classified into two categories: computer assisted semi 
automated and manual outlining techniques. Although these techniques are widely used in 
multiple sclerosis studies, there have been few formal studies of the accuracy and 
reproducibility of these measurement techniques (Losseff, Webb et al. 1996). Hence, before 
commencing Study 2 we performed a quality control (QC) study to compare the performance 
of a computerised, semi-automated cord CSA measurement technique with the manual 
outlining technique used in the pilot study. There were two aims in this QC study. The first 
was to compare the accuracy and longitudinal reproducibility of the manual outlining and 
semi-automated computer assisted techniques in measuring CSA utilising test tube 
phantoms (TTP). The more accurate and reproducible of the two techniques would be 
chosen as the method of choice for measuring cord CSA in human patients. The second aim
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was to assess the inter- and intra-observer (novice vs expert) variability of cord CSA in 
human patients.
2.2 Phantom Studies
2.2.1 Materials and Methods
This study is a replicated, fully crossed multi-factor, single-centre methodology study. 
Experiments were divided into TTP and patient studies.
2.2.2 Test tube phantoms
Test tube phantoms containing doped water of varying contrasts, with similar cross-sectional 
dimensions to human spinal cords were employed (Figure 2.1a). Phantoms were made 
using test tubes specifically commissioned from Scientific Glass Laboratories Ltd. (Stoke-on- 
Trent, UK) to exact measurements. To mimic the spinal cord within the spinal canal, a 
smaller test tube was placed within a larger one and each filled with water. Three inner test 
tubes with different CSA (63.63mm2, 78.55mm2 and 95.04mm2) were used. Each outer test 
tube had the same CSA. Five drops of gadolinium were added to the outer test tube to 
represent bright white cerebrospinal fluid (CSF) as seen on T2 weighted MR image of the 
cervical spine (Figure 2.1b and c). Test tube phantoms (Figure 2.2) were orientated in the 
transverse scan plane and aligned centre of the test object at magnetic isocentre (red line) 
with the light beam, laser or zero point of the bed scale.
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(a) (b) (c)
Figure 2.1: (a) Test tube phantom, (b) cross sectional images of test tube phantoms 
acquired following from magnetic resonance imaging, (c) magnetic resonance image of the 
cervical spine. CSF, cerebrospinal fluid.
Figure 2.2: Test tube phantoms
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2.2.3 MR imaging protocol
Introduction of a semi-automated spinal cord CSA measurement technique relies on good 
image contrast between cord and CSF. Hence, a new MR acquisition protocol was designed 
to satisfy this requirement and optimise cord area measurements. All TTP underwent MR 
imaging using a standard spinal phased-array, receive only radiofrequency coil on a system 
operating at 1.5T (Eclipse, Philips Medical Systems, Cleveland, Oh, USA). T2* weighted 
imaging was performed axially from C1-T2 using a gradient echo technique [echo time (TE) 
= 17.9 ms, repetition time (TR) = 800ms; slice thickness = 4mm, in plane resolution = 
0.78mm X 0.96mm].
2.2.4 Cross sectional area measurement
Inner test tube CSA measurements begin by first defining the boundary between the Inner 
test tube and the doped water surrounding it. To delineate this boundary we used both the 
manual outlining method and the new computerised semi-automated method. The MR 
propriety software (TwinStar, Philips Medical Systems, Cleveland, Oh, USA) then estimates 
the CSA of the inner test tube by pixel counting within the boundary margins. The accuracy 
of each measurement technique was tested against the known CSA of the inner test tubes 
(Figure 2.3).
2.2.4.1 Manual outlining CSA measurement
Online scanner software (TwinStar, Philips Medical Systems, Cleveland, Oh, USA) with a 
‘free hand’ drawing utility was used to manually outline the boundary between the inner test 
tube and surrounding doped water (Figure 2.4).
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Figure 2.3: Magnetic resonance image of test tube phantoms with three different inner test 
tube cross sectional areas.
Figure 2.4: Cross sectional magnetic resonance images of the test tube phantom 
demonstrating measurement of inner test tube cross sectional area using the manual 
outlining technique.
54
2.2A.2 Semi-automated CSA measurement
The computer automatically delineates the boundary between inner test tube and doped 
water using a thresholding method (Figure 2.5) (Losseff, Webb et al. 1996). A simple 
formula, shown below, is used to calculate the signal intensity of pixels that occupy the 
boundary between the two.
If the signal intensity (SI) of the inner test tube and doped water were uniform in their 
composition then a contour drawn in the image at a SI halfway between the SI of the inner 
test tube and doped water would be the true position of the boundary. To calculate the 
boundary SI, a region of interest (ROI) is drawn within the doped water outside the inner test 
tube [Area Outer (AO), Figure 2.5a)] and another within the inner test tube [Area Inner (Al), 
Figure 2.5b]. The computer then calculates the signal intensity (SI) and area (mm2) of both 
inner and outer regions. From these two regions the mean CSF SI is calculated as follows:
SI (Ao) x (AO) -  SI (a¡) x (Al)
Mean doped water(Sn ----------------------------------
(AO -A l)
The boundary signal intensity is taken as the mean of inner test tube SI and doped water SI:
CSF (si)+ Cord (si)
oundary (Si) 2
Using the semi-automated region growing technique in DISPImage on a Sun 
Microsystems workstation (Plummer 1992) the investigator chooses a point (‘seed) at, or 
near, the boundary of the doped water and inner test tube (Figure 2.4c). The program then 
constructs a border around the inner test tube at the boundary SI. The algorithm starts 
contouring following from the “strongest edge point” (a border representing the greatest 
change in intensity from one pixel to another) in the neighbourhood of a user-selected point. 
The strongest edge point is found through a search over a 5 X 5 pixels squared area with the 
selected point in the centre. From the “starting point” (the first strongest edge point) found by 
the algorithm, the program finds the direction of the next contour point by searching north,
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east, south and west from the starting point for the direction with the strongest gradient. The 
next contour point also has to be above the threshold at the starting point. The program then 
traces a contour from the most recent point following the same principle described above. 
The contour is complete when it traces back to the starting point (Figure 2.4d). The algorithm 
uses an interpolated path through the images, for instance, the contour traces its path, 
based on the gradient calculated with relevant fractions of contributing neighbouring image 
pixels.
(c) (d)
Figure 2.5: Cross sectional magnetic resonance images of the test tube phantoms 
demonstrating measurement of inner test tube cross sectional area using the semi 
automated computer assisted technique, (a) A ROI is drawn within the doped water outside 
the inner test tube and another within the inner test tube (b). Using the semi-automated 
region growing technique (in Displmage) the investigator chooses a point (‘seed) at, or near, 
the boundary of the doped water and inner test tube (c). The program then traces a contour 
back to the starting point (d).
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2.2.5 Errors o f cross-sectiona l area measurement
Figure 2.6 below is a schematic representation of differences in inner test tube cross- 
sectional area measurements caused by variation in TTP positioning. Inner test tube CSA 
measurement is also dependent on the angle at which the transverse sections of the inner 
test tube image are acquired (Figure 2.7). As a result of such variations actual inner test tube 
cross-sectional area in slice B is greater that slice A. As all structures in a cross-sectional 
image will experience the same amount of artificial scaling from such effects, we also 
measured the antero-posterior (AP) diameter of the outer test tube and used this as a 
“correction tool” in our subsequent analyses. Textbox 2.1 details the mathematical proof and 
hence justification for employing this correction tool. Instead of using actual inner test tube 
CSA measurements, we calculated the ratio of cord CSA:AP diameter of the outer test tube 
and used this in the final analysis.
Outer test
tube
TTP TTP
position A position B
Slice A Slice B
Area A < Area B
Figure 2.6: Differences in inner test tube cross-sectional area measurement caused by 
variation in patient positioning. TTP, test tube phantom.
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Slice A Slice B
Figure 2.7: Errors in inner test tube cross sectional area that can result from altering the
slice angle.
Textbox 2.1 
Assumptions
• Inner test tube cross sectional area is a circle
• error in slice positioning is only in the anterior posterior direction 
Area of inner test tube in slice a:
71 (P/2 f
Giving arbitrary values
P = 20
Then the area = 314.16 mm2 
Area of inner test tube in slice b:
If slice b is taken at an angle of 30 degrees, then the circular shape becomes an ellipse. Hence 
the length of Q is calculated as follows.
Cos 30 = 20
Q
Therefore Q = 23.09
Hence the area of an ellipse = ?r(Q/2 X P/2)
= 362.70 mm2
The areas are now different.
Correction of error in slice positioning.
By dividing both areas by the AP outer test tube diameter, we correct for this error and the results 
are then the same as shown below.
APa = AP diameter of outer test tube as measured in slice a, = 50 
APb = AP diameter of outer test tube as measured in slice b, = 50/cos30, = 57.73 
Therefore the corrected area of inner test tube for slice a is: 314.16/50 = 6.28 mm 
and the corrected inner test tube area in slice b is: 362.70/57.73 = 6.28 mm
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2.3 Human Studies
2.3.1 Patients and methods
Fifteen randomly selected patients (Healthy Volunteers and diabetic patients) underwent MR 
imaging of the cervical spine. Images acquired were analysed by two observers [an expert 
(myself- involved in analysing all data acquired) and a novice (CJE- an assessor trained to 
perform the analysis specifically for the QC studies)]. The same MR acquisition protocol 
used in the TTP study was used here. Sagittal imaging of the entire cervical spine was 
performed. Pilot images were viewed to ensure the cross sectional images were taken 
perpendicularly to the cord and that the anatomical level of disc space C2/C3 was correct. A 
single cross sectional image was chosen in the middle of disc space C2/C3 for cord CSA 
measurements. The method chosen to analyse the cervical cord CSA was the most accurate 
and reproducible of the two techniques assessed in the TTP study. Inter- and intra-observer 
variability was assessed by averaging ten measurements of cord CSA at the level C2/C3 for 
each patient. Observers were blinded to the name and group of patients. Patients were 
subsequently rescanned after being repositioned on the scanner to determine the scan- 
rescan variation.
2.3.2 Inter-patient variation in cord CSA
Another potential confounding factor that could impact on the outcome of Study 2 is the 
substantial inter-patient variation in spinal cord CSA. This would limit the value of actual cord 
area measurements in a cross-sectional study. Figure 2.8 below is a schematic 
representation of the consequences of inter-patient variability in spinal cord CSA on a cross- 
sectional study. Patient A is a larger diabetic patient who develops neuropathy and 
subsequent cord atrophy. Patient B is a smaller diabetic patient who does not develop 
neuropathy. Comparing actual cord area sampled at time X will show no difference in cord 
CSA between patients A and B. However, the spinal cord has shrunk from a larger size in 
patient A and remains unchanged in patient B. To account for this inter-patient variability we
59
used the AP diameter of the bony canal as a correction tool. We used the spinal cord CSA to 
AP canal diameter ratio as an index to account for inter-patient variations in Study 2. This 
index also served a secondary purpose of correcting for errors in transverse slice positioning 
of the spinal cord (as detailed above).
Spinal Bony Canal 
Cord
Patient A 
Patient B
Time x
Figure 2.8: Variations in cord cross-sectional area in two patients over time.
2.4 Data Analysis
2.4.1 Study end points
Parameters that were calculated and served as end points:
Test tube phantom studies:
1. Inner test tube CSA
CSA area estimated over 24 slices using both manual outlining and semi-automated region 
growing technique.
2. Anterior posterior (AP) diameter
Using a scaled ruler provided by the scanner image workstation (TwinStar, Philips Medical 
Systems, Cleveland, Oh, USA) the outer test tube AP diameter was measured.
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P a tie n t s tu d ie s :
1. Cervical cord CSA to AP canal diameter ratio
The CSA measurement method that proved most accurate and reproducible in the TTP 
studies was subsequently used to calculate cervical cord CSA at the level C2/C3. This level 
was chosen as: 1) the greatest difference in cord area between Painless DPN and Healthy 
Volunteers in the pilot study was at the cervical level (Eaton, Harris et al. 2001); 2) CSF 
encircles the cord and the contrast between CSF (bright) and spinal cord (dark) allows the 
use of a semi-automated voxel based thresholding method to measure cord cross-sectional 
area (Figure 3.1, (Losseff, Webb et al. 1996); 3) positioning the patient to ensure that the 
cord was in the middle of the spinal canal (i.e. not touching bone) was facilitated as the neck 
is kept in the more comfortable, neutral position and 4) there are fewer disc prolapses at this 
level (Thorpe, Kidd et al. 1993).
Using a scaled ruler provided by the Twinstar (Philips Medical Systems, Cleveland, Oh, 
USA) software, the AP diameter of the spinal canal was measured and the ratio of cord CSA 
and AP canal diameter was calculated. The inter- and intra-observer reproducibility of this 
technique was assessed by both an expert (myself) and a novice (CJE).
2.4.2 Statistical Analysis
Accuracy
Accuracy was assessed as the difference between the observed value and the actual 
target value for each end point of TTP studies.
Absolute accuracy was calculated as follows:
(Observed-Target)
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The percentage accuracy was calculated as follows:
^Observed -  Target) x 100]
Target
The number of significant measurement errors was determined for each TTP measurement 
end point. Measurement error for each end point was defined as greater than + 2% of target.
The accuracy of both measurement techniques were assessed by measuring the constant 
and proportional bias compared to known reference measurements of each TTP. The ideal 
measurement technique will produce equivalent results with reference measurements and 
therefore have a constant bias of 0 and proportional bias of 1. The hypothesis test compares 
constant and proportional bias of each measurement technique against the ideal values. If 
the p-value is statistically significant then the bias differs from this ideal value.
Precision
Overall reproducibility was assessed by determining the coefficient of variation (CV = 
standard deviation/mean) of each end point across all measurements compared to the 
reference standard.
Finally, we compared the agreement between the two measurement techniques using 
Bland Altman plots (Bland and Altman 1986). In the human studies, reproducibility was 
expressed as both the mean centred coefficient of variation and the standard deviation of the 
amount of variation in the observed values.
2.5 Results
2.5.1 Test Tube Phantom Studies
Actual CSA of the three TTP used for QC analysis were 63.63mm2, 78.55 mm2 and 95.04 
mm2. The absolute and percentage accuracy of both measurement techniques for each TTP 
is displayed in Table 2.1. Percentage and absolute accuracy of the semi-automated inner
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test tube CSA measurement technique was significantly lower compared to the manual 
outlining method at each level. Of the 24 measurements made for each TTP, the number of 
measurement errors for the semi automated technique ranged from 6 to 11 compared with 
14 to 20 for the manual outlining method. Accuracy of CSA measurements using semi- 
automated technique was far superior with constant bias closer to zero and proportional bias 
closer to 1 across all TTP sizes (Table 2.1). These biases were not significantly different 
from the hypothetical ideal value. Whereas, the proportional bias for measurements made 
using the manual outlining technique was significantly different from the ideal value 
(proportional bias = 1.07, p = 0.03; 95% Cl 1.03:1.11). The scatter plot (Figure 2.9) shows 
the observations of reference (X) plotted against the test method (Y).
The coefficient of variation for the semi-automated technique for repeated measures 
of different size TTPs ranged from 1.3% to 2.5%. The CV range for the manual outlining 
technique was much higher between 5.2% to 6.6%. Figure 2.10 contains precision plots (see 
below) showing the standardised observations from the mean for each measurement 
technique applied to each TTP. Most observations derived from the semi-automated 
technique were within two standard deviations of the mean and hence this proved to be the 
most reproducible technique. The Bland Altman plots show little correlation between the two 
measurement techniques. The average difference (bias) between measurement techniques 
ranged between 2.57 to 4.38 (Table 2.2).
Reference value of outer test tube AP diameter was 42mm. Mean AP diameter of 
measured using the analysis software was 40.7(0.17); 95% Cl 0.12:0.36. The coefficient of 
variation for the AP diameter of repeated measures was 0.4%.
2.5.2 Human Studies
The intra-observer standard deviation and coefficient of variation for the experienced 
observer were 0.01 and 1.0% respectively. The novice observer had a standard deviation of 
0.02 and a coefficient of variation of 2.0% for repeated measurements of the same image.
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The inter-observer reproducibility coefficient of variation was 1.4% and standard deviation of 
0.014. The coefficient of variation and standard deviation of the measurements made by the 
experienced operator on the scan-rescan series of images were 2.0% and 0.02 respectively.
Table 2.1: Accuracy assessment of the semi-automated and manual outlining 
methods.
CB p PB
Manual outlining -0.87(-4.29:2.54) 0.19 1.07(1.03:1.11) 0.03
Semi-automated 0.33(-5.89:6.56) 0.62 1.01(0.93:1.09) 0.37
CB, Constant Bias; PB, Proportional Bias; Results expressed as Bias.95% Confidence 
Interval.
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Table 2.2: Assessm ent o f the sem i-autom ated and manual ou tlin ing  cross sectiona l area measurements.
CSA (mm2) AA* AA (%)* ME* CV (%) Bias*
TTP A 78.55#
Manual outlining 83.0(5.1); 3.9:7.2 4.17(0.3-14.7) 6.89(0.5-18.8) 20 6.6
Semi-automated 79.5(1.9); 1.5:2.8 1.24(0.3-5.4) 1.58(0.3-6.9) 12 2.5
-3.8(-6.3:-1.2)
TTP B 63.63#
Manual outlining 67.2(3.4);2.7:4.8 3.37(-3.9-10.0) 5.30(-6.3-15.7) 20 5.4
Semi-automated 64.6(0.8); 0.6:1.2 0.99(-1.2-2.4) 1.55(-1.8-3.8) 10 1.3
-2.6(-4.1:-1.0)
TTP C 95.04#
Manual outlining 100.8(4.9);3.8:6.9 6.07(0.4-15.5) 6.4(0.4-16.3) 18 5.2
Semi-automated 96.3(1.5);1.2:2.2 1.74(0.2-4.0) 1.83(0.2-4.2) 7 1.6
-4.4(-6.6:-2.1)
CSA, Cross Sectional Area; AA, Absolute Accuracy; AA%, Percentage Absolute Accuracy; ME, Measurement Errors; CV, Coefficient Variation 
and TTP, Test Tube Phantom. Results expressed as mean(SD),95%CI, median(range) and bias(95%CI). * p<0.05. # Reference Value.
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Figure 2.9: Linear Fit of Cross Sectional Area Measurements vs Reference Control A Semi- 
Automated, B Region Growing. 95% Cl, 95% Confidence Intervals
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Figure 2.10: Precision and Bland-Altman Plots of Cross Sectional Area measurements
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2.6 D iscussion
Having analysed the original pilot study by Eaton et al. (Eaton, Harris et al. 2001), we 
identified certain aspects of its methodology and analysis plan, that if modified may improve 
the accuracy and precision of cord CSA. The adoption of a new image acquisition protocol, a 
semi-automated cord CSA measurement technique and the ratio of cord CSA to AP canal 
diameter as an end point theoretically minimised error and improved reproducibility of spinal 
cord CSA. Before adopting these changes, however, we designed a QC study to test the 
hypothesis that these modifications will result in improved accuracy and reproducibility of 
study end points. This QC study enabled a uniform assessment of new versus old 
procedures using in-house manufactured TTP and human patients. These results provide 
insight into the accuracy and reproducibility associated with the measurement of spinal cord 
CSA due to the procedural changes proposed.
Test tube phantom studies demonstrated a high degree of accuracy with relatively 
lower number of measurement errors and high degree of reproducibility of the semi- 
automated computer assisted technique. The cumulative change in percentage accuracy 
was overall low using both measurement techniques. With lower percentage scores, 
however, the semi-automated technique had the least accuracy drift over the three different 
inner test tube size ranges. Hence, the semi-automated technique was chosen to measure 
spinal cord CSA in the QC human studies. These latter inter- and intra-observer variability 
studies demonstrated acceptable coefficient of variation.
Potential sources for error in cord CSA measurements are summarised in Figure 
2.11. Once identified, measures can be put in place to minimise these errors. Errors can be 
divided into sampling and measurement errors. Each of these can be divided into two further 
categories; random and systemic errors. Individually these errors can originate from study 
patients, investigators, MR acquisition protocols and MR equipment and the spinal cord CSA 
measurement technique.
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Systemic sampling and measurement errors of cord CSA estimation were assessed 
by the TTP accuracy protocols. Accuracy is a function of systemic error (i.e. the greater the 
error the less accurate the variable) and defined as how closely the measurement is to the 
actual or true value. The reference standard used was a specifically commissioned TTP, 
built to set dimensions to mimic a range human spinal cord CSA. Two main additional 
sources of errors, which can affect the accuracy, were identified as being investigator bias 
and instrument bias. Investigator bias is defined as the consistent distortion on the reporting 
of a measurement whether conscious or subconscious. Standardising the MR acquisition 
technique and introducing the semi-automated computer assisted cord CSA measurement 
method reduced the impact of this bias. In addition, investigators will be blinded to the spinal 
cord images of patients during analysis.
Instrument bias is the result of a faulty function of a mechanical instrument (MR 
scanner) and/or measurement technique. The MR scanner is calibrated on a regular basis 
and will proceed as per departmental and manufacturer specified guidelines. The 
introduction of a new acquisition protocol has improved the contrast between spinal cord and 
CSF, thereby improving the efficiency of the semi-automated cord CSA measurement 
technique. Furthermore, statistical tests comparing constant and proportional bias against 
ideal values demonstrated that the semi-automated measurement technique was not 
significantly different from the ideal value and hence has greater overall accuracy. 
Percentage absolute accuracy calculations showed that the manual outlining methods was 
particularly flawed at the extreme ends of inner test tube CSA sizes. The semi-automated 
measurement technique, on the other hand, displayed less drift in accuracy over the size 
ranges.
The second set of errors assessed in this study is random sampling and 
measurement errors, which were assessed by precision TTP and human QC studies. 
Precision is defined as the ability to provide the same results from the same patient on 2 or 
more occasions and is susceptible to random errors. The precision protocol utilised TTP and
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human patients to test the reproducibility and inter/intra-observer variability of both the 
sampling and the chosen CSA measurement technique. With smaller coefficient of variations 
in both TTP and human studies, the semi-automated CSA measurement technique 
appeared to be less susceptible to random errors.
In this study, precision was dependent on three factors, first the equipment used (MR 
scanner and cord CSA measurement technique), second the investigator and finally the 
patients studied. Inter- and Intra-operator repeatability using the semi-automated computer 
assisted technique confirmed it was also more reproducible. Additional strategies that will be 
employed to improve reproducibility Include standardising measurement methods (operating 
manuals detailing protocols in use for the acquisition of images, recording procedure, 
positioning patients and step by step guide to using the semi-automated cord CSA 
measurement technique will be employed), training (investigators will be trained in methods 
for image post processing for measuring spinal cord CSA), automating (introduction of a 
semi-automated spinal cord measurement technique will improve precision by reducing 
human error) and repetition (repeating measurements [spinal cord CSA and AP canal 
diameter] and taking the mean will reduce the Impact of random error).
Another strategy that will be employed to minimise errors of spinal cord CSA 
measurement is supplementation. By measuring several different variables to represent the 
characteristics of interest (spinal cord CSA) will add both accuracy and precision to the 
study. An index (spinal cord area:AP canal diameter ratio) which, combines several 
measurements can also enhance precision. This index has the added benefit of accounting 
for both inter-patient variations of cord CSA and errors caused by slice positioning 
(described above).
This QC study has aspects that may limit its interpretation. We did not test accuracy 
of measurement techniques on human patients. The accuracy would be expected to fall 
because of the introduction of MR susceptibility artefacts. In summary, this study provides a
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quantitative assessment of the accuracy and reproducibility of two cord cross-sectional area 
measurement techniques using simulated testing of TTP and human patient. Overall, 
because of the better accuracy and precision of the semi-automated computer assisted 
technique, we chose to use this in the subsequent larger spinal cord DPN study.
Errors
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Random
I
Systemic
I
Random
1
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Precision Test
1
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1
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Figure 2.11: Measurement and sampling errors.
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3 EARLY INVOLVEMENT OF THE SPINAL CORD IN DIABETIC DISTAL 
SYMMETRICAL POLYNEUROPATHY
3.1 Introduction
Distal symmetrical diabetic sensorymotor polyneuropathy is the commonest form of 
neuropathy in the western world with important health and financial implications (Boulton 
1997; Vinik, Park et al. 2000; Boulton, Kirsner et al. 2004). Although various vascular and 
metabolic factors have been implicated, a complete understanding of the pathogenesis of 
DPN remains elusive (Dyck and Giannini 1996; Cameron, Eaton et al. 2001). Consequently, 
apart from glycaemic control, we have no proven rational treatments. DPN has hitherto been 
considered a disease of the PNS only with CNS involvement largely overlooked. However, 
knowledge of the full extent of nervous system involvement is crucial for a greater 
understanding of the pathogenesis of DPN and may have an important role in the 
development of effective therapies.
Involvement of the spinal cord was first suggested by post mortem studies in the 
1960’s and 1970’s. Pryce, Leichtentritt and Williamson described loss of myelinated fibres 
and gliosis of the dorsal columns of the spinal cord in diabetic patients (Leichtentritt 1893; 
Pryce 1893; Williamson 1904). Further histopathological changes reported within the spinal 
cord include long tract, nerve root and dorsal root ganglion degeneration with demyelination 
and axonal loss (Reske-Nielsen and Lundbaek 1968; Reske-Nielsen, Lundbaek et al. 1970). 
However, many of these studies did not examine patients with DPN specifically and it is 
therefore impossible to conclude whether these changes were due to neuropathy or diabetes 
per se. More recently, the observation that electrical spinal cord stimulation failed in relieving 
neuropathic pain in patients with severe loss of vibration and joint position sense, suggests 
that the spinal cord may be involved in the disease process (Tesfaye, Watt et al. 1996).
In a recent pilot study, Eaton et al have demonstrated a significant reduction in cross- 
sectional area of the cervical spine using MR imaging in patients with advanced DPN
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compared to Healthy Volunteers (Eaton, Harris et al. 2001). However, as the relevance of 
these findings to the pathogenesis of DPN is dependent on whether spinal cord shrinkage 
occurs early, a larger, adequately powered study was conducted.
3.2 Methods
3.2.1 Patients
Two hundred and twenty type 1, male diabetic patients from the Royal Hallamshire Hospital 
Diabetes Register were screened for the study (October 2001-January 2004). Selection 
criteria included, type 1 diabetes diagnosed for more than five years and age between 18 - 
65 years. Exclusion criteria included significant back problems (defined as either known 
degenerative back disease or symptoms which have occurred on a regular basis, or have 
required consultation for investigation and treatment), history of spinal trauma, non-diabetic 
neuropathies, history of alcohol consumption of more than 20 units a week, painful 
neuropathy, diabetic neuropathies other than DPN (e.g. mononeuropathies, proximal motor 
neuropathies etc), claustrophobia or other factors which precluded MR imaging. A total of 
122 diabetic patients fulfilled the inclusion and exclusion criteria and were willing to undergo 
neurophysiological assessments (detailed below). Of these, 98 subsequently underwent MR 
imaging. Seventeen withdrew from the study before imaging and seven had 
contraindications to imaging. We also recruited 24 age and sex matched Healthy Volunteers 
and eight patients with hereditary sensory motor neuropathy. Patients with hereditary 
sensory motor neuropathy were diagnosed following nerve conduction studies and genetic 
testing, and all had the disease phenotype. Members from the same family were excluded to 
avoid bias. All patients gave written, informed consent to enter the study, which had prior 
approval by the South Sheffield Regional Ethics Committee.
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3.2.2 Assessment of neuropathy
All patients underwent: 1) assessment of neuropathic symptoms [Neuropathy Symptom 
Score (NSS); (Dyck and Thomas 1999)] and 2) neurological examination from which the 
Neuropathic Impairment Score of the Lower Limbs [NIS (LL); (Dyck and Thomas 1999)] was 
derived and 3) 7 tests of nerve function, in order to determine the “NIS LL+7 tests” 
Neuropathy Composite Score (NCS) (Dyck, Davies et al. 1997; Dyck, Litchy et al. 2003). 
Further details of the neurophysiological assessments and a summary how the NCS, was 
calculated (Dyck and Thomas 1999) please refer to Appendix 2. Vibration perception 
threshold was assessed using the Computer Assisted Sensory Evaluation IV (CASE IV, 
Minnesota, USA) system employing standard techniques (Dyck, O'Brien et al. 1993; Dyck, 
Zimmerman et al. 1993). The electrophysiological measurements (peroneal motor nerve 
conduction velocity, distal latency and compound muscle action potential; sural sensory 
nerve action potential; and tibial motor nerve distal latency) were assessed with surface 
electrodes at a stable skin temperature (31 °C; Medelec, Synergy Oxford Instruments, 
Oxford, UK). Autonomic function assessment of heart rate variation with deep breathing was 
performed with continuous electrocardiographic monitoring (Dyck and Thomas 1999). The 
same, trained physician (DS) performed all the above assessments on each patient.
According to Dyck et al., the minimum criterion for the presence of DPN is a NCS >
4.5 (Painless DPN, as patients with painful DPN were excluded from this study) (Dyck, 
Litchy et al. 2003). Patients with a NCS of 0 were classified as having No DPN (Dyck and 
Thomas 1999). Diabetic patients with NCS between 1 and 4.5, and hence objective 
evidence of functional nerve impairment, were classified as having Subclinical DPN. In all 
patients, assessments to stage the severity of neuropathy were made within 7 days of MR 
imaging.
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3.2.3 M agnetic resonance im aging pro toco l
All patients underwent MR imaging of the cervical spine using a standard spinal phased- 
array receive only radiofrequency coil on a system operating at 1.5 Tesla (Eclipse, Philips 
Medical Systems, Cleveland, Oh, USA). T2* weighted imaging was performed axially from 
C1-T2 using a gradient echo technique [echo time (TE) = 17.9 ms, repetition time (TR) = 
800ms; slice thickness = 4mm, in plane resolution = 0.78mm X 0.96mm]. Cord cross- 
sectional area was measured at the level of disc space C2/C3 in all the patients. Total 
imaging time was 15 minutes.
Before the analysis was performed, an experienced neuroradiologist reviewed the 
standard images acquired (axial T2, sagital T1 and T2) to exclude any anatomical 
abnormalities. A simple four point scoring system was employed to quantify the degree of 
degenerative vertebral disease affecting patients in this study (normal = 0, thecal indentation 
only = 1, thecal indentation touching the cord = 2, cord compression = 3). There were no 
significant differences in the scores for degenerative disc disease between the five groups 
studied. None of the patients recruited had cord compression.
3.3 Data analysis
3.3.1 Spinal cord area measurements
Figure 3.1 shows an example of the images obtained. Average cord area measurements 
from three slices through disc space C2/C3 were calculated. An assessor, who was blinded 
to patient identity, performed the analysis.
Absolute cord area measurements can be of limited value in cross-sectional studies 
because of substantial inter-patient variation in cord area. In addition the cord cross- 
sectional area is also dependent on the angle at which the cord image is acquired. Although 
axial slices of the spinal cord were aligned parallel to cervical disc C2/C3, the spinal cord 
may not have been sectioned perpendicularly due to variations in patient positioning. The
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resultant errors and further details of the correction methods employed are discussed in 
Chapter 2. In summary, as all structures in an image will experience the same amount of 
artificial scaling from such effects (Pelletier, Garrison et al. 2004), we also measured the AP 
diameter of the spinal canal and used it as a “correction tool” in all our subsequent analyses. 
The AP diameter of the spinal canal was measured in the slice below the C2/C3 inter­
vertebral disc using the tools on the proprietary MR system’s software (Eclipse, Philips 
Medical Systems, Cleveland, Oh, USA).
Hence, in order to account for both inter-patient variations and errors caused by patient 
positioning in the scanner, we subsequently analysed the actual cord area measurements in 
two ways:
• Actual cord area adjusted for patient demographics and spinal canal AP diameter
a) To account for errors caused by patient positioning in the scanner, we adjusted 
actual cord area means for AP diameter of the spinal canal and
b) To account for errors caused by inter-patient variability we included age, weight 
and height as additional covariates in the analysis of covariance (see below).
• Normalised cord area
a) To account for errors caused by patient positioning, we calculated a “normalised" 
cord area by dividing each individual’s actual cord area with their AP diameter of 
the spinal canal (cord canal ratio) and
b) Subsequently adjusted normalised cord area for age, weight and height to 
account for inter-patient variability.
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3.3.2 Statistical analysis
All analyses were performed using the statistical package SPSS 11.1. Baseline 
characteristics were described as means and standard deviation for normally distributed 
variables and as medians and 5th and 95th percentiles for variables with a skewed 
distribution. Nerve conduction velocities were below the detection threshold In 18 patients for 
the sural nerve and 4 patients for the peroneal nerve. In all analyses, these extremely low 
values were assumed to equal 0.
We used analysis of covariance (ANCOVA) to compare differences in actual cord 
areas between groups (Healthy Volunteers, those with hereditary sensory motor 
neuropathy, No DPN, Subclinical DPN and Painless DPN) using age, height, weight and AP 
spinal canal diameter as covariates. The relation between actual cord area and individual 
attributes of nerve function (e.g. nerve conduction velocities, vibration perception threshold 
etc.) and NCS was analysed in more detail among patients with diabetes (n=98), using 
linear regression. For the final analysis we used ANCOVA to analyse differences in 
normalised cord area between groups and on this occasion used age, height and weight as 
covariates.
3.3.3 Reproducibility
The reproducibility of both MR acquisition and cord area measurement techniques 
was assessed (Chapter 2). A series of 18 patients, representing the range of spinal cord 
size, were selected. Each patient was scanned, removed from the scanner, repositioned and 
then rescanned (scan-rescan series). One set of images was then analysed twice by two 
investigators using the same cord area measurement technique as described above. One 
investigator was experienced with the technique having analysed all patients, and the other 
with no previous experience of the technique except a brief instruction beforehand. Images 
from both acquisitions (scan-rescan series) were then analysed by the experienced 
investigator to assess the variation in cord area caused by the MR acquisition technique.
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Reproducibility was expressed as both the mean centered coefficient of variation and the 
standard deviation of the amount of variation in the observed values.
Figure 3.1: T2*-weighted magnetic resonance imaging of the cervical spine.
(a) Spin echo magnetic resonance mid-sagittal image of a Healthy Volunteer depicting the 
prescription of axial slices acquired at the level of C2/C3 parallel to disc space C2/C3. (b) 
Axial images at the level of disc space C2/C3 showing a section of the cervical cord in a 
non- diabetic control. Magnified gradient echo MR axial images of the cervical spinal cord of 
(c) a Healthy Volunteers and (d) an age matched patient with Painless DPN illustrating 
differences in cord size and shape. The high contrast between cerebrospinal fluid ( ★ )  and 
spinal cord ( ☆ )  used to define the edge of the cord is evident.
3 .4  R e s u l t s
3.4.1 Demographics
Table 3.1 shows demographic details of the three diabetic groups (No DPN, Subclinical DPN 
and Painless DPN), Healthy Volunteers and patients with hereditary sensory motor 
neuropathy. Table 3.2 and 3.3 shows the results of the neurophysiological and MR 
assessments for each of the five groups.
Table 3.1: Subgroup Demographics [mean (SD)].
No DPN Subclinical DPN Painless DPN HV HSMN
Group Size 22 26 50 24 8
Age (years) 38.9(8.8) 42.6(10.5) 49.2(9.0) 47.6(13.1) 52.6(15.4)
Height (cm) 177.4(5.6) 176.7(6.2) 174.8(7.0) 175.6(5.4) 176.3(5.6)
Weight (Kg) 85.2(11.2) 81.8(11.5) 82.7(13.3) 81.4(14.0) 80.9(14.2)
DD (years) 18.0(8.8) 17.2(9.7) 26.2(10.7) N/A N/A
No DPN, diabetic patients with no neuropathy (NCS = 0); Subclinical DPN, diabetic patients 
with early neuropathy (1<NCS<4.5); Painless DPN, diabetic patients with established 
neuropathy (NCS>4.5); HV, Healthy Volunteers; HSMN, patients with hereditary sensory motor 
neuropathy; DD, Duration of diabetes.
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Table 3.2: Subgroup N europhysio logica l Assessm ents.
No DPN Subclinical DPN Painless DPN HV HSMN
SV 43.6 (37.7-48.4) 38.7 (34.4-49.3) 31.0 (0.0-40.9) 44.6 (32.1-50.8) ND
SA 10.6 (2.3-24.0) 8.3 (3.4-27.9) 2.1 (0.0-13.4) 11.1 (6.4-28.1) ND
PV 43.3 (7.0) 41.7 (3.8) 34.7 (6.9) 44.6 (3.1) ND
PA 5.8 (2.9) 5.5 (1.7) 2.5 (2.0) 7.0 (3.1) ND
HRDB 1.5 (0.2) 1.4 (0.2) 1.3 (0.2) 1.4 (0.2) 1.3(1.2)
Actual cord cross-sectional area measurements, normalised cord cross-sectional area, sural 
sensory nerve conduction velocity (SV, m/s), sural sensory nerve action potential (SA, mA), 
common peroneal nerve conduction velocity (PV, m/s), common peroneal compound muscle 
action potential (PA, mA), R-R variability with heart rate deep breathing (HRDB), and of the 
patients (No DPN, diabetic patients with no neuropathy; Subclinical DPN, diabetic patients with 
early neuropathy; Painless DPN, diabetic patients with established neuropathy; HV, Healthy 
Volunteers and HSMN, patients with hereditary sensory motor neuropathy). Results are given as 
mean (+SD), and median (5th; 95th percentile) for variables with a skewed distribution. ND, not 
detectable. N/A, not applicable.
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Table 3.3: Sugroup N europhysio logica l Assessm ents and Cervical Cord C ross-sectional Area 
Measurement.
No DPN Subclinical DPN Painless DPN HV HSMN
Vib JND 15.4 (2.4) 18.3(3.0) 21.2(2.6) 17.5(3.0) ND
NCS 0.0 (0.0-0.0) 2.0 (1.0-4.0) 10.5 (5.0-29.5) 0.0 (0.0-0.0) N/A
NSS 0.0 (0.0-0.0) 0.0 (0.0-2.8) 2.0 (0.0-10.5) 0.0 (0.0-0.0) N/A
NSS + NIS LL 0.0 (0.0-0.0) 0.0 (0.0-4.8) 9.5 (0.0-42.5) 0.0 (0.0-0.0) N/A
Actual CA 93.9 (7.6) 92.5 (8.8) 87.1 (9.1) 91.2(9.0) 93.7 (11.2)
AP 14.0 (1.8) 15.2 (1.4) 14.9(1.9) 13.4(1.3) 13.8(2.1)
Normalised CA 67.9 (7.0) 61.2(6.6) 59.0 (7.2) 69.1 (7.5) 68.7 (7.4)
Vibration “just noticeable difference” (Vib JND), Neuropathy Composite Scores (NCS), Neuropathy 
Symptom Score (NSS), Neuropathy Impairment Score of the Lower limbs (NIS LL), actual cord area 
(Actual CA) and AP diameter of bony canal (AP) of the patients (No DPN, diabetic patients with no 
neuropathy; Subclinical DPN, diabetic patients with early neuropathy; Painless DPN, diabetic patients 
with established neuropathy; HV, Healthy Volunteers and HSMN, patients with hereditary sensory motor 
neuropathy).
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3.4.2 Reproducibility
The intra-observer standard deviation and coefficient of variation for the experienced 
observer were 0.01 and 1.0% respectively. The novice observer had a standard deviation of 
0.02 and a coefficient of variation of 2.0% for repeated measurements of the same image. 
The inter-observer reproducibility coefficient of variation was 1.4% and standard deviation of 
0.014. The coefficient of variation and standard deviation of the measurements made by the 
experienced operator on the scan-rescan series of images were 2.0% and 0.02 respectively.
3.4.3 Spina! cord area assessments
Figure 3.2 shows the mean actual cord area per group, after adjustment for age, height, 
weight and AP diameter of the spinal canal. Diabetic patients with no neuropathy (No DPN 
group) had a similar, adjusted mean actual cord area as the Healthy Volunteers and the 
patients with hereditary sensory motor neuropathy. We found that adjusted actual cord area 
was progressively smaller in Subclinical DPN and Painless DPN groups. Compared to 
diabetic patients with No DNP, those with Subclinical DNP had an actual cord area that was
3.8 mm2 smaller (95 percent confidence interval: -0.8-8.4) and those with Painless DPN had 
a cord area that was 9.1 mm2 smaller (95 percent confidence interval: 4.9-13.4). The test for 
an inverse linear trend across the three diabetic groups showed a p-value of 0.001.
20.5 percent and 10.3 percent of Painless DPN and Subclinical DPN patients 
respectively had spinal cord atrophy as defined by an adjusted actual cord area less than 
two standard deviations below that of normal controls. Table 3.4 and 3.5 shows the relations 
between the actual cord area and the measures of nerve conduction velocity, NSS and 
NISLL among the patients with diabetes. Adjusting for age, height, weight and AP diameter 
of the spinal canal, we found that higher sural and peroneal nerve conduction velocities were 
associated with larger spinal cord areas. The amplitudes in both nerves were not related to 
the actual cord area at a statistically significant level. Adjusted actual cord area was 
inversely related to NCS with each point associated with a cord area reduction of 0.36 mm2
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(95 percent confidence intervals 0.16-0.56). Heart rate variability and vibration perception 
threshold (“just noticeable difference”) were not related to actual cord area.
Normalised cord area, obtained by dividing calculated cord area with the AP canal 
diameter (as described above), was subsequently analysed. Figure 3.2B shows the mean 
normalised cord area per group, after adjustment for age, height and weight. We confirmed 
all the relations described above between normalised cord areas and nerve conduction 
velocities, and NCS (Table 3.5), except the relation with the peroneal motor nerve 
conduction velocity. Comparison of normalised cord area after adjustment for age, height 
and weight, revealed that both Painless DPN (mean 58.8mm, 95 percent confidence interval 
56.7-60.7) and Subclinical DPN (61.5mm, 58.8-64.2) groups had a significantly lower 
normalised cord area compared to No DPN patients (67.8mm, 64.7-70.9) [p<0.0001 and 
p=0.02 respectively]. The difference in normalised cord area measurements between 
Painless DPN and Subclinical DPN did not reach statistical significance [p=0.11]. 
Furthermore, diabetic patients with No DPN had normalised cord area measurements, which 
were not statistically different from Healthy Volunteers (69.2mm, 66.4-72.0) and hereditary 
sensory motor neuropathy patients (69.1mm, 64.2-74.1) [p=0.51 and p=0.98 respectively]. 
When compared with hereditary sensory motor neuropathy, diabetic patients with Subclinical 
DPN and Painless DPN had a lower normalised cord area [p<0.0001 and p=0.01 
respectively].
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Table 3.4: Relation Between Actual Spinal Cord Area and C lin ica l and
N europhysio logica l Assessm ents D iabetic Patients.
Actual Cord Area, adjusted for age, height, weight and A-P diameter
P 95% Cl Partial r p-value
SV 0.17 0.06:0.27 0.32 0.002
SA 0.20 -0.10:0.49 0.14 0.18
PV 0.32 0.07:0.56 0.27 0.01
PA 0.29 -0.42:1.00 0.09 0.42
HRDB 3.62 -5.93-13.18 0.09 0.45
Vib JND -0.47 -1.07-0.12 -0.17 0.12
NCS -0.36 -0.56--0.16 -0.35 0.001
NSS -1.00 -1.70:0.28 -0.28 0.01
NSS+ NIS LL -0.26 -0.41:0.11 -0.34 0.001
Sural sensory nerve conduction velocity (SV, m/s), sural sensory nerve action potential 
(SA, mA), common peroneal nerve conduction velocity (PV, m/s), common peroneal 
compound muscle action potential (PA, mA), Neuropathy Symptom Score (NSS), 
Neuropathy Impairment Score of the Lower Limbs (NIS LL), ¡3  is the linear regression 
coefficient, indicating the change in cord area (in mm2) per unit change in each of the 
independent variables. Partial r is the partial correlation coefficient obtained from the 
linear regression model. 95 percent confidence interval (95%CI).
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Table 3.5: Relation Between Norm alised Spinal Cord Area and C lin ica l and
N europhysio logica l Assessm ents Diabetic Patients.
Normalised Cord Area, adjusted for age, height, weight
Partial r P-value
SV 0.28 0.01
SA 0.14 0.20
PV 0.18 0.10
PA -0.02 0.82
NSS -0.25 0.01
HRDB 0.11 0.31
Vib JND -0.17 0.10
NCS -0.27 0.01
NSS+NIS LL -0.28 0.01
Sural sensory nerve conduction velocity (SV, m/s), sural sensory nerve action potential 
(SA, mA), common peroneal nerve conduction velocity (PV, m/s), common peroneal 
compound muscle action potential (PA, mA), Neuropathy Symptom Score (NSS), R-R 
variability with heart rate deep breathing (HRDB), vibration “just noticeable difference” (Vib 
JND) Neuropathy Impairment Score of the Lower Limbs (NIS LL). Partial r is the partial 
correlation coefficient obtained from the linear regression model. The normalised cord 
area is the cord area divided by the antero-posterior diameter of the spinal canal.
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Figure 3.2: Group spinal cord area measurements
A Actual spinal cord area (mm2, mean + 95 percent confidence interval) per group, adjusted for age, height, weight and antero­
posterior diameter of the spinal canal. P-value for trend inverse linear relation of actual cord area in diabetic groups: 0.001.
B Normalised spinal cord area (mm, mean + 95 percent confidence interval) per group, adjusted for age, height and weight.
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3.5 D iscussion
Distal symmetrical diabetic polyneuropathy has traditionally been considered a disease of 
the peripheral nerve only, with potentially Important areas such as the spinal cord being 
largely overlooked. In a pilot study, using an MR imaging technique, Eaton et al 
demonstrated that cervical spinal cord area was significantly reduced in advanced DPN 
compared to normal control patients (Eaton, Harris et al. 2001). In this larger study we 
confirmed the results of the pilot study and, more importantly, also clearly demonstrate that 
spinal cord atrophy is an early process being present not only in Painless DPN but also even 
in patients with relatively modest impairments of nerve function (Subclinical DPN). The 
significant trend across diabetic groups and the continuous relations found with the NCS 
indicate a continuing loss of cord area as the disease progresses. Significant correlations 
were found between cord area and neurophysiological parameters. Cord area was not 
significantly different between age and sex matched Healthy Volunteers and diabetic 
patients without DPN. In contrast, unlike DPN, patients with hereditary sensory motor 
neuropathy (neuropathy control group) had normal cord areas suggesting that the 
pathological process in this disease is confined to the peripheral nerve.
Actual spinal cord area measurements are well recognized to be affected by patient 
demographics and positioning in the scanner (Sanfilipo, Benedict et al. 2004). We therefore, 
carefully accounted for these variations using two methods, both of which indicated early 
involvement of the spinal cord in DPN. The first employed a statistical method, which 
adjusted group means of actual cord area for age, weight, height and AP canal diameter. 
The second technique involved calculating a normalised cord area before adjusting group 
means for age weight and height. This “normalisation”, as used in studies of brain atrophy, is 
not only an individualised index of cord atrophy but also minimises the effects of patient 
positioning in the scanner. In addition, systematic errors were minimised by employing a 
semi-automated computerised technique for measuring actual cord cross-sectional areas
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(Losseff, Webb et al. 1996). These steps taken improved both the precision and accuracy 
and hence reliability of the technique.
The San Antonio Consensus Conference on Diabetic Neuropathy recommended 
that, for full classification of DPN, at least one measure from each of the following categories 
needs to be assessed: DPN symptoms, clinical examination, electrodiagnostic tests, 
quantitative sensory tests and autonomic function tests (ADA 1988). All these clinical and 
neurophysiological assessments were carried out in each patient to accurately characterise 
DPN. We then used the NCS, derived from the sum of the NIS LL+7 tests, to quantify the 
severity of DPN. The NCS has been shown to be more sensitive and reproducible than 
single attributes of nerve function for the detection and staging of DPN (Dyck, Litchy et al. 
2003). In the present study, a minimum score of 4.5 was used to diagnose Painless DPN. 
However, we regard DPN as a disease continuum, and therefore studied patients with NCS 
between 1 and 4.5. This, “Subclinical DPN” group, although not fulfilling minimal criteria for 
the diagnosis of DPN, nonetheless has evidence of impaired nerve function. Thus, the 
detection and accurate quantification of DPN, crucial for the study, was conducted using well 
validated methods by a trained physician (Dyck and Thomas 1999).
The findings of this study clearly demonstrate that the neuropathic process in man is 
not confined to the peripheral nerve and does involve the spinal cord. Worryingly, this occurs 
early in the neuropathic process. Even at the Subclinical DPN stage, extensive and perhaps 
even irreversible damage may have occurred. Indeed, with these results in mind, it is not 
surprising that the variety of therapeutic options so far attempted in DPN have not been 
successful (Pfeifer and Schumer 1995).
A group of patients with hereditary sensory motor neuropathy, an autosomal 
dominant inherited form of neuropathy, was studied to represent a disease control group as 
1) it is well recognized to only affect the PNS and 2) vascular factors have not been 
implicated in its pathogenesis (Harding and Thomas 1980; Llewelyn, Thomas et al. 1988).
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The absence of spinal cord involvement in hereditary sensory motor neuropathy argues 
against a “dying back” mechanism, i.e. peripheral nerve damage causing secondary spinal 
cord “shrinkage” in a progressive “dying back” fashion, in DPN. Hence, it is likely that the 
insult of diabetes is generalised, concomitantly affecting the PNS and CNS. The significant 
correlation between neurophysiological parameters and cord area in DPN supports this.
There is increasing evidence for the involvement of microvascular factors in the 
pathogenesis of axonal loss in the peripheral nerve (Malik 1997). Nerve biopsy and in-vivo 
studies in man have revealed the presence of endoneurial microangiopathy (Malik, Tesfaye 
et al. 1994) impaired nerve blood flow (Tesfaye, Harris et al. 1993; Eaton, Harris et al. 2003) 
and nerve hypoxia (Newrick, Wilson et al. 1986). Additionally, the severity of peripheral 
nerve fiber loss correlates with the degree of endoneurial microangiopathy. Post-mortem 
findings of microvascular disease within the spinal cord (Olsson, Save-Soderbergh et al. 
1968), similar to that seen in the peripheral nerve (Tesfaye, Malik et al. 1994), suggest that 
the same pathogenic mechanisms may be involved in both areas. It is, therefore, likely that 
the metabolic insult of diabetes (hyperglycemia, insulin resistance, dyslipidemia, 
hypertension etc.) has a generalised effect on the nervous system with similar vascular 
processes and axonopathy (neuronal loss) resulting in the observed cord atrophy in DPN 
(DeFronzo, Hendleretal. 1982; Tesfaye, Stevens etal. 1996).
Our secondary objective was to evaluate the effectiveness of this technique as an 
early marker for DPN, as we currently have no “microalbuminuria equivalent” for DPN. By 
the time DPN is clinically detectible, severe peripheral nerve fiber loss and endoneurial 
microangiopathy is present (Malik, Veves et al. 2001). Furthermore, unlike other 
microvascular complications of diabetes, the early diagnosis of DPN currently relies on a 
combination of detailed clinical and neurophysiological assessments, that not only are time 
consuming and costly, but also have major limitations including high inter-observer 
variability, insensitivity to changes over time and non-linearity of the measured parameters 
(Perkins and Bril 2003). Our findings suggest that spinal cord cross-sectional area
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measurement using this quick, non-invasive and operator independent MR technique, may 
serve as an additional tool in the early detection and accurate quantification of DPN.
Finally, this demonstration of early spinal cord involvement builds on a history of hints 
throughout the literature that DPN is more than just a disease of the peripheral nerve, and 
calls into question the concept of pure “peripheral” diabetic neuropathy. Apart from 
glycaemic control, there are no treatments that are able to halt the neuropathic process in 
diabetes. A complete understanding of the full extent of CNS involvement is crucial to 
elucidating the pathogenesis of DPN and facilitating the development of rational treatments. 
Recognition that DPN is, in part, a disease which affects the whole nervous system, should 
trigger a critical rethinking of this disorder, opening a new direction for further research. 
Prospective studies are now required to determine the natural history of cord involvement In 
DPN.
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4 THALAMIC NEURONAL DYSFUNCTION IN PATIENTS WITH TYPE I DIABETES
MELLITUS AND CHRONIC SENSORIMOTOR DISTAL SYMMETRICAL 
POLYNEUROPATHY
4.1 Introduction
Diabetes is a leading cause of neuropathy (Boulton, Malik et al. 2004) with important 
associated health (Jeffcoate and van Houtum 2004) and economic implications (Boulton 
1997). Relatively little is known about the pathophysiology underlying DPN (Dyck and 
Giannini 1996; Cameron, Eaton et al. 2001; Malik, Veves et al. 2001) although it has recently 
been shown to be associated with cardiovascular risk factors (Tesfaye, Chaturvedi et al. 
2005).
Research into DPN has focused mainly on the PNS with CNS involvement being 
overlooked. However, we have demonstrated a significantly lower cross-sectional area of the 
cervical spine in DPN on MR imaging (Eaton, Harris et al. 2001). In Chapter 3, we reported 
that spinal cord ‘atrophy* is present not only in patients with Painless DPN but also in those 
with early (Subclinical) DPN (Selvarajah, Wilkinson et al. 2006). This suggests that the 
metabolic insult of diabetes has a generalised effect on the whole nervous system, and has 
made us question whether the brain too may be involved.
Anatomical studies have demonstrated that ascending sensory pathways of the 
spinal cord terminate within the thalamus before higher order sensory projections are sent to 
the cortex (Wilson, Kitchener et al. 1999). The representation of body surface in the form of 
somatotopic maps is a fundamental feature of somatosensory organisation. Such maps have 
been demonstrated at all levels of the somatosensory system including the thalamus in 
many mammalian species. Within the central core of the ventroposterior thalamus, the tactile 
receptors of the body surface are represented as a single complete map of the contralateral 
body. In apparently all mammals, the central region of the ventroposterior complex Is 
composed of a lateral division (VPI), which represents the body and a medial division (VPm),
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which represents the face (Figure 4.1). The thalamus is not merely the principal sensory 
relay station but is thought to processes/modulates the information that is presented to the 
cortex. It is exposed to rich modulatory influences that come from the cortex, the thalamic 
reticular nucleus, and the brain stem (Sherman and Guillery 2002). This modulation 
represents an important function of the thalamic relay, allowing it to modulate transmission to 
the cortex in accord with current attentional needs. The modulation can be global or it can be 
highly localised and specific; it can allow for changing interactions between one circuit (or 
part of one circuit) and another in a complex pattern of interactions. Hence, in the presence 
of sensory nerve dysfunction that accompanies painless DPN, the specific aim of this study 
was to investigate whether thalamic function is also impaired.
Figure 4.1 : Somatotropic representation of tactile receptors of the body surface in the 
thalamus. VPL, ventroposterior lateral, VPM, ventroposterior medial.
The investigative modality used to test this hypothesis was H-MRS. In-vivo H-MRS is 
a non-invasive technique that can provide metabolic information from different body tissues, 
including the brain. In the latter context, it has been used to study the classification and 
pathophysiology of various neurological conditions including neoplasms, viral and retroviral 
infections, ischaemia, demyelination and some forms of epilepsy and dementias. 
Spectroscopy and imaging can be performed during the same patient examination, the 
information yielded by H-MRS often being considered an adjunct to that provided by imaging
MEDIAL
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(Wilkinson, Griffiths et al. 2001). Indeed, in some pathologies, neurochemical abnormalities 
may be present on H-MRS prior to abnormalities being detected on imaging (Wilkinson, 
Hadjivassiliou et al. 2005). Conventional MRI and H-MRS rely on the same physical 
principles to collect the MR signal, but differ in the way the data is processed, displayed, and 
interpreted. H-MRS, as used in the present study, produces spectra that contain several 
resonances or peaks. In brain parenchyma, the three major peaks detected are due to N- 
acetyl groups, total creatine (Cr) and choline (Cho) containing compounds. 
Immunohistochemical studies have suggested that N-Acetyl Aspartate (NAA), the major 
constituent of the N-acetyl group resonance at long echo time (TE), is localised exclusively 
in neurons and their processes throughout the CNS (Moffett, Namboodiri et al. 1991; 
Simmons, Frondoza et al. 1991; Urenjak, Williams et al. 1993).
In-vivo cerebral NAA determined using H-MRS has been shown to correlate with 
histological neuronal density in a variety of animal models (Wilkinson, Lunn et al. 1997). It is 
also used as a surrogate neuronal marker for the assessment of neuroprotective therapeutic 
compounds/strategies in humans (Matthews, Andermann et al. 1990). It Is generally 
accepted that the NAA resonance on H-MRS can provide a useful marker for brain neuronal 
and axonal integrity in-vivo (De Stefano, Matthews et al. 1995; Tsai and Coyle 1995; Hugg, 
Kuzniecky et al. 1996; Nakano, Ueda et al. 1998).
An H-MRS study was conducted utilising NAA resonance as a surrogate marker for 
neuronal function to test the hypothesis that damage to the peripheral sensory nerves 
caused by diabetes mellitus may be accompanied by thalamic neuronal dysfunction. This 
study also aimed to characterise the relationship between thalamic neuronal biochemistry 
and traditional neurophysiological assessments of the peripheral nerves reflecting severity of 
painless DPN.
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4.2 Methods
4.2.1 Patients
Twenty eight right handed male patients with diabetes from the Royal Hallamshire Hospital 
Diabetes Register were screened for the study. To be eligible, participants had to fulfil the 
following inclusion criteria: type 1 diabetes diagnosed for more than five years and age 
between 1 8 - 6 5  years. Patients were excluded for the following reasons: cerebrovascular 
disease, significant back problems (either known degenerative back disease or symptoms 
which have occurred on a regular basis, or have required consultation for investigation and 
treatment), history of spinal trauma, non diabetic neuropathies, history of alcohol 
consumption of more than 20 units a week (one measure of alcohol e.g. glass of wine equals 
one unit), diabetic neuropathies other than DPN (e.g. mononeuropathies, proximal motor 
neuropathies etc), painful DPN, internal diseases potentially affecting cerebral metabolism 
(hepatic disease, Cushing’s disease etc), diabetic ketoacidosis in the preceeding six months, 
hypoglycaemia in the previous 24 hours, claustrophobia or factors which precluded MR 
imaging (e.g. cardiac pacemaker). Six age- and sex-matched non-diabetic Healthy 
Volunteers were also recruited. All patients gave written, informed consent before 
participation in the study, which had prior approval by the South Sheffield Regional Ethics 
Committee.
4.2.2 Assessment of neuropathy
Detailed neurological assessment was undertaken to identify the presence and quantify the 
severity of neuropathy in each patient. Neuropathic symptoms were documented by 
completion of the NSS questionnaire and then the outcome of a detailed neurological 
examination was graded by defined criteria according to the standard NIS questionnaire 
(Dyck and Thomas 1999). All patients underwent: 1) perception cooling detection thresholds 
acquired from the dorsal aspect of the right foot using the Computer Assisted Sensory 
Evaluation IV (CASE IV, W.R. Electronics, Stillwater, MN, USA) system employing standard
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techniques (Dyck, O'Brien et al. 1993; Dyck, Zimmerman et al. 1993); 2) cardiac autonomic 
function tests performed with a computer assisted technique (Dyck and Thomas 1999) and 
3) nerve conduction studies performed, at a stable skin temperature of 31°C and a room 
temperature of 24°C, using a Medelec electrophysiological system (Synergy Oxford 
Instruments, Oxford, UK). The following nerve attributes were measured: 1) sural sensory 
nerve action potentials and conduction velocities and 2) common peroneal and tibial motor 
nerve distal latency, compound muscle action potential and conduction velocity. Further 
details on the neurophysiological procedures employed can be found in Appendix 2.
Based on these clinical and neurophysiological assessments diabetic patients were 
divided into two groups: 1) No DPN consisting of asymptomatic patients with normal clinical 
and neurophysiological assessments; 2) Painless DPN, comprising of pain free patients with 
both clinical and neurophysiological abnormalities (at least two abnormalities of 
neurophysiologic assessment)(ADA 1988). In addition, a NCS derived from the assessments 
described above (NISLL+7) was calculated (Dyck, Davies et al. 1997; Dyck, Litchy et al. 
2003). A full description of the method of calculation has been described in Appendix 2. This 
scoring system takes into account the findings of neurological examination and 
neurophysiological assessments with a higher score indicating a more severe neuropathy.
4.2.3 Magnetic resonance spectroscopy protocol
All patients underwent H-MRS examination on a 1.5T MR system (Eclipse, Philips Medical 
Systems, Cleveland, Ohio) using a standard quadrature receive-only head coil. Prior to 
spectroscopy, a set of transaxial T2-weighted images (TE=90ms; TR=10500ms, ETL=16; 30 
contiguous slices of thickness 5mm; acquisition matrix=256x256 over a 240mm field of view) 
was acquired using a fast-spin-echo technique to guide the placement of the spectroscopic 
region-of-interest. Single-voxel spectra were obtained from an 8ml cubic volume of interest 
placed within the right thalamus to encompass the ventral posterior lateral sub-nucleus
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(Figure 4.2). Care was taken to avoid inclusion of ventricular CSF within the spectroscopic 
voxel. Two spectra were acquired from each patient:
1) Long echo time (long TE) (TE=135ms, TR=1600ms) using a point-resolved (PRESS) 
technique (Figure 4.3).
2) Short echo time (short TE) (TE=20ms, TR=5000ms) a using a stimulated-echo 
acquisition mode (STEAM) technique with a mixing time of 12ms (Figure 4.4).
Figure 4.2: Axial section of the brain with voxel positioned to encompass the 
ventroposterior thalamic subnucleus.
:-i Ji
v \i \,\
‘A
I l \  * W  r '  \  n
\ J VVi
Il II fm  i fu  11 f i i 11 fi l II 111 Ì i f i III,
Figure 4.4
Figure 4.3: Example spectra obtained at long echo time using a point-resolved acquisition 
technique.
Figure 4.4: Example spectra obtained at short echo time using a stimulated-echo acquisition 
technique.
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For each acquisition, an automated shimming algorithm was used prior to water 
suppression to maximise the homogeneity of the magnetic field within the spectroscopic 
volume of interest. Following shimming, the optimum amplitude of the water suppression 
pulse was determined manually in an iterative fashion. A total of 1024 data points were 
sampled and averaged 192 times on both occasions. A reference water spectrum 
(suppression pulse set at zero) was obtained automatically following the acquisition of the 
water suppressed data.
4.3 Data analysis
MR spectra were analysed and reviewed independently by an MR physicist with extensive 
experience using H-MRS in neurological diseases and clinical research studies. Throughout 
the analyses the assessor was unaware of the group classification of individual patients. All 
post acquisition processing was performed using fully integrated proprietary software from 
the manufacturer of the MR system. By convention long TE results are expressed as ratios 
under the three prominent resonances assigned to Cho (3.22ppm), Cr (3.02ppm) and NAA 
(2.02ppm) ie. NAA:Cho; NAA:Cr and Cho:Cr ratios. Short TE results were calculated as the 
areas under the myo-lnositol (ml at 3.56ppm), Cho (3.22ppm), Cr (3.02ppm) and NAA 
(2.02ppm) resonances relative to that of unsuppressed water.
4.3.1 Statistical method
All analyses were performed using the statistical package SPSS 11.1. Subgroup 
demographics were described as means and standard deviation for normally distributed 
variables and as medians and 5th and 95th percentiles for variables with a skewed 
distribution.
The appropriate tests for normality were conducted to guide subsequent statistical 
analysis. The appropriate tests for normality were conducted to guide subsequent analysis. 
Subgroup H-MRS metabolite endpoints were compared using non-parametric tests
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(Kruskal-Wallis). Any relationships between these endpoints and neurophysiological 
assessments were analysed in more detail among participants with diabetes, using 
Spearman’s rank correlation coefficients.
4.4 Results
4.4.1 Subgroup Demographics
Demographics of the study groups are summarised in Table 4.1. The mean ages, height and 
weight of the Painless DPN, No DPN and Healthy Volunteer groups were not significantly 
different (ANOVA, p=0.63, 0.62, 0.12 respectively). As expected, patients in the DPN group 
had a longer duration of diabetes (p=0.02) and higher HbA1c levels (p=0.02).
Table 4.1: Subgroup Demographics [mean(SD)].
HV No DPN Painless DPN
Group Size (n) 6 8 10
Age (years) 42.5(15.4) 42.9(8.7) 48.3(11.5)
DD (years)* N/A 11.6(7.7) 22.1(8.8)
HbA1c (%)* N/A 7.8(0.9) 9.1(1.2)
Weight (Kg) 82.7(15.1) 91.6(15.6) 80.0(6.9)
Height (m) 176.2(13.6) 171.6(6.4) 178.6(5.3)
NCS N/A 0.57(0.8) 7.83(3.3)
HV, Healthy Volunteers; No DPN, Diabetic patients with no neuropathy; Painless DPN, 
Diabetic patients with painless neuropathy. DD, Diabetes Duration, NCS, Neuropathy 
Composite Score, N/A, not applicable. * denotes statistically significant difference between 
No DPN and Painless DPN (p=0.02).
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4.4.2 MR spectroscopy assessments
The Painless DPN group had lower mean NAA:Cr ratios at long TE (median [range] 1.55 
[0.81]; p=0.04) than No DPN participants (1.79 [0.98]) and healthy volunteers (1.90 [0.42]) 
(Table 4.2, Figure 4.5a). NAA:Cho ratio was also lowest In participants with Painless DPN 
(1.55 [0.56]; p=0.02) compared with No DPN (1.80 [0.46]) and healthy volunteers (0.76 
[0.28], Figure 4.5b). The Cho:Cr ratio obtained at long TE did not vary significantly between 
the groups (Painless DPN 1.04 [0.6], No DPN 0.95 [0.82], Healthy Volunteers 1.06 [0.76]; 
p-0.87).
Analysis of mean NAA metabolite resonances obtained at short-TE revealed no 
statistically significant difference between these groups (p=0.07). No significant differences 
were observed with any of the other metabolites at short TE between any of the groups.
4.4.3 Spectroscopy and neurophysiological correlations
A significant positive association between both sural amplitude (r =0.61, p=0.004) 
and sural nerve conduction velocity (r =0.58, p=0.006) and long TE NAA:Cr ratio signal was 
observed among participants with diabetes. In addition, the NAA:Cr ratio signal was 
significantly associated with peroneal latency (r =-0.53, p=0.01), amplitude (r =0.67, 
p=0.001) and velocity (r =0.37, p=0.06) In this group. Similar correlations among participants 
with diabetes were noted with tibia! nerve latency (r =-0.51, r=0.02), but not with velocity (r 
=0.23, p=0.18). In this groups, vibration perception threshold was related to NAA:Cho ratio at 
a significant level (r =-0.70, p=0.004), and we also observed a significant correlation 
between heart rate variability with deep breathing and NAA:Cr ratio (r =-0.46, p<0.05). In 
addition, the NAA:Cr ratio was also found to relate to overall NCS (r =-0.53, p=0.03) among 
diabetic participants.
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Table 4.2: H-MRS subgroup m etabolite ra tios (acquired at long echo tim e) and 
m etabolite areas relative to  that o f unsuppressed water (acquired at short echo 
time).
Healthy Volunteers No DPN Painless DPN
Long TE
NAA:Cho 1.74(0.11)* 1.80(0.15)* 1.58(0.16)*
NAA:Cr 1.87(0.15) 1.82(0.35) 1.55(0.24)
Cho:Cr 1.08(0.14) 0.95(0.28) 1.01(0.13)
Short TE
NAA 0.78(0.08) 0.88(0.10) 0.77(0.11)
Cho 0.52(0.16) 0.50(0.11) 0.49(0.16)
Cr 0.60(0.18) 0.58(0.19) 0.59(0.06)
N-Acetyl Aspartate to Choline ratio (NAA:Cho), N-Acetyl Aspartate to Creatine ratio 
(NAA:Cr), Choline to Creatine ratio (Cho:Cr), N-Acetyl Aspartate (NAA), Choline (Cho), 
Creatinine (Cr). No DPN, diabetic patients with no neuropathy, Painless DPN, diabetic 
patients with painless DPN. Results are given as mean (SD) for variables with a normal 
distribution. * ANOVA p=0.01, Painless DPN vs No DPN p=0.005, Painless DPN vs 
Healthy Volunteers p=0.004.
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Figure a Figure b
Figure 4.5 a and b: Mean N-Acetyl Aspartate/Choline [NAA/Cho (A)] and N-Acetyl Aspartate/Creatine [NAA/Cr (B)] ratios at long echo 
time in Healthy Volunteers (HV), diabetic patients with neuropathy (Painless DPN) and no neuropathy (No DPN).
The inferior and superior margins of each box represent the first and third quartiles, the central line is the mean, and the bars at either end 
represent the standard deviations. 0 represents outliers. * ANOVA p=0.01, Painless DPN vs No DPN p=0.005, Painless DPN vs Healthy 
Volunteers p=0.004.
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4.5 D iscussion
Distal symmetrical diabetic polyneuropathy, as the name indicates, has hitherto been 
considered a disease of the peripheral nerve. However, evidence is now emerging that the 
impact of this metabolic disorder may be more generalised than previously thought, involving 
the spinal cord. It seems logical therefore to investigate if key areas of the brain, such as the 
thalamus, may also be involved in the neuropathic process, as a fuller appreciation and 
understanding of the disease process is likely to lead to more effective treatments. All 
somatosensory information that reaches the cerebral cortex from the spinal cord must first 
pass through the thalamus, which controls the flow of information to the cortex and 
subcortical nuclei. The ventral posterior lateral nucleus of the thalamus contains the 
somatosensory representation of the contralateral body surface and serves as an 
information modulator for this region.
Using the spectroscopic resonance attributable to NAA as a surrogate marker of 
neuronal involvement, we aimed to address the question whether thalamic sensory neuronal 
function is impaired in DPN. H-MRS has been used to investigate a wide range of CNS 
diseases; to the best of our knowledge no H-MRS study has been previously reported 
showing alterations in thalamic metabolites in patients with DPN.
The main finding of this preliminary study is the significantly lower long TE thalamic 
NAA/Cho ratio in the group of patients with Painless DPN compared to patients with No DPN 
and Healthy Volunteers. The data also demonstrates significant correlations between short 
TE signal from NAA and neurophysiological markers (overall NCS and individual nerve 
function tests) of DPN severity.
N-acetyl Aspartate is one of the highest concentrations of free amino acids in the 
brain. It is widely used as a neuronal marker of both brain pathology and disease 
progression in the CNS. The compound, when present in the brain appears to reflect a high
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degree of cellular integration, and therefore may be a unique metabolic construct of the 
Intact vertebrate brain. It is believed that a reduction in the NAA resonance or NAA/Cho ratio 
is associated with neuronal and/or axonal loss, loss of neuron viability and dysfunction. By 
showing metabolite signal changes, our results may reflect the presence of thalamic 
neuronal dysfunction in patients with Painless DPN. As NAA is measured in a voxel i.e. a 
unit of volume, reduction in NAA could be due to either a decreased density of neurons or a 
change in neurochemistry accompanying neuronal injury/dysfunction. We used two H-MRS 
acquisition techniques at different echo times (short TE and long TE) to interrogate NAA 
signals within the ventral posterior lateral thalamic subnucleus. Each technique can provide 
unique information on the structure and function of neuronal cell bodies and axons. Reduced 
NAA signal at short TE is thought to represent irreversible neuronal loss/shrinkage whereas 
possible reversible neuronal injury/dysfunction can be implicated when the NAA/Cho signal 
ratio is reduced at long TE [17]. We demonstrated a significant difference in NAA/Cho ratio 
at long TE but no significant difference in the NAA resonance at short TE between the 
patient groups. In such a scenario our findings may reflect thalamic neuronal dysfunction in 
DPN rather than overt neuronal death.
Previous H-MRS studies in diabetes have mainly focused on its metabolic impact on 
the developing brain (Cameron, Kean et al. 2005; Sarac, Akinci et al. 2005) and the cerebral 
consequences of hypoglycaemia (Criego, Tkac et al. 2005; Rankins, Wellard et al. 2005) or 
diabetic ketoacidosis (Wootton-Gorges, Buonocore et al. 2005). Observations of cerebral 
NAA-moeties in diabetes mellitus that have previously been reported are contradictory. Kreis 
et al. found several metabolic abnormalities in the brain of patients with diabetes (Kreis and 
Ross 1992). In particular they found a significantly lower NAA/Cr ratio in the parietal region 
of patients with diabetes compared with that in age-matched controls. This contrasts with a 
study by Geissler et al. that found no differences in NAA signal between patients with 
diabetes and Healthy Volunteers in either the parietal or the occipital lobes (Geissler, Frund
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et al. 2003). Neither of these studies, however, performed detailed neurophysiological 
assessments to quantify DPN nor focused H-MRS examination on the thalamus.
The mechanism of thalamic involvement is unclear. One possible explanation for 
thalamic neuronal dysfunction in DPN may be that loss of afferent input, as a result of 
peripheral nerve damage, subsequently causes changes to occur at progressively higher 
levels in the CNS (“dying back” mechanism). The correlations observed between NAA 
acquired at short TE, duration of diabetes and severity of neuropathy would seem to support 
this. Another possible explanation is that the observed changes in the thalamus may be 
occurring concomitantly to the changes seen in the PNS. Nonetheless, thalamic neuronal 
involvement whether early, late or concomitant, is likely to result in disturbed sensory gating 
in DPN. This may have consequences on sensory perception and pain modulation. Further 
studies utilising these techniques on a subgroup of patients with painful DPN are necessary 
to elucidate this.
Taken together with the previously described early spinal cord involvement in DPN, 
the possibility of thalamic sensory neuronal dysfunction suggests that nervous system 
involvement is not merely confined to the peripheral nerves but involves the spinal cord and 
brain. Prospective studies are required to determine at what stage during the course of the 
disease these abnormalities occur. It is noteworthy that a variety of therapeutic interventions 
specifically targeted at peripheral nerve damage in DPN have thus far been ineffective, and 
it is possible that this may in part be due to inadequate appreciation of the full extent of CNS 
involvement in DPN.
Major advances in non invasive MR imaging including H-MRS, tractography and 
functional MR imaging offer non-invasive techniques capable of elucidating various aspects 
of brain pathophysiology and function in DPN. Recognition that DPN is, in part, a disease 
which affects the whole nervous system, should trigger a critical rethinking of this disorder, 
opening a new direction for further research.
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5 RAISED LEVELS OF GLUTAMATE/GLUTAMINE IN DIABETES, A CLUE TO THE 
PATHOGENESIS OF THALAMIC NEURONAL DYSFUNCTION IN DISTAL
SYMMETRICAL DIABETIC POLYNEUROPATHY
5.1 Introduction
Distal symmetrical diabetic sensory motor neuropathy is one of the commonest 
diseases to affect the nervous system and a leading cause of amputations in the western 
world (Hollingshead 1991). Involvement of the CNS is increasingly being recognised. Using 
H-MRS, we have reported the presence of thalamic neuronal dysfunction in patients with 
Painless DPN (Selvarajah, Wilkinson et al. 2008). The thalamus plays a central role in 
somatosensory perception (Wilson, Kitchener et al. 1999) and understanding the 
pathological changes that lead to thalamic impairment is vitally important. Although these 
changes are currently unknown, it is likely that metabolic and vascular processes that have 
been implicated in the pathogenesis of diabetic microvascular complications are involved.
In this chapter the possible role of metabolic factors in the pathogenesis of thalamic 
neuronal dysfunction in DPN were examined. Glutamate is the main excitatory 
neurotransmitter in the brain (Shepherd and Huganir 2007) and has been implicated in the 
induction of neuronal injury and apoptosis in several neurodegenerative disorders (e.g. 
Alzheimer’s disease) (Mattson and Magnus 2006). Astrocytes are essential for maintaining 
cerebral glutamate homeostasis, responsible for recycling released glutamate back to 
neurons in the form of glutamine (Takahashi, Billups et al. 1997). Thalamic astrocyte 
dysfunction may contribute to elevated extracellular glutamate, and hence exictotoxicity to 
thalamic neurons and glia in diabetic patients with DPN. Little is known regarding changes in 
glutamate levels In the thalamus In diabetics patients with DPN.
This study used H-MRS to assess thalamic metabolite abnormalities in diabetic 
patients with DPN. We hypothesized that diabetic patients would show elevated 
glutamate/glutamine (Glx) resonance due to a hyperglutamertergic state, decreased
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myoinnositol (ml), an astrocyte marker, due to possible astrocyte dysfunction (Brand, 
Richter-Landsberg et al. 1993).
5.2 Methods
5.2.1 Patients
Twenty four right handed male patients with diabetes from the Royal Hallamshire Hospital 
Diabetes Register were screened for the study. To be eligible, participants had to fulfil the 
following inclusion criteria: type 1 diabetes diagnosed for more than five years and age 
between 1 8 - 6 5  years. Patients were excluded for the following reasons: cerebrovascular 
disease, significant back problems (either known degenerative back disease or symptoms 
which have occurred on a regular basis, or have required consultation for investigation and 
treatment), history of spinal trauma, non diabetic neuropathies, history of alcohol 
consumption of more than 20 units a week (one measure of alcohol e.g. glass of wine equals 
one unit), diabetic neuropathies other than DPN (e.g. mononeuropathies, proximal motor 
neuropathies etc), painful DPN, internal diseases potentially affecting cerebral metabolism 
(hepatic disease, Cushing’s disease etc), diabetic ketoacidosis in the preceeding six months, 
hypoglycaemia in the preceding 24 hours, claustrophobia or factors which precluded MR 
imaging (e.g. cardiac pacemaker). Six age- and sex-matched non-diabetic Healthy 
Volunteers were also recruited. All patients gave written, informed consent before 
participation in the study, which had prior approval by the South Sheffield Regional Ethics 
Committee.
5.2.2 Assessment of Neuropathy
Detailed neurological assessment was undertaken to identify the presence and quantify the 
severity of neuropathy in each patient. Neuropathic symptoms were documented by 
completion of the NSS questionnaire and then the outcome of a detailed neurological 
examination was graded by defined criteria according to the standard NIS questionnaire
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(Dyck and Thomas 1999). All patients underwent: 1) vibration and cooling perception 
thresholds acquired from the dorsal aspect of the right foot using the Computer Assisted 
Sensory Evaluation IV (CASE IV, W.R. Electronics, Stillwater, MN, USA) system employing 
standard techniques (Dyck, O'Brien et al. 1993; Dyck, Zimmerman et al. 1993); 2) cardiac 
autonomic function tests performed with a computer assisted technique (Dyck and Thomas 
1999) and 3) nerve conduction studies performed, at a stable skin temperature of 31 °C and 
a room temperature of 24°C, using a Medelec electrophysiological system (Synergy Oxford 
Instruments, Oxford, UK). The following nerve attributes were measured: 1) sural sensory 
nerve action potentials and conduction velocities and 2) common peroneal and tibial motor 
nerve distal latency, compound muscle action potential and conduction velocity. Please refer 
to Appendix 2 for further details on the neurophysiological procedures employed.
Based on these clinical and neurophysiological assessments diabetic patients were 
divided into two groups: 1) No DPN consisting of asymptomatic patients with normal clinical 
and neurophysiological assessments; 2) Painless DPN, comprising of pain free patients with 
both clinical and neurophysiological abnormalities (at least two abnormalities of 
neurophysiologic assessment) (ADA 1988). In addition, a NCS derived from the 
assessments described above (NISLL+7) was calculated (Dyck, Davies et al. 1997; Dyck, 
Litchy et al. 2003). A full description of the method of calculation is described in Appendix 2. 
This scoring system takes into account the findings of neurological examination and 
neurophysiological assessments with a higher score indicating a more severe neuropathy.
5.2.3 Magnetic Resonance Spectroscopy Protocol
All patients underwent H-MRS examination on a 1.5T MR system (Eclipse, Philips Medical 
Systems, Cleveland, Ohio) using a standard quadrature receive-only head coil. Prior to 
spectroscopy, a set of transaxial T2-weighted images (TE=90ms; TR=10500ms, ETL=16; 30 
contiguous slices of thickness 5mm; acquisition matrix=256x256 over a 240mm field of view) 
were acquired using a fast-spin-echo technique to guide the placement of the spectroscopic
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region-of-interest. Single-voxel spectra were obtained from an 8ml cubic volume of interest 
placed within the right thalamus to encompass the ventral posterior lateral sub-nucleus 
(Figure 4.2). Care was taken to avoid inclusion of ventricular CSF within the spectroscopic 
voxel. Short echo time (short TE, TE=20ms, TR=5000ms) a using a stimulated-echo 
acquisition mode (STEAM) technique with a mixing time of 12ms.
For each acquisition, an automated shimming algorithm was used prior to water 
suppression to maximise the homogeneity of the magnetic field within the spectroscopic 
volume of interest. Following shimming, the optimum amplitude of the water suppression 
pulse was determined manually in an iterative fashion. A total of 1024 data points were 
sampled and averaged 192 times on both occasions. A reference water spectrum 
(suppression pulse set at zero) was obtained automatically following the acquisition of the 
water suppressed data.
5.3 Data Analysis
MR spectra were analysed and reviewed independently by an MR physicist with extensive 
experience using H-MRS in neurological diseases and clinical research studies. Throughout 
the analyses the assessor was unaware of the group classification of Individual patients. All 
post acquisition processing was performed using fully integrated proprietary software from 
the manufacturer of the MR system. By convention short TE results were calculated as the 
areas under the Glx (2.1-2.5ppm), myo-lnositol (ml 3.56ppm) and NAA (NAA 2.02ppm) 
resonances relative to that of unsuppressed water.
5.3.1 Statistical Method
All analyses were performed using the statistical package SPSS 11.1. Subgroup 
demographics were described as means and standard deviation for normally distributed 
variables and as medians and 5th and 95th percentiles for variables with a skewed 
distribution. Analysis of variance (ANOVA) was used to compare subgroup demographics.
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The appropriate tests for normality were conducted to guide subsequent statistical analysis. 
Group (Healthy Volunteers, No DPN and Painless DPN) mean Glx and NAA metabolite 
areas at short TE relative to unsuppressed water were compared using ANOVA. Mean 
differences in cerebral metabolites were also analysed using analysis of covariance 
(ANCOVA) with age as a covariate.
5.4 Results
5.4.1 Subgroup Dem ographics
Demographic details of the study groups are summarised in Table 5.1. The mean ages, 
height and weight of the Painless DPN, No DPN and Healthy Volunteers groups were not 
significantly different (ANOVA, p=0.63, 0.62, 0.12 respectively). As expected, patients in the 
No DPN group had a longer duration of diabetes and higher HbA1c levels (p=0.02).
Table 5.1: Subgroup Demographics.
HV No DPN Painless DPN
G roup Size (n) 6 8 10
Age (years) 42.5(15.4) 42.9(8.7) 48.3(11.5)
DD (years)* N/A 11.6(7.7) 22.1(8.8)
W eight (Kg) 82.7(15.1) 91.6(15.6) 80.0(6.9)
HbA1c (%)* N/A 7.8(0.9) 9.1(1.2)
NCS N/A 0.57(0.8) 7.83(3.3)
HV, Healthy Volunteers; No DPN, Diabetic patients with no neuropathy; Painless DPN, 
Diabetic patients with neuropathy. DD, Duration of Diabetes, N/A, not applicable. NCS, 
Neuropathy Composite Score. Mean(SD), * denotes statistically significant difference 
between No DPN and Painless DPN (p=0.02).
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5.4.2 MR Spectroscopy Assessments
5.4.2.1 Glutamine and glutamate
Two patients (one patient from each diabetic subgroup) were excluded from the final 
analysis because of poor spectra quality. Spectroscopic data obtained at short TE are 
summarised in Table 5.2. In the full sample of patients with diabetes thalamic Glx levels 
were significantly higher [mean(SD) 0.47(0.12)] compared with Healthy Volunteers 
[0.27(0.13), p=0.001]. A one-way ANOVA revealed a main effect of group [Healthy 
Volunteers, 0.27(0.14); No DPN, 0.53(0.13); Painless DPN, 0.45(0.12)] on thalamic Glx 
levels (p=0.002). Post hoc pairwise comparisons showed that Healthy Volunteers had 
significantly lower Glx in comparison with all diabetic subgroups [No-DN (p=0.001; 95% 
confidence interval (95%CI) -0.41 :-0.12), Painless DPN (p=0.006; 95%CI -0.31 >0.06)]. 
There was no significant difference in Glx between diabetic subgroups (p=0.15; 95%CI - 
0.03:0.20).
5.4.2.2 myolnnositol
Mean ml signal of patients with diabetes [0.38(0.16)] was lower compared with Healthy 
Volunteers [0.53(0.15); p=0.67, 95% Cl -0.29:0.01]. Diabetic patients with Painless DPN had 
lowest ml levels [0.36(0.16)] compared with patients with No DPN [0.42(0.17)] and Healthy 
Volunteers [0.52(0.15), ANOVA p=0.14). Post hoc pairwise comparisons showed that 
Painless DPN patients were significantly lower compared with Healthy Volunteers (p=0.05; 
95% C l-0.32:0.001).
110
Table 5.2: H-MRS patient g roup m etabolite  areas relative to  that o f unsuppressed 
water (acquired at short echo time).
Healthy Volunteers (n=6) Diabetes (n=24)
Short TE
Glx* 0.27(0.14) 0.48(0.12)
ml 0.52(0.15) 0.38(0.16)
Healthy Volunteers No DPN (n=16) Painless DPN (n=8)
Short TE
Glx* 0.27(0.14) 0.53(0.13) 0.45(0.11)
ml 0.52(0.15) 0.42(0.17) 0.36(0.16)
Glutamate-glutamine (Glx), myolnnositol (ml), N-Acetyl Aspartate (NAA). No DPN, 
diabetic patients with no neuropathy, Painless DPN, diabetic patients with painless DPN. 
Results are given as mean (SD) for variables with a normal distribution. * ANOVA p<0.05.
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5.5 Discussion
Apart from good glycaemic control, there is an overall lack of effective treatments for DPN. 
This may be because most therapeutic agents have been developed to target pathological 
changes in the peripheral nerves (Ziegler, Pritchett et al. 2007), with changes occurring 
within the CNS being overlooked. We have previously demonstrated that the pathological 
process of DPN may also affect the thalamus, which plays an important role in 
somatosensory perception. A better understanding of the mechanisms that lead to thalamic 
neuronal dysfunction may aid the development of new therapeutic agents.
The main finding of this chapter is significantly elevated Glx levels in all patients with 
diabetes compared with Healthy Volunteers. There was no significant difference in Glx levels 
between diabetic patients with DPN or without DPN. There was a trend for lower ml signal in 
patients with Painless DPN compared with No DPN and Healthy Volunteers. Elevated Glx 
may reflect a hyperglutamatergic state, while decreased ml suggests decreased glial content 
or function in the thalamus of diabetic patients.
The Glx peak on H-MRS is made up of two compounds, glutamate and glutamine. 
Glutamate serves as an important excitatory neurotransmitter and has functional role in 
synaptic plasticity crucial to learning and memory (Lessmann 1998). It is also a potentially 
damaging agent, involved in neurodegenerative diseases. The pathological effect of 
glutamate occurs when present in excessive levels as shown in Alzheimers’s disease (Upton 
2005). Glutamate in the CNS comes mainly from either glucose, via the Kreb’s cycle, or 
glutamine which is synthesised by glial cells and taken up by neurons. Therefore elevated 
thalamic Glx levels in our diabetic subgroup could represent either a generalised ‘diabetes’ 
effect or a susceptibility to develop thalamic neuronal dysfunction or both.
Unlike previous papers that have used H-MRS to probe changes in brain metabolites 
related to diabetes (Kreis and Ross 1992; Geissler, Frund et al. 2003), which have shown
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increases in ml, in this study there were no significant differences in thalamic ml across 
study groups. Conversely, however, in this study ml was non-significantly lower in diabetic 
subgroups. Most of the previous studies, however, did not include the thalamus or quantify 
the presence of DPN. Myo-innositol is a glial marker and is typically elevated during glial 
activation or hypertrophy associated with active inflammation or demyelination, such as in 
the white matter of patients with HIV (Wilkinson, Lunn et al. 1997) or multiple sclerosis 
(Fernando, McLean et al. 2004). The absence of ml elevation in our diabetic subgroup, 
especially in patients with DPN, is also different from degenerative brain disorders, such as 
Alzheimer’s and frontotemporal dementia, which show increased ml along with decreased 
NAA (Kantarci, Knopman et al. 2008; Small, Bookheimer et al. 2008). In these degenerative 
dementias, elevated ml is thought to reflect a glial response to the neuronal injury. 
Conversely, our findings suggest decreased or dysfunctional glial response despite 
abnormal neuronal function (decreased NA:Cho- Chapter 4). Reduced ml has also been 
demonstrated in the peripheral nerves of diabetic rats and implicated in the pathogenesis of 
DPN.
Data from animal literature suggests that diabetes can significantly impair glial 
function (Lechuga-Sancho, Arroba et al. 2006). An important function of glia, especially 
astroglia, is reuptake of glutamate from the extracellular space after neurotransmission, 
astroglial dysfunction might prevent this reuptake and lead to excess extracellular glutamate 
concentration. Glutamate accumulation can lead to overstimulation of postsynaptic 
glutamate receptors resulting in intracellular calcium overload and neuronal injury/cell death 
(Upton and Rosenberg 1994). Hence, elevated thalamic Glx levels amongst patients with 
diabetes may provide the substrate for subsequent neuronal injury. Glutamate reuptake is 
also important for shaping of excitatory post-synaptic currents; dysfunctional or decreased 
glutamate reuptake by glia may also interfere with neuronal function (Lisman 2003).
One limitation of this study is that with a standard short TE H-MRS sequence (TE = 
30ms) on a 1.5T MR scanner, the spectral peaks of glutamate and glutamine were
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overlapping and difficult to distinguish. Our H-MRS acquisition protocol did not allow 
sufficiently accurate expression of the glutamate component of the total Glx signal Intensity 
as an absolute concentration of glutamate. Future studies performed on a 3T scanner with 
spectral editing analyses will aim to address this limitation. A second potential limitation is 
the inability of H-MRS to distinguish between synaptic and extrasynaptic Glx. We have 
demonstrated elevated Glx in our diabetic subgroups suggesting these patients have an 
overall higher precursor pool of glutamate. In a model proposed by Sanacora et al, they 
postulate that impaired glial function results in elevated extrasynaptic glutamate and 
glutamine levels (Kugaya and Sanacora 2005). In their model, they distinguished synaptic 
glutamate levels from extrasynaptic concentrations and suggest that reduced glial function 
could lead to decreased synaptic release and increases in extrasynaptic glutamate 
secondary to spillover. The accumulation of glutamate in the extrasynaptic space may trigger 
a cascade of events that results in neuronal dysfunction/death.
Finally, the thalamus may be inherently susceptible to the complications of diabetes 
as it is more metabolically active given its central role in somatosensory perception. 
Thalamic astrocyte dysfunction secondary to diabetes and resultant glutamatergic 
dysfunction maybe the pathogenetic mechanism leading to thalamic neuronal dysfunction. 
Given the pathophysiological importance of glutamate further evaluation of the relationship 
between thalamic H-MRS abnormalities and DPN is needed.
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6 CEREBROVASCULAR PERFUSION ABNORMALITIES IN DISTAL SYMMETRICAL
DIABETIC POLYNEUROPATHY AND TYPE 1 DIABETES MELLITUS
6.1 Introduction
The presence of thalamic sensory neuronal dysfunction in DPN suggests that CNS 
involvement is not limited to the spinal cord but also other important areas in the brain, 
responsible for somatosensory perception, may be affected (Selvarajah, Wilkinson et al. 
2008). Although the pathogenesis of thalamic involvement remains unknown, it is likely that 
both vascular and metabolic aetiological factors that have been postulated in the 
pathogenesis of DPN and other microvascular complications of diabetes (retinopathy and 
nephropathy) are involved. A better understanding of the pathogenesis of thalamic 
dysfunction in DPN could provide new therapeutic targets to treat or prevent this condition.
Neurophysiological and neuropsychological studies of the pathophysiological 
disturbances caused by diabetes on the human brain reveal both functional and structural 
abnormalities (Mijnhout, Scheltens et al. 2006). These structural abnormalities appear to 
mimic those attributable to normal aging (atrophy and leukoariosis), but seem to develop 
prematurely. Diabetes alters endothelial function and permeability of the blood brain barrier, 
thus affecting microcirculation and regional metabolism (Horani and Mooradian 2003). Single 
proton emission computer tomography (SPECT) studies suggest that chronic 
hyperglycaemia alters CBF in the frontal, temporal, parietal, occipital and cerebellar ROI. 
These studies analysed regional cerebral perfusion by subdividing the brain into different 
anatomical ROI and not by regions defined by major vascular territories (anterior cerebral 
artery [ACA], middle cerebral artery [MCA] and posterior cerebral artery [PCA]). A more 
accurate assessment of cerebral perfusion abnormalities in diabetes is obtained by 
investigating regional perfusion of the major vascular territories.
Advances in modern in-vivo MR technology have enabled the acquisition of high 
quality multi-slice echo planar imaging of the brain with sub-second temporal resolution.
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Chelates of gadolinium, a rare earth metal, are commonly used as exogenous contrast 
agents in MR imaging because of its modulatory effect on both T1 and T2* of tissue within 
their sphere of influence. This is coupled with fast T2*-weighted MR imaging, which provides 
the ability to detect the passage of a bolus of gadolinium as it passes through the capillary 
bed. The result is a spatial map of the brain parenchymal perfusion characteristics (Patel, 
Siewertetal. 1995).
This study sought to utilise dynamic contrast enhanced MR perfusion to test our 
hypothesis that thalamic neuronal dysfunction that accompanies DPN is associated with 
unique perfusion abnormalities and diabetes results in global perfusion abnormalities of the 
major vascular territories. Thus the aims of this study were firstly, to investigate regional 
cerebrovascular perfusion in type 1 diabetes and secondly to assess the characteristics of 
thalamic microcirculation in DPN.
6.2 Methods
6.2.1 Patients
Eighteen right handed male patients with type 1 diabetes from the Royal Hallamshire 
Hospital Diabetes Register were recruited consecutively for the study. To be eligible, 
participants had to fulfil the following inclusion criteria: type 1 diabetes diagnosed for more 
than five years and age between 1 8 - 6 5  years. Patients were excluded for the following 
reasons: stroke, myocardial infarction, congestive cardiac failure, arrhythmia, other clinically 
important cardiac disease, non diabetic neuropathies, history of alcohol consumption of 
more than 20 units a week (one measure of alcohol e.g. glass of wine equals one unit), 
diabetic neuropathies other than DPN (e.g. mononeuropathies, proximal motor neuropathies 
etc), kidney or liver transplant, renal failure, carotid stenosis and neurological or other 
systemic disorders, diabetic ketoacidosis In the proceeding six months and hypoglycaemia In 
the preceding 24 hours. Patients with MRI Incompatible, metal implants, pacemakers, 
arterial stents, claustrophobia, history of allergy to iodine or radiological contrast compounds
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also were excluded. Diabetic patients were treated for hypertension when clinically 
diagnosed and all patients were on statins. Medications that could potentially affect 
cerebrovascular perfusion characteristics were omitted on the morning of the test. These 
included antihypertensives and antiarrhythmics medications. Six age- and sex-matched non­
diabetic Healthy Volunteers who were normotensive and not being treated for any systemic 
disease were also recruited. All patients gave written, informed consent before participation 
in the study, which had prior approval by the South Sheffield Regional Ethics Committee.
6.2.2 Assessment of Neuropathy
Detailed neurological assessment was undertaken to identify the presence and quantify the 
severity of neuropathy in each patient. Neuropathic symptoms were documented by 
completion of the NSS questionnaire and then the outcome of a detailed neurological 
examination was graded by defined criteria according to the standard NIS questionnaire. All 
patients underwent: 1) vibration and cooling perception thresholds acquired from the dorsal 
aspect of the right foot using the Computer Assisted Sensory Evaluation IV (CASE IV, W.R. 
Electronics, Stillwater, MN, USA) system employing standard techniques; 2) cardiac 
autonomic function tests performed with a computer assisted technique and 3) nerve 
conduction studies performed, at a stable skin temperature of 31 °C and a room temperature 
of 24°C, using a Medelec electrophysiological system (Synergy Oxford Instruments, Oxford, 
UK). The following nerve attributes were measured: 1) sural sensory nerve action potentials 
and conduction velocities and 2) common peroneal and tibial motor nerve distal latency, 
compound muscle action potential and conduction velocity.
Based on these clinical and neurophysiological assessments diabetic patients were 
divided into two groups: 1) No DPN consisting of asymptomatic patients with normal clinical 
and neurophysiological assessments; 2) Painless DPN, comprising of pain free patients with 
both clinical and neurophysiological abnormalities (at least two abnormalities of
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neurophysiologic assessment) and 3) Painful DPN, patients with painful symptoms together 
with clinical and neurophysiological abnormalities.
6.2.3 Magnetic Resonance Perfusion Protocol
MR examinations were performed on a 1.5T system (Eclipse, Philips Medical Systems, 
Cleveland, Ohio, USA). The MR protocol included the acquisition of transaxial, cranial 
images using dual-echo fast spin-echo (TE = 20, 90ms; TR = 2000ms) and fluid-attenuated 
inversion recovery (FLAIR) (TE = 95.9ms; TR = 6000ms; Tl = 1800ms) techniques, the latter 
being acquired both before and after the perfusion assessment.
Parenchymal perfusion was assessed using a multi time point, single shot T2* 
weighted EPI sequence (TESff = 60ms; TR = 1.4s; acquisition matrix = 192 x 188, zero filled 
prior to Fourier transformation to 256 x 256; FOV = 25cm). Twelve 5mm thick contiguous 
axial slices were acquired over the cerebrum every 1.4s for a total imaging time of 98s, 
yielding 70 time points. Exogenous perfusion contrast was provided by a 20ml bolus of 
gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA, Magnevist, Schering AG, 
Germany), which was followed by a 20ml saline flush, administered intravenously using a 
power injector (Spectris, Medrad, Netherlands) at a rate of 5ml/sec starting at the 10th 
imaging time point.
Post acquisition processing was performed using software integrated with the 
imaging system, in a manner similar to that described previously (Doerfler, Eckstein et al. 
2001). As the bolus of gadolinium chelate passes through a ROI, a loss in signal occurs as 
the transverse relaxation rate increases due to localised dephasing. For each scan episode, 
the timing of the signal change within user defined ROI’s were obtained with respect to those 
defined by the signal time [S(t)j course of a circular ROI placed within the proximal 
intracranial internal carotid artery. Haemodynamic anatomical ROI’s were applied to outline 
eight regions as illustrated on Figure 6.1 and 6.2. These regions outline major intracranial
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vascular territories (ACA, MCA and PCA) and deep brain nuclei (thalamus and caudate 
nucleus). The caudate nucleus was chosen as an internal control for subgroup comparisons.
6.3 Data analysis
Two levels of analyses were performed. Firstly, we compared perfusion of the major 
vascular territories (ACA, MCA and PCA; Figure 6.2) between Healthy Volunteers with all 
diabetic patients. Variables in these analyses were derived using Model A (described below). 
Next, we subdivided diabetic patients into three neuropathy subgroups (No DPN, Painful 
DPN and Painless DPN) and compared deep brain nuclei perfusion characteristics with 
Healthy Volunteers. Variables for this latter analysis were derived using Model A and B 
(described below).
Caudate 
Nucleus
Thalamus
Figure 6.1: Cross sectional image of the cerebral cortex at the level of the thalamus. Red 
circles denote regions of interests within the thalamus and caudate nucleus.
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Figure 6.2: White circles are regions of interests within the three major vascular territories; 
ACA, anterior cerebral artery, MCA, middle cerebral artery and PCA, posterior cerebral 
artery
6.3.1 Modelling of gadolinium concentration-time curves
Exogenous tracer methods in MR perfusion imaging use a model that assumes the tracer is 
restricted to the intravascular compartment and does not diffuse into the extracellular space. 
Imaging can be performed either dynamically (rapid imaging over time during bolus injection) 
or in the steady state (imaging after a constant infusion has reached an equilibrium 
concentration in the blood). In this study we chose the former imaging technique. The signal 
time course of the average pixel value within each ROI was inverted to produce a 
concentration time profile.
Figure 6.3 shown as typical concentration-time profile of the passage of gadolinium 
through the thalamus in a healthy volunteer. From this profile, several peaks are found, 
which suggests that gadolinium has not diffused or mixed well in the body within the short 
observation period (100 sec). The mixing is assumed to be a function of the distance from 
the heart to the ROI, and vascularity in relation to cardiac output. Thus, the exposure of the
120
ROI to gadolinium takes place as episodes of high concentrations followed by lower values. 
Several peaks are seen until the mixing has been complete in the body. The height of the 
peaks is expected to go down as gadolinium is distributed and eliminated in each cycle. 
Gadolinium signal rerun does not return to the baseline (zero), but shows an apparent 
constant level 100s after administration.
We analysed this concentration time curve using two 
A) analysed the first pass of gadolinium bolus through the 
(Model B) analysed in detail the whole concentration-time 
over 100sec as it recycles through the thalamus.
models. The first model (Model 
ROIs, while the second model 
profile of the contrast material
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Figure 6.3: Relative concentration-time profile of gadolinium passage through the thalamus in a healthy volunteer.
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Model A
Time (sec)
Figure 6.4: First pass relative concentration time profile of gadolinium through the thalamus in a healthy volunteer.
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Blue line in Figure 6.4 represents the observed profile; red dotted line represents the 
gamma-variate fit. The area under the red dotted line (shaded) represents the cerebral blood 
volume (CBV) and the black dotted line denotes the first moment transit time.
This is the conventional way of analysing MR perfusion data. As mentioned above, 
the signal-time profile was inverted and a gamma-variate fitted to this data using a non-linear 
least square fitting procedure to produce the concentration-time profile.
The fitted concentration-time curve, for a given ROI is:
C(t) = -(k/TEeff)ln[S(t)/S(t=0)]
Where k is a constant and TEeff is the effective echo time. The concentration-time curve is 
directly proportional to the change in transverse relaxation rate, AR2* at time t brought about 
by the proximity of the gadolinium ion as it passes through the capillary bed:
C(t)<xAR2*(t)
Three variables were used to characterise C(t), which relate to local blood volume and flow:
• the relative cerebral blood volume (rCBV), i.e. the area under the fitted curve: 
rCBV = o fC (t)d t
refers to the volume of blood per unit time passing through a given region of brain 
tissue relative to the proximal internal carotid artery; and
• the first moment (TTFm of the mathematical ‘centre of mass’) of the fitted gamma- 
function:
TTFm = o f  C(t).t dt / 0 fC ( t ) d t
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refers to the average time it takes blood to pass through a given region of brain 
tissue, measured in seconds.
• finally we calculated the relative cerebral blood flow (rCBF) through each ROI by:
rCBF = rCBV 
TT fm
refers to the average volume of blood passing through the ROI per unit time.
We calculated the average rCBV, TTFm and rCBF for all ROIs in the right and left 
cerebral hemispheres. Study end points were mean average rCBV, TTFM and rCBF. These 
were compared between Healthy Volunteers and all diabetic patients.
Model B
With the assistance of ARH and colleagues, we constructed a mathematical model to 
describe the concentration-time profile of the passage of gadolinium through the thalamic 
ROI, using pharmacokinetic drug modelling principles.
The following empirical model was derived:
Concentration of gadolinium = A(1-e'kel(t'tla9)) + c.(e'kC0S(,'tla9)) x [1-cos((B(t-tlag)+B2)(t-tlag))] 
This model consists of three components.
Component A: to represents the episodic delivery profile, which are seen as waves of 
descending heights until it becomes a smooth line.
Component B: to account for accumulation of the gadolinium in the organ that reaches a 
constant level after several peaks.
Component C: to account for the delay in bolus arrival time (ti_AG)
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Com ponent A
A. Waves B. Concentration = C.sin(B.t)
C. Concentration = C.e'ksint.sin(B.t) D. Concentration = C.e'ksint
E. Concentration = C.e'ksin' + C.e‘ksin '.sin(B.t)
F. Concentration = C.e‘kcost - C.e'kcost.cos(B.t)
= C.e+coslx [1- cos(B.t)
G. Concentration = C.e'kcostx [1- cos(B.t + B2).t]
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Com ponent B
A. Concentration = A(1-e'kelt)
B. Concentration = A(1-e'kelt) + C.e'kcostx [1- cos(B.t + B2).t]
Component C
t tO t-t|ag
A. Concentration =  A ( 1 . e -kei (t-tiag)) +  c  e -kcos.(t-tiag) x  j - | .  COs((B.(t-tlag) + B2).(t-tlag))]
Final Fitted Result
WinNolin Professional (Pharsight Co. Ver. 4.0.1) was used for the fitting (weighting scheme was set at M y 2). Sample results for a healthy 
volunteer and diabetic patient with DPN are shown in Figure 6.5.
Healthy Volunteer Painless DPN
Figure 6.5: Relative concentration time profile of gadolinium DTPA tracer bolus as it passes through the left thalamus in a healthy volunteer 
and a patient with painless DPN. (0) represent data points of observed gadolinium concentration sampled from time Omin to 100min and (— ) 
represent the predicted concentration of gadolinium calculated from the empirical model.
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From Figure 6.5, there are several differences in the concentration time profile of 
gadolinium tracer bolus as it passes through the thalamus, between the two study patients. 
Firstly there is a delay in bolus arrival time (t|ag) In the patient with Painless DPN compared 
with the Healthy Volunteer. Secondly, the first pass peak concentration in the healthy 
volunteer is greater but the duration of the first peak is longer In Painless DPN. Finally it also 
takes longer to reach a steady state concentration of gadolinium in Painless DPN. The 
differences seen between these two patients are likely the combined effects of vascularity of 
the thalamus, cardiac output, body size and cerebrovascular disease. Seven biomarkers are 
used in this model which we propose are related to these variables.
A: Combined effects of the size of the thalamus and the affinity of gadolinium to the tissue.
Kei: the uptake rate of gadolinium, possibly determined by the ratio of organ size/affinity to its 
vascularity.
C: the size of the initial pool for dilution of gadolinium in the body (the smaller the size the 
taller the peak).
KcoS: the rate of gadolinium mixing in the body (possibly related to blood volume and cardiac 
output).
B: the constant for short circuiting and recirculation through the thalamus (possibly related to 
cardiac output and size of the organ).
B2: similar to B but in the absence of any short circuiting.
tiag: time it takes for the bolus to arrive at the thalamus.
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6.3.2 Statistical analysis
All analyses were performed using statistical package SPSS 14.0. Subgroup demographics 
were described as means and standard deviation for normally distributed variables and as 
medians and 5th and 95th percentiles for variables with a skewed distribution. Demographic 
and laboratory variables were compared between groups using one-way ANOVA.
• Healthy Volunteers vs Patients with Diabetes
We compared regional perfusion (Model A) of the major vascular territories (ACA, MCA and 
PCA) between Healthy Volunteers with all diabetic patients. Variables assessed were 
average rCBV, TTFMand rCBF for each vascular territory.
• Healthy Volunteers vs Diabetic Subgroups
We subsequently divided diabetic patients into No DPN, Painful and Painless DPN. Using 
variables derived from Model A we compared thalamic and caudate nuclei perfusion 
characteristics of each diabetic subgroup with Healthy Volunteers. More in depth analysis of 
thalamic perfusion using variables derived from Model B was then performed. Non 
parametric median tests were used to compare biomarkers A, B, B2, C, Kei, Ka* and Tiag.
6.4 Results
6.4.1 Comparisons between Healthy Volunteers and patients with diabetes: regional 
perfusion of major vascular territories
6.4.1.1 Subgroup Demographics
The quality of the perfusion data obtained was graded using patientive assessments of the 
time-intensity curves. The method used is described in more detail elsewhere (Griffiths, 
Pandya et al. 2006). Perfusion results from one patient were excluded from the final analysis 
because of the poor quality of data obtained. Demographics of Healthy Volunteers (n=5) and
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patients with diabetes (n=18) are displayed in Table 6.1. Age, height and weight differences 
did not reach statistical significance.
Table 6.1: Demographics of Healthy Volunteers and Patients with Diabetes.
Healthy Volunteers All Diabetic Patients
Age (years)
45.8(14.7)
51.9 (9.3)
Height (m)
178.2(14.2)
174.3 (10.1)
Weight (kg)
88.2 (7.5)
86.5(14.0)
HbA1c (%)
N/A
8.4 (0.8)
DD (years)
N/A
15.8(10.7)
DD, Duration of Diabetes. Results presented as mean (SD). Not applicable (N/A).
6.4.1.2 Model A
Overall Healthy Volunteers had lower global rCBV compared to diabetic patients. Mean 
rCBV differences between these two groups, within the anterior, middle and posterior 
cerebral artery territories reached statistical significance (Table 6.2). Diabetic patients had 
longer transit times and greater rCBF compared to Healthy Volunteers but this did not reach 
statistical significance.
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Table 6.2: Regional Cerebral Perfusion Characteristics of Healthy Volunteers and 
Patients with Diabetes.
Average rCBV Average TTFm Average rCBF
Anterior Cerebral HV 205.3 (57.2)* 31.8(6.9) 6.7 (2.1)
Artery DM
264.4 (55.2)* 34.9 (5.2) 7.8 (2.2)
Middle Cerebral HV 189.0(55.2)* 31.6 (6.8) 6.17 (1.9)
Artery
DM
244.6 (43.3)$ 34.7 (4.8) 7.2 (1.5)
Posterior Cerebral HV 190.8 (36.5)# 32.1 (7.2) 6.2 (1.7)
Artery
DM
248.4 (43.8)# 35.2 (5.0) 7.2 (1.8)
Results are presented as mean(SD). Healthy Volunteer (HV), Patients with Diabetes 
(DM), relative Cerebral Blood Volume (rCBV), first moment Transit Time (TTFM), relative 
Cerebral Blood Flow (rCBF). * p=0.05; 95% Confidence Interval (Cl) -118.7:0.6,$ p=0.03; 
95% Cl -103.8:-7.4, # p=0.01; 95% Cl -102.3:-12.9.
6.4.2 Comparison between Healthy Volunteers and diabetic patients divided into 
neuropathy subgroups: thalamic perfusion
6.4.2.1 Subgroup Demographics
Table 6.3 presents the demographics of Healthy Volunteers and diabetic patients divided 
into No DPN, Painless DPN and Painful DPN. Diabetic patients with Painful DPN were 
significantly older than those with No DPN and Healthy Volunteers (ANOVA p=0.03, Painful
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DPN vs No DPN p=0.005; 95% Cl 5.7:28.5, Painful DPN vs Healthy Volunteers p=0.01; 95% 
Cl 3.8:28.5). There were no statistical significant differences in the other demographics 
studied.
Table 6.3: Demographics of Healthy Volunteers and Diabetic Neuropathy 
Subgroups.
HV No DPN Painless DPN Painful DPN
N 5 6 7 5
Age* 45.8 (14.7) 44.9 (7.1) 51.7 (9.1) 62.0(3.9)
Height 178.2(14.2) 170.4 (6.2) 176.3(3.9) 177.8(17.1)
Weight 88.2 (7.5) 88.4(15.8) 80.0 (7.6) 90.4(16.5)
HbA1c N/A 8.4 (0.2) 8.9 (0.9) 7.7 (0.9)
Retinopathy N/A 2 2 3
Microalbuminuria N/A 1 3 3
HV, Healthy Volunteers. Results presented as mean(SD). Distal Symmetrical Diabetic 
Polyneuropathy (DPN), not applicable (N/A). * ANOVA p=0.03.
6.4.2.2 Model A
Perfusion results of the four groups studied are summarised in Table 6.4. Overall group 
comparison showed that patients with Painful DPN have significantly higher mean thalamic 
rCBV compared with Healthy Volunteers and diabetic patients with No DPN and Painless 
DPN (p=0.04). Patients with Painful DPN had the longest thalamic tracer transit time (TTFM)
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compared to the other study groups (p=0.07) and the lowest mean thalamic rCBF amongst 
diabetic patients (p=0.8). Perfusion parameters within the caudate nucleus (control region) 
were not significantly different between subgroups.
Table 6.4: Regional Cerebral Perfusion Characteristics of Healthy Volunteers and 
Diabetic Patients Divided into Neuropathy Subgroups.
Av rCBV Av TTfm Av rCBF
HV 181.9 (51.7)* 33.7 (14.9) 5.77(1.6)
Thalamus
No DPN 202.3 (25.8)* 35.3(13.2) 6.52(1.3)
Painless DPN 216.5 (65.5)* 35.9 (13.7) 6.51 (2.8)
Painful DPN 228.7 (19.5)* 38.4 (3.6) 5.93 (0.5)
HV 186.8 (53.0) 33.0 (15.5) 6.03 (1.6)
Caudate No DPN 207.4 (28.0) 35.3 (14.7) 6.95(1.8)
Nucleus Painless DPN 237.9 (84.3) 34.9(13.3) 7.15(2.8)
Painful DPN 238.1 (66.1) 37.0 (5.0) 6.41 (2.0)
Results presented as median (range). Healthy Volunteers (HV), Distal Symmetrical Diabetic 
Polyneuropathy (DPN), Relative Cerebral Blood Volume (rCBV), First Moment Transit Time 
(TTFm). Relative Cerebral Blood Flow (rCBF). * Median test, p=0.045.
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6.4.2.3 Model B
Biomarkers derived from pharmacokinetic modelling of tracer passage through the thalamus 
for the different study groups are summarised in Table 6.5 and displayed in Figure 6.6. We 
found that patients with Painful DPN had a significantly lower B2 compared with Healthy 
Volunteers (p=0.04). Subgroup differences in the other biomarkers were not statistically 
significant.
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Figure 6.6: Relative concentration time profile of the passage of exogenous contrast agent (gadolinium DTPA) though the thalamus in each 
subgroup. [ ♦ ]  Healthy Volunteers, [ ♦ ]  diabetic patients with no neuropathy (No DPN), [ ] diabetic patients with painless DPN (Painless 
DPN) and [ ♦ ]  diabetic patients with Painful DPN (Painful DPN).
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Table 6.5: Thalamic Perfusion Biomarkers of Healthy Volunteers and Patients with Diabetes.
HV No DPN Painless DPN Painful DPN P Chi-Sq
A 3.4 (12.5) 3.0 (2.1) 3.8 (4.0) 4.7 (6.1) 0.17 5.1
B -0.0038 (0.0) -0.0036 (0.01) -0.0021 (0.0) -0.0029 (0.0) 0.17 5.1
B2 0.43 (0.1) 0.42 (0.2) 0.38 (0.1) 0.37 (0.06) 0.04 5.1
C 28.5 (8.7) 28.9 (19.7) 30.6 (21.1) 35.9 (33.3) 0.68 1.5
Tlag 25.9(11.6) 26.2(13.8) 26.7(11.5) 28.4 (4.6) 0.24 4.2
Ke, 0.09 (0.4) 0.11 (1.1) 0.1 (0.7) 0.06 (0.6) 0.84 0.83
KCos 0.1 (0.03) 0.12(0.05) 0.1 (0.05) 0.09 (0.04) 0.84 0.83
Results presented as median (range). Distal Symmetrical Diabetic Polyneuropathy (DPN), Healthy Volunteers (HV).
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6.5 D iscussion
This preliminary study demonstrated that patients with diabetes had significantly greater 
rCBV in all major cerebral vascular territories (ACA, MCA and PCA) compared to age, sex 
and BMI matched Healthy Volunteers. This was accompanied by a non significant trend 
towards longer TTFM and greater rCBF amongst diabetic patients. In addition, patients with 
Painful DPN had significantly greater thalamic rCBV compared to other Painless DPN and 
Healthy Volunteers. There were no differences in the perfusion characteristics of the caudate 
nucleus between study groups.
The finding of greater rCBV in the major vascular territories of diabetic brains 
suggests a persistent resting vasodilatatory state. This could reflect either a compensatory 
mechanism, utilising cerebrovascular reserve capacity, to overcome diabetic 
microangiopathy or impairment of cerebral autoregulation. Previous studies have 
demonstrated reduced cerebrovascular reserve capacity in patients with diabetes using C02 
inhalation and acetazolamide challenge (Paulson, Strandgaard et al. 1990; Jimenez-Bonilla, 
Quirce et al. 2001). In addition, similar changes in cerebral perfusion demonstrated in this 
study have been described in the diabetic kidney; where the early stages of diabetes is 
characterised by increases in renal blood flow and glomerular filtration rate. This has been 
shown to be secondary to impairment of renal autoregulation resulting in nitric oxide 
mediated renal vasodilatation.
We also found that diabetic patients with Painful DPN had significantly higher 
thalamic rCBV compared with other study groups. Further detailed analysis of thalamic 
perfusion using pharmacokinetic derived biomarkers suggests that thalamic recirculation 
time (B2) is longer in patients with Painful DPN compared to Painless DPN, No DPN and 
Healthy Volunteers. Greater blood volume and longer recirculation time within the thalamus 
in patients with Painful DPN suggests that abnormal thalamic vascularity could be an 
important contributing factor in Painful DPN.
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To quantify flow within the ROIs, we used two mathematical models to describe the 
concentration-time curve of a bolus of gadolinium as it passes through the thalamus. The 
first (Model A), uses a gamma variate model to fit the data to produce two parameters that 
are often used: localised blood volume and flow. Blood volume and flow are related to each 
other by the transit time, according to the central volume principle: flow = volume/transit 
time. For a review of these concepts, see the article by Griffiths et al (Griffiths, Pandya et al. 
2006). When purely intravascular tracers are imaged, the mean transit time cannot be 
calculated in a straightforward manner form the first moment of a concentration time curve, 
as the first moment is related to the second moment which has a dependence on vascular 
topology (Griffiths, Gaines et al. 2005). To highlight this concept, we denoted the first 
moment of the calculated concentration time curve as the TT fm rather than the mean transit 
time. TT fm has a high dependence on mean transit time, and therefore it does provide 
information about the temporal characteristics of tissue perfusion. No attempt was made to 
quantify CBV (based on knowledge of the arterial input), and thus, relative values were 
obtained and compared.
The second model (Model B) used to interrogate the concentration-time curve 
utilises mathematical principles commonly employed in pharmacokinetic studies. Unlike the 
first, this model incorporated the whole concentration time profile (0 -  100mins) until the 
concentration of gadolinium reaches a steady state. Hence it includes the recirculation of 
gadolinium through the body, thereby indirectly quantifying potential confounding factors 
such body size, cardiac output, vascular disease and medication use.
Thalamic perfusion abnormalities demonstrated in Painful and Painless DPN were 
not found in the caudate nucleus, another deep brain nucleus which served as an internal 
control. Unlike the caudate, the thalamus plays a central role in modulating/processing 
somatosensory information that is relayed to the cerebral cortices and is therefore possibly 
more metabolically active in DPN. This greater metabolic capacity increases thalamic 
sensitivity to diabetic metabolic disturbances. Diabetes has been shown to alter endothelial
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function and permeability of the blood brain barrier, thus affecting microcirculation and 
regional metabolism. This increased susceptibility to diabetic metabolic disturbance may 
then lead to thalamic neuronal dysfunction and eventually neuronal loss. Our finding of MR 
spectrospic reduction in thalamic NA:Cho ratios in Painless DPN would seem to support this 
hypothesis (Selvarajah, Wilkinson et al. 2008). Other studies in type 1 diabetes have shown 
that the fronto-temporal cortex and periventricular white matter are also affected by diabetic 
metabolic disturbance. This is manifested by atrophy and the increased presence of 
leukoariosis or white matter hyperintensities (van Harten, de Leeuw et al. 2006). It is 
possible, therefore, that regional differences in cerebral metabolic capacity may increase 
sensitivity to hyperglycaemia in these regions.
As we have previously demonstrated, thalamic sensory neuronal dysfunction 
accompanies Painless DPN and preservation of thalamic function maybe a prerequisite for 
perception of pain in this condition. Understanding the pathogenesis of thalamic dysfunction 
may lead to new insights into CNS involvement in diabetes. Increased thalamic vascularity 
demonstrated in this study has similarities to findings of increased blood flow in epineural 
vessels in sural nerve studies in Painful DPN (Eaton, Harris et al. 2003) and increased 
proliferation of new vessels in the diabetic retina. Various metabolic and vascular factors 
have been postulated to explain the pathogenesis of different diabetic microvascular 
complications (nephropathy, neuropathy and retinopathy); given the systemic nature of 
diabetes, we postulate similar pathophysiological changes may occur within the thalamus.
To our knowledge, this is the first report of the use of MR perfusion imaging to 
assess capillary bed perfusion in the thalamus in DPN. Limitations of the current study need 
to be considered. Group classification is prone to bias in small samples and requires cross 
validation for these results to be generalised beyond the current sample. In addition our 
study groups comprised an age spread of several years, and age is a factor in cerebral 
hypoperfusion, a larger study is needed to allow analysis of covariance with age as a 
covariate to account for age-related effects. Paradoxically, however, In this study patients
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with Painful DPN comprised the oldest cohort but nonetheless possessed the highest 
thalamic rCBV.
Although these are clearly shortcomings of the current study, our goals were to 
assess whether: 1) MR perfusion imaging In patients with diabetes might detect changes in 
regional brain perfusion and 2) thalamic perfusion abnormalities are present in DPN. The 
data presented here at least preliminarily support these views. Several other areas need 
additional research. Evaluating a larger sample, including greater numbers of cases of 
Painful and Painless DPN; along with studying patients with Subclinical DPN will not only 
provide more information about the sensitivity and specificity of MR perfusion imaging but 
also may lead to new insight into the pathogenesis of CNS complications in DPN. Also 
important will be following up patients with DPN over time to help better define the 
relationship between clinical measures of progression, such as NCS, and regional thalamic 
haemodynamic function measured with MR perfusion imaging. In turn, this information 
(together with MR spectroscopic determined biochemical abnormalities) might provide a 
means to assess the efficacy of clinical interventions in slowing the pathophysiological 
changes associated with DPN.
Finally, MR perfusion is a promising technique for assessing regional brain 
heamodynamic function in DPN. The results of this study using semiquantitative analysis of 
MR perfusion imaging was effective in assessing thalamic haemodynamic dysfunction in 
patients with diabetes as a whole and patients with DPN. These novel findings suggest a 
pathogenic microvascular mechanism for thalamic neuronal dysfunction in DPN, which may 
be amenable to modifications of microvascular disease risk factors.
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7 A RANDOMISED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF CANNABIS 
BASED MEDICINAL PRODUCT (SATIVEX) IN PAINFUL DPN: IS DEPRESSION A 
MAJOR CONFOUNDING FACTOR?
7.1 Introduction
Distal symmetrical diabetic polyneuropathy is one of the commonest long-term complications 
of diabetes mellitus and leads to significant morbidity and mortality, resulting in a huge 
economic burden for diabetes care (Vinik, Park et al. 2000). Painful DPN affects 15-26% of 
all patients with diabetes and about a third of patients with DPN (Daousi, Benbow et al. 
2006; Davies, Brophy et al. 2006). The intractable symptoms experienced cause great 
distress and disability to sufferers and affect quality of life immensely (Quattrini and Tesfaye 
2003). The cause of DPN, or indeed neuropathic pain, is not known although metabolic and 
vascular factors may be involved (Tesfaye, Malik et al. 1994; Cameron, Eaton et al. 2001). 
Whilst the search for potential therapeutic agents to halt or reverse the neuropathic process 
continues (Cameron and Cotter 1993), the first step should be to improve glycaemic control, 
with additional drug treatments required to alleviate painful symptoms (Ziegler 2008). 
Unfortunately these drugs are not always effective and often complicated by unwanted side 
effects. A recent review of trials in painful DPN has shown that at best only a third of patients 
achieve 50% pain relief with conventional treatments (Jensen, Backonja et al. 2006). Thus, 
there is need for more effective treatments with fewer side effects.
In our centre we have had anecdotal reports by patients who gained relief of painful 
symptoms and had better nights’ sleep after smoking cannabis. In several randomised 
controlled trials, cannabis and cannabis based medicinal products (CBME) have been 
shown to provide effective pain relief in a variety of mainly, non diabetic neuropathic pain 
conditions (Rog, Nurmikko et al. 2005; Abrams, Jay et al. 2007). A meta-analysis of these 
clinical trials concluded that further valid randomised controlled studies are required before 
cannabinoids can be considered for treating neuropathic pain (Campbell, Tramer et al.
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2001). In this study we report the first randomised placebo controlled trial assessing the 
efficacy and safety of a CBME (Sativex) in the treatment of intractable painful DPN.
7.2 Methods
7.2.1 Patients
Forty diabetic patients from the Royal Hallamshire Hospital Diabetes Database (Sheffield, 
UK) with chronic painful DPN were screened to take part in this study. Patients with stable 
glycaemic control (Hbalc <11%) and over the age of 18 with painful DPN (Neuropathy Total 
Symptom Score - NTSS 6 >4 and <16) for at least six months were assessed. Only those 
with intractable neuropathic pain in whom symptoms persisted despite an adequate trial with 
a tricyclic antidepressant (minimum three months) were recruited. Exclusion criteria included 
history of previous cerebrovascular event or other neurological disorders, history or 
electrocardiograph evidence of cardiovascular disease, schizophrenia or any other 
psychiatric illnesses, epilepsy, current or past history of substance abuse, current or past 
history of consuming more than 20 units of alcohol a week, neuropathy caused by other 
aetiologies, known or suspected hypersensitivity/adverse reaction to cannabinoids and 
significant hepatic or renal impairment. All patients gave written informed consent prior to 
taking part in this study, which had ethical approval from the South Sheffield Regional Ethics 
Committee.
7.2.2 Study Design
A prospective, randomised, double-blind, placebo controlled trial design was employed. This 
study was divided into three phases with seven assessment visits at regular intervals (Figure 
7.1). During the screening visit detailed clinical and neurophysiological assessments were 
performed to quantify the severity of neuropathy. The presence of depression and anxiety 
was assessed by completion of the Hospital Anxiety and Depression Scale (HADS) 
questionnaire. During the subsequent 2 week screening phase patients were given a study
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diary to complete to assess baseline pain and sleep scores. Patients were asked to 
complete the diary each morning upon awakening and reflect upon the pain intensity and 
sleep quality over the preceding 24 hours. Three modalities of pain in the lower limbs 
(superficial, deep and muscular) were assessed daily using a 100 mm visual analogue scale 
(VAS). On the second visit patients were block randomised to receive either the active or 
placebo study medication. Over the subsequent two weeks the dose of the study medication 
was titrated up to reach a maximum tolerated level when either unacceptable side effects 
prevented further dose escalation or pain/symptom control was apparent. We used a 
predetermined dose titration regime to standardise the process across the study. Patients 
were then instructed to remain on their maximum tolerated dose for the remaining duration 
of the study (Maintenance Phase for 10 weeks).
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Figure 7.1: Treatment Phases and Study Visits.
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Two health care professionals, a treating physician and a nurse assessor conducted 
the study. The physician was responsible for dose titrations and assessing adverse events, 
while the nurse assessor completed study questionnaires and case report forms at each 
visit. This measure was undertaken to prevent inadvertent unblinding which could occur if 
the responsibility of both these tasks were to fall on a single individual.
7.2.3 Assessment of Neuropathy
Detailed clinical and neurophysiological assessments were performed to quantify the 
severity of neuropathy at Visit 1 and Visit 6. The outcome of a detailed neurological 
examination was graded by defined criteria according to the standard NIS questionnaire.
All patients underwent: 1) vibration perception thresholds acquired from the dorsal 
aspect of the right foot using Computer Assisted Sensory Evaluation IV (CASE IV, 
W.R.EIectronics, Stillwater, MN, USA) system employing standard techniques;16,17 2) cardiac 
autonomic function tests performed with a computer assisted technique18 and 3) nerve 
conductions studies performed, at a stable skin temperature of 31 °C and a room 
temperature of 24°C, using a Medelec electrophysiological system (Synergy Oxford 
Instruments, Oxford, UK). The following nerve attributes were measured: 1) sural sensory 
nerve action potential amplitude and conduction velocities and 2) common peroneal and 
tibial motor nerve distal latency, compound muscle action potential and conduction velocity.
7.2.4 Concomitant Medication Use
Patients were allowed to continue taking concurrent medications for neuropathic pain for the 
duration of the study. Additional analgesia, if required, was prescribed according to the 
following algorithm. Week 1: paracetamol or aspirin; Weeks 2 through 6 (if further therapy is 
needed and indicated): non-steroidal anti-inflammatory medication, co-proxamol or co- 
codamol. If Class 2 controlled substances were required (with the exception of codeine), 
then the patient was discontinued form the study.
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7.2.5 Primary Outcome Measure
Improvements in pain symptoms (superficial, deep and muscular) as assessed by daily pain 
diary and Neuropathic Pain Scale (NPS) questionnaire (completed at each study visit) were 
used as the primary outcome measure. The endpoint chosen was each mean score for pain 
while taking the maximum tolerated dose of the assigned drug during the final week of 
Maintenance Phase 2 in both treatment arms. In addition the total pain score, which was the 
average score of all three pain modalities, was also calculated. The change in average 
baseline and endpoint (average final week scores prior to termination visit) scores for each 
modality of pain and the total pain score was compared between sativex and placebo. 
Similarly average change in NPS questionnaire scores from baseline (screening visit) to 
endpoint (termination visit) was compared.
7.2.6 Secondary Outcome Measure
McGill Pain and Quality of Life (Melzack 1975), SF-36 Health Survey (Jenkinson, Coulter et 
al. 1993) and EuroQOL (EQ-5D) (The EuroQol group 1990) questionnaires were employed 
to assess quality of life at each study visit. Average change from baseline (Visit 1) to 
endpoint (Visit 6) for these questionnaires was compared between study groups. Tolerability 
and side effect profile of the study medication was evaluated by completion of a 
standardised case report form at each study visit. To assess DPN disease progression over 
the study period, differences in neurophysiological assessment parameters between 
baseline (Visit 1) and endpoint (Visit 6) were compared between study groups.
7.2.7 Study Medication
Sativex and its matching placebo were presented in a pump action spray formulated with 
ethanol 50% and propylene glycol 50%. The active preparation comprised of approximately 
equal (1:1) concentrations of tetrahydrocannabinol (THC, 27 mg/ml) and cannabidiol (CBD, 
25 mg/ml). One dose increment comprises one actuation of the spray which releases
147
100mcl, containing THC 2.7 mg and CBD 2.5 mg. Doses were administered sublingually in 
divided doses up to four times a day.
7.2.8 Data Analysis and Statistical Methods
Analyses were conducted using the intent-to-treat population, which included all randomised 
patients. Before the analysis was performed, we define the intensity of pain as an average of 
pain scores in the patient’s diary if no more than 50 % of the scores were missing. If more 
than 50 % of the scores were missing, the mean daily score for pain intensity was 
considered to be missing. For patients missing post-baseline measurements, the last 
observation carried forward approach was applied by imputing the last non-missing post­
baseline value.
The first analysis step was to examine differences in the baseline characteristics 
between the two treatment arms. Imbalances in the baseline characteristics that are strong 
predictors of the primary outcome were then assessed by sensitivity analysis. Subsequently 
adjustment for a baseline covariate was performed if the covariate is correlated to the 
outcome at a correlation coefficient >0.50.
The second step was to assess the distribution of the primary outcome measure with 
each of the predictors (covariates). If the response is a continuous variable with a normal 
distribution then multiple linear regression was used. However a response with a skewed 
distribution will first be transformed.
As a sensitivity analysis, the level of change in the intensity of pain was calculated as 
the difference between the scores for pain at baseline (the mean score during the Screening 
Phase) and the scores for pain during the treatment (mean of the last week of Maintenance 
Phase 2). The percentage change was calculated as the change in pain divided by the score 
for pain at baseline times 100 percent. A significant improvement was defined as at least a 
30 percent improvement in pain scores from baseline. These estimates was analysed by 
multiple linear regression analysis. Data on proportions was analysed with the use of 
Fisher’s exact test.
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To assess disease progression in both treatment groups, changes from baseline to 
endpoint were assessed using univariate analysis of covariance (ANCOVA) with baseline 
measures as covariates for the following neurophysiological parameters: vibration perception 
threshold, heart rate variation with respiration and each attribute of nerve electrophysiology 
(sural, peroneal and tibial nerves). For each parameter, patients with possible outlying 
changes (any value < the 5th or > 95th percentile) were identified for each treatment group 
and reviewed for clinical relevance.
To assess the impact of depression on the outcome of this study we performed a 
post hoc analysis. All patients were divided into two groups based on HADS [no depression 
(HADS<10) and depression (HADS>10)]. Using ANCOVA we compared mean change from 
baseline of total pain score between depressed and non depressed patients after adjusting 
for study medication received.
7.3 Results
7.3.1 Baseline Characteristics
Of the 38 patients screened, 30 were randomised, of these 24 had type 2 diabetes. The 
average duration of diabetes was 12.5 years. Figure 2 displays participant flow for the 
duration of the study. None of the patients had previously used cannabis medicinally and 2 
(7.1%) had used it recreationally. Baseline demographics of both groups are presented in 
Table 7.1. There was no significant difference in baseline characteristics between study 
groups. The mean number of spray taken during the analysis period is shown in Table 7.1. 
Neurophysiological assessments performed are displayed in Table 7.2. Concomitant 
analgesic medications taken during the study is shown in Table 7.3.
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Table 7.1: Baseline Characteristics o f S tudy Partic ipants.
Sativex Placebo P
N 15 15
Age (Yr) 58.2 (8.8) 54.4 (11.6) 0.24
Sex (Female) 4 7 0.38
Weight (kg) 96.6 (18.4) 92.6 (24.7) 0.63
Height (m) 1.74 (0.1) 1.71 (0.10) 0.38
BMI (kg/M2) 31.9(6.3) 31.6 (8.2) 0.92
Alcohol (U) 5.96 (7.4) 3.40 (3.7) 0.33
Cannabis 2 0 0.60
Smokers 4 3 0.75
HbA1c (%) 8.64(1.7) 8.39 (1.6) 0.72
Type 2 Diabetes 13 11 0.23
Duration (Yr) 11.2(8.4) 13.7 (6.0) 0.37
No. of Sprays 7.0 (3.8) 7.3 (3.8) 0.84
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Table 7.2: Baseline and Endpoint N europhysio log ica l Assessm ents.
BASELINE ENDPOINT
Sativex Placebo Sativex Placebo
Vib JND 23.4 (2.6) 23.7(1.4) 23.4 (3.1) 23.6 (1.3)
HRDB 0.42 (0.8) 0.79(1.0) 0.57 (0.9) 0.9 (1.0)
SA 2.7 (4.1) 4.4 (6.8) 5.1 (6.0) 1.4 (2.1)
SV 18.8 (20.1) 22.5(21.3) 24.8 (20.8) 12.1 (18.4)
PV 29.1 (13.5) 31.6(11.9) 31.4(11.9) 34.6 (5.6)
PA 2.7 (2.7) 2.2 (1.9) 3.0 (3.0) 2.2 (2.0)
TV 22.0(17.5) 27.5(15.6) 29.9(15.5) 29.6 (11.5)
TL 3.5 (2.7) 3.7 (2.2) 3.6 (2.1) 4.7 (2.0)
TFWL 21.2(23.6) 33.1 (20.9) 18.7(26.4) 21.4 (23.0)
Vibration “just noticeable difference” (Vib JND), R-R variability with heart rate deep 
breathing (HRDB), sural sensory nerve action potential (SA, pV), Sural sensory nerve 
conduction velocity (SV, ms'1), common peroneal nerve conduction velocity (PV, ms'1), 
common peroneal compound muscle action potential (PA, pV), tibial motor nerve velocity 
(TV, ms'1), tibial motor nerve distal latency (TL, msec) and tibial motor nerve F-wave 
latency (TFWL, msec). Results are given as mean (SD).
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Table 7.3: C oncom itant Analgesic M edication.
Sativex Placebo Sativex Placebo
No Meds Taken 3 (20%) 1 (7%) Ibuprofen 0 2(13%)
Amitriptyline 1 (7%) 2(13%) Imipramine 2(13%) 5 (33%)
Carbamazepine 2(13%) 1 (7%) MST 1 (7%) 0
Celebrex 1 (7%) 0 Naproxen 1 (7%) 0
Cocodamol 2(13%) 4 (27%) Panadol AF 0 1 (7%)
Codeine 1 (7%) 0 Paracetamol 3 (20%) 2(13%)
Codydramol 2(13%) 1 (7%) Pregabalin 2(13%) 0
Diclofenac 2(13%) 0 Solpadol 1 (7%) 0
Dihydrocodeine 1 (7%) 2 (13%) TENS 1 (7%) 0
Gabapentin 5 (33%) 7 (47%) Temazepam 1 (7%) 0
7.3.2 Withdrawals
Of the 30 patients randomised, six withdrew before completing the study. Five patients were 
receiving sativex. In this group, there was one serious adverse event (confusion) and two 
adverse events (migraine and dysphoria), which led to withdrawal. Two other patients 
withdrew consent. One patient, receiving placebo, withdrew due to headaches and
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listlessness. We excluded one placebo treated patient from the intention to treat analysis 
(n=29) because of a protocol violation (Figure 7.2).
Screened
(n=38)
Randomised
(n=30)
Sativex
(n=15)
f
Placebo
(n=15)
Figure 7.2: Participant Flow Plan.
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7.3.3 Prim ary outcom e measure
Covariates used in the analysis were duration of diabetes, baseline scores, age and sex. 
Figure 7.3 displays mean total pain scores and each individual pain component scores for 
the duration of the study. There was no significant difference in mean change in total pain 
VAS between placebo and sativex treatments [-13.7mm vs -21.9mm (sativex vs placebo); 
p=0.40 (SEM=9.5; 95%CI -11.3:27.8)]. Similarly there was no significant difference in mean 
change in superficial [-13.4mm vs -16.7mm; p=0.72 (9.1 ;-15.3:21.93)], deep [-16.0mm vs - 
25.3mm; p=0.38 (10.5;-12.2:30.8)] and muscular [-11.7mm vs -23.6mm; p=0.26 (10.3;- 
9.15:33.0)] pain VAS between study groups. Differences in NPS (Table 7.4) between study 
groups also did not reach statistical significance [-15.4 vs -11.5, p=0.62 (7.8; -20.1:12.1)].
Eight (53%) patients in the sativex arm responded to treatment (defined as at least a 
30% improvement in total pain VAS) versus nine (64%) in the placebo arm (p=0.55, odds 
ratio 0.63, 95% Cl 0.14:2.82).
7.3.4 Secondary outcome measures
McGill pain questionnaire did not show a significant difference in sensory scale (p=0.65, 
3.3;-5.39-8.44), affective scale (p=0.81, 1.3;-3.0:2.4), VAS (p=0.24, 1.0;-0.91:3.4) and 
present pain intensity (p=0.57, 0.53;-0.79:1.4) (Table 5). Quality of life as assessed using the 
EQ-5D questionnaire showed improvement in both study groups (Table 5) but the 
differences between groups were not statistically significant (health state index p=0.87; SEM 
0.09, 95% Cl -0.19:0.16; health status VAS p=0.92; 7.2, -14.2:15.7). Similarly there was no 
significant difference in each of the quality of life measures assessed by SF-36 questionnaire 
between study groups (Table 7.5 and and 7.6).
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Table 7.4: Prim ary O utcom e Measures.
BASELINE ENDPOINT
Sativex Placebo Sativex Placebo
PAIN DIARY SCORES
Superficial Pain 52.3 (33.0) 45.9 (24.6) 37.9(32.1) 30.2(30.1)
Deep Pain 63.1 (29.4) 47.4 (21.4) 44.5 (32.7) 24.99 (29.5)
Muscular Pain 52.0 (34.2) 41.4 (28.3) 37.9 (32.9) 20.4 (29.9)
Total Pain 55.8 (26.7) 44.9 (21.5) 40.1 (28.5) 25.2 (28.8)
NPS
Total Score 67.1 (19.4) 63.6(14.0) 51.6 (21.9) 51.9(24.1)
Pain diary scores derived from 100mm visual analogue scale (VAS) completed daily. Total 
pain score derived from average of superficial, deep and muscular pain scores. NPS, 
Neuropathic Pain Scale. Results expressed as Mean (SD).
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Table 7.5: Secondary Outcome Measures (Part 1).
BASELINE ENDPOINT
Sativex Placebo Sativex Placebo
McGill
Sensory Scale 19.2(6.9) 16.3(6.3) 14.7 (7.2) 12.5(8.7)
Affective Scale 4.6 (4.3) 5.0 (3.8) 3.1 (2.3) 3.6 (3.8)
VAS 7.6 (1.8) 6.9 (1.7) 5.1 (2.2) 3.8 (2.6)
PPI 2.5 (1.1) 2.0 (1.0) 2.1 (1.1) 1.4(17)
EQ-5D
Health Status Index 0.40 (0.21) 0.43 (0.21) 0.54 (0.22) 0.56 (0.22)
Health Status VAS 46.0 (20.4) 44.6 (21.8) 58.1 (20.5) 56.4(11.7)
EQ-5D, EuroQOL questionnaire; McGill, McGill Pain Questionnaire, VAS, Visual
Analogue Scale, PPI, Present Pain Intensity.. Results expressed as Mean (SD).
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Table 7.6: Secondary O utcom e Measures (Part 2).
BASELINE ENDPOINT
Sativex Placebo Sativex Placebo
SF-36
Physical Func. 26.9 (15.1) 30.8 (22.7) 30.5 (16.6) 36.5 (27.9)
Role Physical 8.9(27.1) 12.5(23.5) 12.5 (32.1) 39.3 (47.7)
Bodily Pain 22.4 (15.5) 25.7 (11.3) 35.6 (16.6) 41.2(24.6)
General Health 33.5 (18.7) 28.4 (20.8) 34.1 (18.2) 29.6(19.5)
Vitality 28.3 (23.2) 30.8 (19.2) 33.9 (22.4) 39.6(19.4)
Social Func. 50.8 (32.5) 48.2 (24.9) 55.4 (25.3) 67.0 (27.6)
Role Emotional 38.1 (41.1) 33.3 (40.8) 54.8 (46.4) 47.6 (48.4)
Mental Health 57.9 (22.6) 57.1 (19.9) 64.4 (20.3) 59.4 (20.6)
SF-36, Short Form-36 Health Survey questionnaire. Results expressed as Mean (SD).
7.3.5 Neurophysiological assessments
Results of neurophysiological assessments that were performed are displayed in Table 7.2. 
Over the 13 week treatment period there were improvements in most parameters of nerve 
conduction studied in those receiving sativex compared with placebo. Mean differences 
nerve conduction velocity between sativex patients and placebo patients in change from 
baseline to endpoint ranged from 2.3 to 7.9 m/s and -10.4 to 3.0m/s respectively. The 
direction of change for nerve conduction amplitude from baseline also favoured the sativex
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group (mean difference range: sativex 0.3 to 2.4 pV vs placebo 0.0 to -3.0pV). Only sural 
amplitude (mean change from baseline 1.70 vs -2.5 p=0.038, SEM 1.7; 95%CI 0.23:7.5) 
reached statistical significance. There was no significant difference in vibration perception 
threshold (p=0.81, 2.6;-6.0:4.8) and heart rate variation during deep breathing (p=0.62, 
0.32;-0.82:0.50) between groups.
7.3.6 Depression post hoc analysis
Of the 29 patients included in the intention to treat analysis, we excluded one patient (sativex 
arm) from this analysis because of a failure to complete the HADS questionnaire at baseline. 
Mean HADS for patients with depression (n=10) and no depression (n=18) were 13.4(SD 
3.5) and 5.94(2.2) respectively. Patients with depression had significantly higher baseline 
total pain scores (mm) compared to those without depression [62.3(22.1) vs 43.4(24.3); 
p=0.05, Figure 7.3]. Patients with depression also had significant improvement in total pain 
score compared to those without depression, after adjusting for allocation to the active or 
placebo arm of the study [mean change in total pain scores (SD) -31.6(24.2) vs -10.7(25.0); 
p=0.04, SEM 9.8, 95%CI 0.54:41.1],
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95% -37.6: -35.8: -39.2: -28.2: -30.1: -29.7: -29.0: -21.3: -21.7: -22.7: -23.1: -22.6: -21.8:
Cl -0.001 7.00 5.67 14.2 13.6 15.9 17.4 23.9 24.5 24.7 25.0 26.6 26.8
Figure 7.3: Mean weekly total pain scores (visual analogue scale, mm) of patients categorised according to Hospital Anxiety and Depression
Scores (HADS). * p = 0.05, # p > 0.05.
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7.4 D iscussion
Despite being a common illness, to date there exist few effective treatments that provide 
symptomatic relief for painful DPN. For centuries, cannabinoids have been consumed for 
their analgesic properties and more recently studied in other neuropathic conditions, namely 
multiple sclerosis (Kalant 2001). This is the first randomised, placebo-controlled trial 
assessing the efficacy and tolerability of a sativex in the treatment of painful DPN.
In this study, when compared to placebo, Sativex failed to show statistically 
significant improvements in primary and secondary outcome measures. However, there 
were small but modest improvements in objective neurophysiological assessments of 
peripheral nerve function in patients receiving the active treatment. These improvements 
were demonstrated in assessments of large nerve fibre but not small fibre function. Notably, 
the observed changes in nerve conduction parameters approached clinical significance, 
which has been defined as a d-value ranging from 2.2 to 2.9m/s for conduction velocity and 
0.7 to 1.2mV for amplitude (Dyck and O'Brien 1989). Overall, however, the differences in 
scores between study groups were relatively small compared to the observed variance.
One potential confounder of the more patientive outcomes (pain and quality of life 
assessments) of this study was depression. As demonstrated in our post hoc analysis, 
patients with depression had higher baseline pain scores compared to those without 
depression. In addition, patients with even moderate levels of depression (HADS 13.4[3.5]) 
were more likely to respond favourably to intervention (regardless if active or placebo) with 
significant improvements in study end points.
Several studies have demonstrated that quality of life is significantly reduced in 
patients with painful DPN (Benbow, Wallymahmed et al. 1998; Galer, Gianas et al. 2000; 
Vinik, Hayes et al. 2005). These patients are also more likely than patients without DPN to 
have additional co-morbidities which include anxiety and pain associated interference with
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sleep and activities of daily living (Gore, Brandenburg et al. 2005). It is not surprising, 
therefore, when these combinations lead to depression (Berger, Dukes et al. 2004). Most 
painful DPN clinical trials to date have not screened for depression and those that have use 
it as a reason to exclude patients from the study (Max, Lynch et al. 1992; Wernicke, Pritchett 
et al. 2006). Depression was a significant factor affecting the outcome of this study and 
could potentially be a major confounder in trials assessing the efficacy of therapeutic 
interventions in painful DPN. Future clinical trials should therefore consider screening for the 
presence of depression before recruiting patients to prevent its impact on outcomes.
Improvements in neurophysiological parameters observed in this study are novel, 
incidental findings and require confirmation in a larger, adequately powered study. There 
have previously been no human studies investigating the effects of cannabinoid agonists on 
nerve electrophysiology in DPN. Cannabinoid receptors have been identified throughout the 
nervous system and divided into two main classes: CB1 and CB2 (Grant and Cahn 2005). 
CB1 receptors have been demonstrated in both the PNS and CNS, including areas in the 
brain and spinal cord involved in pain transmission and modulation (Hohmann and 
Herkenham 1999) (Farquhar-Smith, Egertova et al. 2000). Electrophysiological and 
neurochemical studies in rats provide further evidence that cannabinoids suppress 
nociceptive transmission in vivo (Ahluwalia, Urban et al. 2000). This suppression is mediated 
by cannabinoid receptors and is generalised to different modalities of noxious stimulation 
(mechanical, thermal and chemical) (Iversen and Chapman 2002). Cameron et al. reported 
the antinociceptive property of cannabinoids in painful DPN in diabetic rats (Ellington, Cotter 
et al. 2002). They demonstrated that activation of peripheral CB1 receptors results in 
analgesia by inhibition of capsacin evoked neuropeptide (calcitonin gene related peptide) 
release. None of these studies, however, assessed changes in nerve electrophysiology 
following the administration of cannabinoids. Recently, new non-CB1/CB2 cannabinoid 
receptors have been found in capsaicin sensitive sensory nerves in rats (Duncan, Kendall et 
al. 2004). These receptors modulate arterial vasoconstriction/relaxation. Hence we postulate
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that improvements in nerve electrophysiology demonstrated in our study maybe the 
consequence of changes/improvements in nerve blood flow.
In addition to depression, the use of concurrent analgesic medications may also be 
another confounding factor. We allowed patients to continue these medications because of 
the proposed adjunctive use of Sativex for painful DPN. Also ethically we were reluctant to 
stop these medications as patients could have been benefiting from them. This may have 
attenuated the analgesic response to Sativex that was eventually observed.
In this study, as in a number of recent studies, there was a large placebo effect that 
led to a failure to show a difference in outcome measures. This study provides a unique 
insight into the placebo effect in a painful DPN trial. The patient population studied consisted 
of individuals with severe intractable neuropathic pain, causing significant morbidity and 
limitations to quality of life. The average duration of symptoms was long, over which period 
patients have tried and failed on a number of conventional medications. Hence, this group of 
individuals reflected the more severe end of the spectrum of DPN and were desperate for 
any intervention to improve their pain. These terribly disabled patients, not uncommon in 
clinical practice, were studied to see if adjunctive treatment with Sativex could provide 
additional pain relief. However, the high expectations of improvement upon entering the 
study, together with the psychological effects of taking medication combined with frequent 
interactions with a team of researchers interested in their well being and tendencies to 
please their doctors, may have resulted in the unexpectedly large placebo response. Notably 
there was no difference in the use of rescue medication between study groups to account for 
the improvements seen in the placebo group.
Recent clinical trials of pain relieving compounds in painful DPN have failed to show 
significant improvements in both clinical and neurophysiological surrogate neuropathy end­
points. The Ruboxistaurin Study Group recently reported on the placebo treated arms of two 
large, randomised, controlled trials (Tesfaye, Tandan et al. 2007). They found significant
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improvements not only in symptoms but also in signs and quantitative vibration testing, in 
both the placebo and active arms even after one year follow-up. It was surprising that 
despite such a long follow-up period, there was (Boulton 2007) a strong placebo effect.
Given the strong interaction between chronic pain and depression and the findings of 
our study, concomitant depression could have been another confounding influence. This 
underlines the need for development of robust and objective clinical endpoints for use in 
clinical trials of painful neuropathy. Finally, whilst the search for therapeutic agents to halt or 
reverse the neuropathic process continues, more effective treatments are required which 
provided better symptom control with fewer side effects. In this first ever study assessing the 
efficacy of CBME in painful DPN, there was a large placebo response that led to negative 
findings. However, we identified depression as a major contributory factor influencing the 
outcome of this study. Therefore assessment of depression is important in future clinical 
trials into painful DPN.
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8 FINAL DISCUSSION AND FURTHER WORK
A principal aim of this work was to investigate the involvement of the CNS in DPN. In 
chapter 3, I report that spinal cord atrophy is present not only in patients with established 
painless DPN, but appears to be an early phenomenon in patients with subclinical DPN. In 
addition, I also found significant correlations between spinal cord area and traditional 
neuropathy severity markers and Composite Neuropathy Score. Hence I postulate that 
spinal cord involvement may occur concomitantly with peripheral nerve damage. The 
findings of this study clearly demonstrate that the neuropathic process in man is not confined 
to the peripheral nerve and does involve the spinal cord. Worryingly, this occurs early in the 
neuropathic process. Even at the Subclinical DPN stage, extensive and perhaps even 
irreversible damage may have occurred. Prospective studies are now required to determine 
the natural history of spinal cord involvement in DPN.
As the spinal cord is the caudal portion of the CNS, its involvement made us question 
whether the brain too may be involved. Ascending sensory pathways traverse the spinal 
cord to terminate within the thalamus. The thalamus does not merely act as a sensory relay 
station but recently has been found to modulate/process information before it is transmitted 
to the sensory cortex. Using NAA resonance derived from H-MRS as a marker of neuronal 
integrity, I reported in chapter 4 the presence of thalamic neuronal dysfunction in patients 
with Painless DPN. This suggests the impact of diabetes on the nervous system appears to 
be far more generalised than previously thought. A larger study is required to confirm the 
findings of this preliminary study but also to investigate if neuronal dysfunction affects other 
regions of the brain responsible for sensory perception e.g. somatosensory cortex. A more 
thorough appreciation of the nature and extent of involvement of the thalamus a) at different 
stages of neuropathy and b) in painful neuropathy may be important to the understanding 
and hence treatment of this condition.
Little is known of the pathogenesis of thalamic neuronal impairment in DPN. In Chapter 
5 I investigate a metabolic hypothesis involving abnormal glutamatergic homeostasis and 
astrocyte dysfunction. We report elevated Glx resonance and impaired thalamic astrocyte 
glial response to neuronal impairment in DPN. With evidence from histopathological studies 
that have shown glutamatergic dysfunction potentially results in neurotoxicity and 
subsequent neuronal dysfunction, our demonstration of elevated Glx suggests that 
glutamate mediated neuronal injury/cell death may be one of the mechanisms resulting in 
thalamic neuronal dysfunction in DPN. The diminished thalamic astrocyte response to 
neuronal impairment, as evidenced by lower ml resonance in patients with DPN, suggests 
that astrocyte dysfunction could be the underlying cause for abnormal thalamic 
glutamatergic homeostasis. Given the pathophysiological importance of glutamate further 
evaluation of the relationship between thalamic H-MRS abnormalities and DPN is needed.
In Chapter 6 I report on an MR perfusion study of the thalamus to in DPN. Using 
exogenous intravenous contrast and fast acquisition sequence we were able to study the 
microvascular perfusion characteristics of the thalamus. Diabetic patients with Painful DPN 
had significantly higher thalamic rCBV and shorter recirculation time compared to the other 
study groups. This suggests that abnormal thalamic vascularity could be an important 
contributing factor to the development of pain in diabetes. These novel findings suggest a 
pathogenic microvascular mechanism for thalamic neuronal dysfunction in DN, which may 
be amenable to modifications of microvascular disease risk factors. MR perfusion is a 
promising technique providing biomarkers for assessing regional brain haemodynamic 
function in DN Evaluating a larger sample of patients and including a subgroup with 
Subclinical DPN will not only provide more information on the reproducibility of MR perfusion 
imaging but also may lead to a new insight into the pathogenesis of CNS complications in 
DPN.
Painful diabetic neuropathy is a relatively common complication of diabetes that 
causes great distress and disability to sufferers and affects quality of life immensely.
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Unfortunately current drugs are empirically given to sufferers of neuropathic pain of many 
origins and at best provide clinically significant (>50%) pain relief in only one third of 
patients, and this is achieved at the expense of often intolerable side-effect. Many patients 
turn to alternative therapies seeking adequate pain relief. In our clinical practice, we have 
had anecdotal reports of patients receiving significant pain relief from the use of cannabis. 
Hence we designed a randomised placebo controlled trial to assess the efficacy, tolerability 
and safety of sativex, in painful DPN. I reported the results of this study in Chapter 7. There 
was no significant difference in primary or secondary outcome measures of pain relief 
between patients randomised to sativex compared with placebo. In a subsequent post-hoc 
analysis, I reported that a potential major confounder to this trial and possibly future clinical 
trials in painful DPN is the presence of depression. Patients with depression had higher 
baseline pain scores and responded more favourably to the intervention regardless of 
receiving the active compound or placebo. A subsequent larger multi centre clinical trial 
based on this study showed similar results. Another factor which may have Influenced the 
outcome of this trial was the unexpected large placebo response. Whilst the search for 
therapeutic agents to halt or reverse the neuropathic process continues, more effective 
treatments are required which provide better symptom control with fewer side effects. The 
assessment of depression may be important when designing future clinical trials Into painful- 
DPN.
Our limited knowledge of the pathophysiological mechanisms involved In the onset and 
persistence of painful neuropathy possibly explains the lack of rationale (mechanism-based) 
treatment approaches that specifically target painful DPN. Recent evidence points to 
changes (central sensitisation) that occur at different levels within the CNS that may play an 
Important role In the pathogenesis of painful DPN.
Future studies to address this will take advantage of recent advances in non-lnvasive, 
In-vivo neuroimaging techniques which allow Investigation of regional brain activation In 
response to painful stimuli (BOLD fMRI). Utilising fMRI to study any disruption of the pain
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matrix may provide sensitive and specific biomarkers of the sensation of DPNP. As well as 
clarifying disease mechanisms, identifying the neural correlates of pain-processing in DPN 
will result in opportunities to target specific components of the pain pathway 
pharmacologically. Combination of fMRI and drug administration, known as pharmacological 
fMRI (phMRI) may prove useful in the future development of new analgesic compounds. 
Experience from other chronic pain conditions strongly supports the view that neuro-imaging 
will aid our understanding of the basic mechanisms contributing to chronic pain states. 
These techniques might help diagnose a patient's pain condition in a more objective and 
robust way, enabling better targeting of therapies and rapid development of compounds to 
alleviate pain. A better understanding of these processes may lead to: i) a novel way of 
monitoring disease activity, natural history, response to treatment (quantify objectively the 
placebo effect) and ii) the identification of new targets for future therapies.
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APPENDIX 1: Metabolic and Vascular Consequences of Diabetes on the Central 
Nervous System.
Diabetes mellitus is a common metabolic disorder that results in considerable morbidity, 
most of which is the results of target end-organ damage. The kidney, retina, peripheral 
nervous system (PNS), and small and large blood vessels are the predominant organs, 
which have been the focus of most clinical and experimental studies. The central nervous 
system (CNS), which is both functionally and structurally connected to the PNS, has been 
largely ignored. In recent years it has become evident that diabetes causes significant CNS 
complications, resulting in Important functional Impairments (Mijnhout, Scheltens et al. 
2006). The CNS is affected by both the metabolic and vascular consequences of diabetes.
Cognitive Dysfunction
It Is well established that the frequency of both diabetes and cognitive dysfunction Increases 
with age (Brands, Henselmans et al. 2003). Epidemiologic studies have reported that 
diabetes Is an independent risk factor for cognitive Impairment (Fagot-Campagna, Bourdel- 
Marchasson et al. 2005; van den Berg, de Craen et al. 2006). Thus, It is not surprising then 
that both prospective and cross-sectional studies have suggested a link between diabetes 
and an Increased risk of dementia (Lobo, Launer et al. 2000; Areosa and Grlmley 2002; 
Allen, Frier et al. 2004). However, whether this refers to an increased risk of vascular 
dementia or Alzheimer’s disease Is still a cause of much debate. In most studies the 
definition of Alzheimer’s disease is the presence of dementia in the absence of other 
systemic disorders (ie, vascular disease), which could account for the progressive decline 
(Stewart and Liolitsa 1999). It appears that categorising dementia into distinct subgroups 
limits etiologic research because this does not adequately recognize mixed, often 
overlapping disorders such as diabetes that may have effects on more than one pathologic 
process (Stewart and Liolitsa 1999).
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Epidemiology
There have been a number of studies investigating the association between diabetes and 
cognitive decline and dementia (Heyman, Wilkinson et al. 1984; Broe, Henderson et al. 
1990; Mortel, Wood et al. 1993; Ott, Stolk et al. 1996; Lindsay, Hebert et al. 1997). Two 
community-based prospective studies that have been performed are the Hisayama Study 
(Yoshitake, Kiyohara et al. 1995) and the Rotterdam Study (Ott, Stolk et al. 1996). The 
Hisayama Study reported a relative risk (RR) conferred by diabetes of 2.77 and 2.18 for 
vascular dementia and Alzheimer’s disease, respectively. However, the diagnosis of 
diabetes was based only on history alone and, therefore, possibly overestimated its impact. 
The Rotterdam Study, on the other hand, used a more robust combination of history and 
random blood glucose, and if necessary an oral glucose tolerance test to diagnose diabetes. 
Here there was a significant increase in the RR of 1.9 in developing dementia and 
Alzheimer’s disease. A nonsignificant increase in the RR of 1.0 was found for vascular 
dementia (Ott, Stolk et al. 1996).
Risk factors and pathogenesis
A number of factors coexist with diabetes that could explain its association with cognitive 
impairment and dementia.
Atherosclerotic disease
The Framingham Study demonstrated that hypertensive disease has clear modulating 
effects on cognitive dysfunction in diabetes (Elias, Elias et al. 1997). Diabetic hypertensive 
patients have low A/-acetylaspartate (NAA) in deep white matter regions compared with 
hypertensive and normotensive individuals (Walker, Ben Salem et al. 2006). Cerebral NAA is 
an indicator of functional neuronal and axonal mass. Previous MRI studies showed that 
ischemic white matter lesions are associated with cognitive dysfunction, depression, gait 
disturbance, and future stroke (Sabri, Ringelstein et al. 1999; Firbank, Minett et al. 2003).
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Thus, the decreased NAA in diabetic hypertensive patients indicates an increased risk for 
cognitive dysfunction.
In addition, raised triglyceride levels are also associated with worse performance on 
cognitive tests assessing attention, concentration, and psychomotor speed in patients with 
diabetes (Perlmuter, Nathan et al. 1988). These effects were independent of the cholesterol 
level, hypertension, and the rate of glycaemic control. Therefore, it is likely that when these 
risk factors combine, they mediate the development of cognitive dysfunction through 
acceleration of atherosclerotic disease.
Being overweight (body mass index □ 25 kg/m2) and obese (□ 30 kg/m2) seems to 
be a risk factor for early dementia, whereas variation within the healthy range of body mass 
index (18.5-24.9 kg/m2) during midlife may not (Gustafson 2006) . Because being 
overweight or obese may indicate a vascular burden increasing the risk for subsequent 
vascular disorders, these states may be an initial trigger eventually leading to Alzheimer’s 
disease and vascular forms of dementia (Gustafson 2006) . However, it is overlooked that 
adipose tissue is the largest endocrine organ in the human body and that the effects of being 
overweight or obese on brain health might be independent of vascular effects and instead be 
due to adipocyte hormones and cytokines (Gustafson 2006).
Glycaemic control
Glycaemic control may also be involved because elevated fasting plasma glucose and 
higher glycosylated hemoglobin (HbAic) have been found to increase error on the Mini- 
Mental State Examination and are associated with impairment in concentration and memory 
in patients with diabetes (Kalmijn, Feskens et al. 1995). Both the Rotterdam and 
Framingham studies found increased risk of dementia among patients with diabetes treated 
with insulin (Ott, Stolk et al. 1996; Elias, Elias et al. 1997)[5,8], Patients on oral 
hypoglycaemic agents had an intermediate risk, suggesting that insulin treatment is not
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causally related to the development of dementia but rather Is a reflection of glycaemic 
control.
HbA1c is also a risk factor for a greater risk of brain atrophy. In fact, the only 
significant correlate of the rate of brain atrophy other than age was greater HbA1c in 
individuals without diabetes (Enzinger, Fazekas et al. 2005). The ARIC (Atherosclerosis Risk 
in Communities) study was a population-based magnetic resonance prospective 
investigation of atherosclerosis, cardiovascular risk factors, and cerebral atrophy as 
assessed by ventricular and sulcal size (Knopman, Mosley et al. 2005). Diabetes was found 
to be associated with increased ventricular size and, therefore, may contribute to pathologic 
reductions in brain volume. Using a more precise method, the Framingham Offspring Study 
reported that both diabetes and hypertension were associated with whole-brain volume 
reductions (Seshadri, Wolf et al. 2004). Another population-based study, in a larger 
European cohort (CASCADE [Cardiovascular Determinants of Dementia]), also reported a 
strong association between diabetes and cortical atrophy (Schmidt, Launer et al. 2004).
Insulin resistance
Investigators of the Rotterdam study observed that the association between diabetes and 
cognitive decline persisted despite adjustments for evidence of strokes and other 
cardiovascular risk factors (Ott, Stolk et al. 1996). In fact the impact of traditional risk factors 
for atherosclerotic disease on the RR of incident dementia was minimal (Ott, Stolk et al. 
1996). This suggests that other nonvascular mechanisms may also play a major role in the 
pathogenesis of dementia (Stewart and Liolitsa 1999). One possible underlying mechanism 
may be the apparent similarity between the pathogenesis of insulin resistance and 
Alzheimer’s disease. The structure of amylin, characteristically found in the pancreatic islets 
of Langerhans in type 2 diabetes, is similar to the p amyloid found in the neuronal plaques of 
Alzheimer’s disease (Cooper, Leighton et al. 1988; Edgington 1994; Dore, Kar et al. 1997). 
They both are peptides made of p pleated sheets that induce toxic effects in both
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Alzheimer’s disease and diabetes. Defects in the insulin-like growth factor-1 signaling 
pathway may also be important in both amyloid plaque formation and neuronal loss in 
Alzheimer’s disease and in amylin-induced toxicity in diabetes (Dore, Kar et al. 1997).
Acetylcholine levels, an important neurotransmitter thought to have a major role in 
mediating the effect of cognitive decline in Alzheimer’s disease, have been found to be 
reduced in the brain of patients with diabetes (Coyle, Price et al. 1983). Other abnormalities 
related to diabetes that may have negative consequences on cognitive function are 
mitochondrial dysfunction (Odawara, Tada et al. 1995) and the neurotoxic processes of the 
aldose reductase pathway (Greene, Sima et al. 1992).
Advanced glycation end products
Advanced glycation end products (AGEs), the byproducts of chronic hyperglycemia, may 
also have a role in promoting cognitive decline. Postmortem studies have shown that AGEs 
are present within the matrix of neurofibrillary tangles and senile plaques of Alzheimer’s 
disease (Dickson, Sinicropi et al. 1996; Horie, Miyata et al. 1997; Takeda, Wakai et al. 
2001). This has led several investigators to postulate a role for glycation as a mechanism 
contributing to amyloidogenesis and the assembling of tau proteins, the building blocks of 
neurofibrillary tangles in Alzheimer’s disease (Finch and Cohen 1997). In addition, the 
activation of the RAGE receptor by AGEs may also result in disturbances in vascular 
homeostasis, leading to further ischemic damage (Renard, Chappey et al. 1997). The 
binding of p amyloid to the RAGE receptor may also contribute to neuronal loss in 
Alzheimer’s disease (Yan, Fu et al. 1997).
What remains uncertain, however, is whether these vascular and nonvascular 
abnormalities that have so far been demonstrated in patients with diabetes induce the 
development of Alzheimer’s disease or simply exacerbate a pre-existing disposition to 
development of Alzheimer’s disease. Only long-term prospective postmortem and magnetic 
resonance studies will be able to address this question.
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Despite the wealth of evidence for the relationship between diabetes, dementia, and 
cognitive dysfunction, studies assessing the impact of diabetes management on modifying 
the rate or nature of cognitive decline have been few and far between. Gradman et al. 
(Gradman, Laws et al. 1993) assessed the impact of glycaemic control on cognitive function 
in patients with type 2 diabetes treated with glipizide for 7 months. These investigators 
concluded that poor glycaemic control in older patients with type 2 diabetes is associated 
with impaired cognitive functioning and that verbal learning and memory improved with 
better control. In a larger randomized controlled study, Ryan et al. (Ryan, Freed et al. 2006) 
found similar and statistically significant cognitive improvement with both rosiglitazone and 
glyburide following a 24-week treatment period. The magnitude of this effect was correlated 
with the degree to the improvement in fasting plasma glucose, although improvements in 
circulatory insulin and insulin sensitivity in the thiazolidinedione cohort did not impact on 
cognitive function.
Hypoglycaemia
Hypoglycemia and Cognitive Dysfunction
In healthy humans, brain glucose supply is maintained by an efficient homeostatic 
mechanism, which keeps blood glucose concentrations in a narrow range, sufficient to 
support normal brain function (Maran, Lomas et al. 1995). Falling blood glucose levels, 
unless corrected, would lead progressively from cognitive impairment to convulsion, coma, 
and eventually death. Using clamp techniques, moderate levels of hypoglycemia impair 
general cognitive abilities, including reaction time, analytical ability, verbal fluency, and 
verbal and visual memory (Frier and Fisher 1999). Cognitive performance as assessed by 
neurophysiologic methods, such as the P300 wave evoked potential (considered to 
represent stimulus processing and selection), are abnormal during moderate hypoglycemia 
indicating slower information processing (Picton 1992). Studies using the stepped glucose 
clamp have reported varying levels, between 2.3 to 3.1 mmol/L, at which cognitive
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impairment occurs (Widom and Simonson 1990; Fanelli, Epifano et al. 1993; Veneman, 
Mitrakou et al. 1994).
There are also suggestions in the literature that some cognitive processes are more 
sensitive to hypoglycemia than others. For example, during moderate hypoglycemia, working 
memory is completely abolished, whereas short- and long-tern memory only deteriorate in 
the same patients (Deary, Sommerfield et al. 2003). Simple reaction time was less affected 
than choice reaction time and finger tapping was insensitive to hypoglycemia (Cox, Gonder- 
Frederick et al. 1993). Using functional MRI to study regional changes in oxygenation status 
of the brain, Rosenthal et al. have shown that the effect of acute hypoglycemia on the 
human brain is both task and region specific (Rosenthal, Amiel et al. 2001). When the 
performance of simple tasks (finger tapping) is impaired by hypoglycemia, associated 
localized reduction in brain activation is seen. For more complex tasks (four choice reaction 
time), on the other hand, there is increased activation in planning areas compatible with 
recruitment of brain regions in an attempt to limit dysfunction. This may help explain the 
differences in sensitivity to hypoglycemia observed in different cortical functions.
The consequences of chronic recurrent severe hypoglycemia on the brain are not 
fully defined. The prospective DCCT (Diabetes Control and Complications Trial) and the 
Stockholm Diabetes Intervention Study have not shown any adverse effects of hypoglycemia 
on cognitive ability (DCCT research group 1996; Reichard, Pihl et al. 1996). However, these 
studies may not have been sufficiently long, and in the case of the DCCT there appeared to 
be a rather low rate of severe hypoglycemia (Warren and Frier 2005). Nonetheless, it is 
likely that hypoglycemia probably acts in conjunction with the other insults of diabetes 
(hyperglycemia, insulin resistance, hypertension, dyslipidemia, and so forth) to cause 
“diabetic encephalopathy” (Mijnhout, Scheltens et al. 2006).
Counterregulation
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In healthy patients there are separate blood glucose thresholds for the sequence of events 
that occur during hypoglycemia. The triggering of autonomic activation occurs before 
significant cortical dysfunction develops. This allows an individual to remain able to take 
appropriate corrective action before coma ensues (Hepburn, Deary et al. 1991). 
Unfortunately, the adaptation of these thresholds to glycaemic exposure can subsequently 
lead to severe or life-threatening hypoglycaemic episodes (Cryer 1999).
In humans, Boyle et. al. demonstrated preservation of whole-brain glucose uptake In 
patients with strictly controlled diabetes during experimental hypoglycemia (3.0 mmol/L) 
compared with a 20% fall In glucose uptake in nondiabetic patients and patients with poorly 
controlled diabetes (Boyle, Kempers et al. 1995). A recent study using magnetic resonance 
spectroscopy demonstrated increased glucose content during hyperglycemia in patients who 
were hypoglycemia unaware compared with nondiabetic patients (Criego, Tkac et al. 2005). 
This suggests that hypoglycemia counterregulation is at least partly triggered by a glucose- 
sensitive brain region and so the brain must be responsible for adaptation to some degree.
One mechanism proposed for adaptation is brain upregulation of the GLUT1 
transporter (Boyle, Nagy et al. 1994). Other authors have proposed the production of 
alternative brain fuels; however, neither the nature nor the existence of a second adaptive 
mechanism is clear (Me 1953; Sloviter, Shimkin et al. 1966; Agardh, Westerberg et al. 1980). 
The adaptive mechanisms appear to be both dynamic and reversible. Mitrakou et al. 
demonstrated the preservation of cognitive function at blood glucose levels as low as 2.3 
mmol/L in patients with insulinomas and that this effect was abolished after surgical 
resection (Mitrakou, Fanelli et al. 1993). Fanelll et al. showed that careful avoidance of 
hypoglycemia by hypoglycaemic-unaware patients led to an increase In the blood glucose 
level for cognitive impairment (Fanelli, Epifano et al. 1993).
Hypoglycemia and brain damage
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Prolonged severe hypoglycemia eventually leads to coma and brain damage (Auer 
2004). As the levels of blood glucose fall progressively to the range of 1 to 2 mmol/L, 
patients start to become stuporous and drowsy. Cerebral tissue energy failure results when 
blood glucose falls by more than 97% (Feise, Kogure et al. 1977). Before this period, 
alternative fuels (lactate, glycerol, and ketone bodies) can sustain energy requirements. 
Lactate alone can substitute roughly for a quarter of glucose utilization. As the duration of 
hypoglycemia increases, coma finally supervenes when the threshold of energy failure is 
reached (< 1 mmol/L). Over time, this is accompanied electroencephalographically by 
isoelectricity. Once the electroencephalogram goes flat, neuronal necrosis appears over the 
ensuing minutes as the neurotransmitter aspartate is released into the extracellular space 
and floods excitatory amino acid receptors located on neuronal dendrites (Agardh, 
Folbergrova et al. 1978; Sandberg, Butcher et al. 1986)]. Calcium fluxes occur and resultant 
membrane breaks lead rapidly to neuronal necrosis. Significant neuronal necrosis occurs 
after 30 minutes of electrocerebral silence.
Hypoglycaemic brain damage is unique in its distribution. Unlike ischemia, the 
neuropathologic distribution of hypoglycaemic brain damage has a predilection for superficial 
cortical layers and necrosis of the dentate nucleus of the hippocampus is often seen (Auer, 
Wieloch et al. 1984). These characteristic appearances are called cortical laminar necrosis 
and occur as a result of delayed selective neuronal necrosis of the cerebral cortex, with the 
cerebellum and brain stem universally spared (Agardh, Kalimo et al. 1981; Agardh and 
Siesjo 1981). Hypoglycemia also results in asymmetrical brain damage. This is because 
electrocerebral silence, which is a prerequisite for the initiation of neuronal necrosis, is 
asynchronous between the cerebral hemispheres (Harris, Wieloch et al. 1984).
Diffusion-weighted MRI is an established tool In the assessment of patients with 
hypoglycaemic coma (Fujioka, Okuchi et al. 1997; Barkovich, Ali et al. 1998; Bakshi, Morcos 
et al. 2000; Finelli 2001; Chan, Erbay et al. 2003; Aoki, Sato et al. 2004). It is sensitive for 
detecting neuronal energy depletion and subsequent cytotoxic edema, visualizing such
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changes as a high intensity area. Within minutes, images can demonstrate abnormal signal 
and only fresh lesions are defined. The clinical outcome after a severe hypoglycaemic coma 
correlates with the basal ganglia involvement. Patients with basal ganglia involvement tend 
to survive in a persistent vegetative state, whereas those with the basal ganglia spared 
survive with lesser degrees of neurologic impairment.
Cerebrovascular Disease
Numerous prospective studies, mainly in type 2 diabetes, have shown a two- to 
fivefold increase in the RR of ischemic strokes (Abbott, Donahue et al. 1987; Davis, 
Dambrosia et al. 1987; Barrett-Connor and Khaw 1988; Stamler, Vaccaro et al. 1993; 
D'Agostino, Wolf et al. 1994; Kuusisto, Mykkanen et al. 1994; Tuomilehto, Rastenyte et al. 
1996; Folsom, Rasmussen et al. 1999). In the Framingham Study, the increased risk 
attributable to diabetes was independent of other risk factors such as systolic blood 
pressure, atrial fibrillation, antihypertensive treatment, smoking, cardiovascular disease, and 
left ventricular hypertrophy (Elias, Elias et al. 1997).
Risk factors
Nonmodifiable risk factors
Sex appears to be an important modulator for stroke risk. In women, diabetes is as 
potent a risk factor as cigarette smoking; compared with men, diabetes is associated with a 
higher stroke case fatality with an odds ratio of 2.33 (Rothwell, Coull et al. 2004). Age is a 
risk factor that increases the incidence of stroke as the population ages (You, McNeil et al. 
1997). Race and ethnicity also impact on the risk of stroke. The NOMAS (Northern 
Manhattan Stroke Study) found that blacks and Hispanics have a 2.4- and twofold increased 
risk of stroke, respectively, compared with whites (Sacco, Benson et al. 2001). This may be 
attributed to a greater role for diabetes and hypertension, which have a higher prevalence in 
these ethnic populations.
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M odifiable risk factors
Given the strong association between diabetes and stroke, it is perhaps not surprising that 
both fasting and random plasma glucose were among the baseline characteristics in a 
variety of prospective studies that most strongly predict stroke in patients with type 2 
diabetes mellitus. The UKPDS (United Kingdom Prospective Diabetes Study) reported that 
each 1% rise in HbA10 resulted in an increase in case fatality odds ratio by 1.37 (Stevens, 
Coleman et al. 2004). Hypertension is a frequent complication in patients with diabetes 
compounding the risk of stroke in this population. As in the general population, well- 
controlled blood pressure can reduce the risk of stroke significantly among patients with 
diabetes. Data from the UKPDS showed a 44% RR reduction for stroke in the groups where 
blood pressure was well controlled (mean blood pressure 144/82 mm Hg) (UK Prospective 
Diabetes Study group 1998). In fact, tight blood pressure control has a greater impact in 
reducing the risk of any diabetes-related end point than intensive glucose control (24% RR in 
tight blood pressure vs 12% RR in intensive glucose control group, P = 0.026).
The relationship between hypercholesterolemia and stroke risk, on the other hand, is 
more tenuous. Meta-analysis of epidemiologic studies has not shown a clear relationship 
between cholesterol levels and stroke (Atkins, Psaty et al. 1993). This possibly reflects the 
more heterogeneous nature of cerebrovascular disease compared with coronary artery 
disease, with fewer strokes attributable to large-vessel atherosclerotic disease. Nonetheless, 
two prospective intervention studies (LIPID [Long-term Intervention with Pravastatin in 
Ischaemic Disease] and CARE [Cholesterol and Recurrent Events]), which had 
cerebrovascular events as a primary end point, showed a big RR reduction with statin 
treatment compared with placebo (1998; LIPID Study Group 1998; Plehn, Davis et al. 1999). 
More recently, the CARDS (Collaborative Atorvastatin Diabetes Study) trial randomized 
2338 patients with type 2 diabetes without high low-density lipoprotein cholesterol, but with 
one other risk factor to receive either 10 mg of atorvastatin or placebo daily. Active treatment 
with atorvastatin significantly reduces the incidence of new stroke by 48%, independent of
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patient’s age, gender, baseline cholesterol, and blood pressure levels (Colhoun, Betteridge 
et al. 2004). In the NOMAS study, lower high-density lipoprotein (HDL) cholesterol has been 
shown to be associated with an increased risk of stroke (Sacco, Benson et al. 2001). This 
may suggest a link between diabetes through its association with metabolic syndrome and 
increased risk of stroke. This is possible because low HDL cholesterol levels are thought to 
contribute to the acceleration of atherosclerosis in many of these patients.
“Nontraditional”  risk factors
In the ARIC study, the influence of diabetes on stroke incidence was not entirely explained 
by a set of traditional risk factors with which it is known to be associated (Folsom, 
Rasmussen et al. 1999). Similar outcomes were seen in the Physicians’ Health Study, where 
clinical obesity increased stroke risk independent of blood pressure, cholesterol, and 
diabetes (Kurth, Gaziano et al. 2002). More recently, the Framingham Offspring Study found 
that the influence of the metabolic syndrome on stoke incidence persists after adjustment of 
its component risk factors (Najarian, Sullivan et al. 2006). This suggests that other factors of 
the metabolic syndrome, such as systemic inflammation, abnormal endothelial function, and 
vascular factors, may be operative. Thus, in addition to plasma glucose, the components of 
the metabolic syndrome both individually and collectively contribute to increased stroke risk.
Diabetic versus nondiabetic strokes
The distribution or pattern of ischemic stroke involvement differs with the presence or 
absence of diabetes. Autopsy studies suggest a higher rate of lacunae infarcts in the basal 
ganglia, paramedian basis pontis, thalamus, and cerebellum (Kane and Aronson 1968; 
Aronson 1973; Peress, Kane et al. 1973). These changes termed “encephalomalacia” have 
been seen in in vivo neuroimaging studies, where lacunar and subcortical infarcts are more 
common in patients with diabetes compared with complete middle cerebral artery territory 
infarcts (Karapanayiotides, Piechowski-Jozwiak et al. 2004). A prospective MRI study found 
that 41% of patients with type 2 diabetes who were initially free of lacunes developed them
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over the 5-year follow-up period (Inoue, Fushiml et al. 1998). This association between 
diabetes, lacunar infarct, and subcortical infarct points to small-vessel disease of the deep 
penetrating vessels of the brain. In fact, histopathologic vascular abnormalities commonly 
found in diabetic retinopathy and nephropathy have also been shown to affect cerebral 
vessels (Fischer, Barner et al. 1979; Factor, Okun et al. 1980). These changes dubbed 
“nonatherosclerotic diabetic microangiopathy” are characterized by the accumulation of 
periodic acid-Schiff-positive material in the tunica media of vessels (Andresen, Rasmussen 
et al. 1996). Therefore, common pathogenic mechanisms causing both macro- and 
microvascular complications are implicated. Impaired cerebrovascular reactivity as 
demonstrated by transcranial Doppler ultrasound is a risk marker for first-ever lacuna infarct 
(Molina, Sabin et al. 1999). Cerebrovascular reserve capacity is lower in patients with 
diabetes, suggesting that diabetic microangiopathy reduces the vasodilatory ability of 
cerebral arterioles, placing additional strain on already ischemic regions (Fulesdi, Limburg et 
al. 1999). Chronic hyperglycemia is also thought to increase anaerobic metabolism and 
acidotoxicity, which results in poorer prognosis after stroke (Fanelli, Epifano et al. 1993). All 
these factors in combination result in a higher mortality rate (Stamler, Vaccaro et al. 1993) 
and slower recovery (Megherbi, Milan et al. 2003) after stroke in patients with diabetes 
compared to patients without diabetes.
Poststroke hyperglycemia
Poststroke hyperglycemia is a frequent finding in patients presenting with acute stroke and is 
an established predictor of poor outcome in both diabetic and nondiabetic patients (Capes, 
Hunt et al. 2001). It is not clear if this is simply a reflection of the catabolic stress response to 
stroke and thus an association by proxy to stroke severity, or if hyperglycemia could have a 
detrimental affect by inducing serum hyperviscosity and promoting acidosis by acting as a 
substrate for anaerobic lactic production in an ischemic milieu (Idris, Thomson et al. 2006). 
Trials are currently underway to assess the benefits of maintaining euglycemia in patients 
with acute stroke (Gray, Scott et al. 2004). Another possible explanation for the greater
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prevalence of hyperglycemia in the acute stroke setting may be the unmasking of 
undiagnosed diabetes in this select group of patients who are already at high risk. A recent 
study estimated the prevalence of undiagnosed diabetes to range between 16% to 24% 
(confirmed by an oral glucose tolerance test 12 weeks after acute stroke)(Gray, Scott et al. 
2004). Two thirds of patients with poststroke hyperglycemia had either impaired glucose 
tolerance or diabetes in this study.
Intracerebral hemorrhage
Intracerebral hemorrhage (ICH) appears to be less common in diabetes. ICH was six times 
less frequent in diabetic patients in the Copenhagen Stroke Study (Jorgensen, Nakayama et 
al. 1994). In the Honolulu Heart Program, the risk of ischemic stroke increased across 
categories of increasing glucose intolerance, whereas the risk of ICH did not vary and was 
not significantly increased (Burchfiel, Curb et al. 1994). These findings from epidemiologic 
studies seem to support the pathologic evidence that diabetes may be a protective factor 
against ICH. In a series of consecutive autopsies, Kane and Aronson found that fibrinoid 
necrosis occurred infrequently in the arterioles and small arteries in the diabetic brain even 
in those with hypertension (Aronson 1973). Alex et al. postulated that basement membrane 
thickening and endothelial cell proliferation, commonly seen in diabetic brains, render the 
cerebral vessels less prone to rupture (Alex, Baron et al. 1962).
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APPENDIX 2: Standard Operating Procedures
DPN is usually easily detected by careful history and simple clinical examination. 
Sophisticated investigations are often unnecessary. Shoes and socks should be removed 
and the feet examined. Very occasionally, further investigations, including 
neurophysiological and radiological tests (e.g. MRI of the lumbosacral spine) may be 
required. For clinical trials and research purposes, a more detailed clinical assessment is 
require
Clinical Assessments 
Neuropathy Symptoms Assessments
When examining diabetic patients, it is important to ascertain that symptoms are of 
neuropathic origin (Table A7.1). The distribution and character of the sensory disturbance 
needs to be carefully documented, in order to exclude other causes of similar symptoms, 
such as lumbar disc prolapse, peripheral vascular disease, or musculoskeletal disorder (e.g. 
arthritis).
Table A7.1: Symptoms of DPN.
Sensory symptoms
Numbness, paraesthesiae, pain (burning, stabbing, shooting, deep aching), unusual 
sensations (‘tightly wrapped’, ‘swelling’, etc), allodynia, inability to identify objects in hands
Motor symptoms
difficulty climbing stairs, difficulty lifting/handling small objects
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Motor nerve fibres may be evaluated by measuring clinical strength. One may divide 
muscular weakness into ascendant degrees of severity, paralysis being the highest degree. 
The physician may ask the patient to perform a movement against a resistance. Reflex 
testing is an important part of this examination, although it may be normally reduced in a 
significant portion of the population older than 50.
Motor Assessment
Muscle strength is usually normal early during the course of the disease; however mild 
weakness may be found in toe extensors. However, with progressive disease there is 
significant generalised muscular wasting, particularly in the small muscles of the hands and 
feet. The fine movements of the fingers are then affected, and there is difficulty in handling 
small objects. The clawing of the toes is believed to be due to unopposed (because of 
wasting of the small muscles of the foot) pulling of the long extensor and flexor tendons.
Sensation Assessment
Sensation assessment is performed by looking at touch, vibration, temperature and pain 
sensations. Touch sensation can be tested by lightly rubbing a piece of cotton wool on the 
foot skin. More accurately, a nylon monofilament, which has been standardised to deliver a 
10 gram force when it applied perpendicularly to the skin’s surface and buckles, may be 
used. This is also known as Semmes-Weinsten monofilament. It has been validated for 
screening of patients at risk of developing ulcers. The test is positive if a patient fails to feel 2 
out of 5 sites tested (NHS electronic library for diabetes, 2001). Vibration sensation can be 
evaluated by using a tuning fork. In severe cases, patients will not perceive the sensation at 
all but in milder cases, perception will be reduced but present. Some tuning forks have 
weighted ends with a printed Hertz scale on them, which allows a more accurate 
determination of vibration threshold.
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Thermal sensations can be evaluated by using a metal rod, which induces a cold 
sensation in the normal patient but may not be perceived in those with small fibre DPN. 
Tubes filled with water can be warmed up to different temperatures so that sensitivity to 
warming may also be tested. Pain sensation is assessed by the pin prick test. The patient is 
asked whether he/she can distinguish between a blunt and a sharp object. Weighted 
needles can also be employed in order to establish a threshold (Chan, 1990, Bennett, 2001). 
The most common presenting abnormality is a reduction or absence of vibration sense in the 
toes. As the disease progresses there is sensory loss in a “stocking” and sometimes in a 
“glove” distribution involving all modalities. When there is severe sensory loss, 
proprioception may also be impaired, leading to a positive Romberg’s sign. Ankle tendon 
reflexes are lost and with more advanced neuropathy, knee reflexes are often reduced or 
absent.
Simple bed-side investigations
Vibration perception threshold may also be accurately determined using a biothesiometer 
(Figure A7.1). This device is relatively simple and provides a rapid and reproducible result. 
The stylus is placed on the great toe or any bony prominence and the patient asked to 
indicate when the vibratory sensation is first felt. The voltage at which this happens is the 
vibration perception threshold.
Figure A7.1: Biothesiomether
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Autonomic fibre function can be impaired very early in the natural history of diabetic 
neuropathy, long before autonomic symptoms develop. Recognising such impairment is 
important because the affected patients may benefit from a tight glycaemic control. The 
simplest way to measure autonomic function is by studying the cardiovascular system. 
Orthostatic hypotension has been proposed to occur when small fibres in the splanchnic 
vascular bed are damaged in advanced diabetic neuropathy (McLeod and Tuck 1987). This 
can be done by assessing the postural fall in blood pressure. Systolic blood pressure is 
recorded at rest with the patient lying on the couch, and then pressure is measured again 
after approximately 60 seconds of the patient standing up. Normally, the autonomic nervous 
system is able to keep the level of blood pressure relatively constant in such a situation. If 
the level falls by at least 30 mmHg, sympathetic autonomic failure is diagnosed. 
Parasympathetic autonomic function may be assessed by recording the ECG for a few 
minutes and looking at heart rate (R-R) variations. Physiologically, heart rate variations 
should be present at rest. However, these variations are lost in the presence of 
parasympathetic denervation. To enhance the sensitivity of this technique, the patient may 
perform slower and deeper breathings (6 in a minute) while the ECG is recorded.
Heart rate normally changes according to breathing, orthostatism, increased intra- 
thoracic pressure and sympathetic activation. O’Brien et al. have standardised a number of 
simple tests to evaluate autonomic nerve function (O'Brien, O'Hare et al. 1986). Age-related 
normative values have been established. However, these tests should be performed by a 
well-trained health care professional and demand particular care in interpretation. The 
sympathetic nervous system is assessed by the Valsalva manoeuvre (especially late phase 
II and phase IV) and by the blood pressure response to standing or tilt. The parasympathetic 
cardio-vagal axis may be assessed by measuring the R-R variation during deep breathing 
and during the Valsalva manoeuvre. Computer assisted autonomic function tests, including 
lying to standing R-R variation, response to the Valsalva manoeuvre, response of diastolic 
blood pressure to sustained handgrip; evaluation of genitor-urinary function. Autonomic
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neuropathy may also affect small fibres in the periphery, namely those innervating blood 
vessel and sweat glands. These are sympathetic fibres, either noradrenergic or cholinergic. 
Sweating may be quantified by droplets morphometry (Silastic imprint method) following 
iontophoresis of sympathetic agonist (Kennedy and Navarro 1989).
Assessment of neuropathic pain
Visual analogue and verbal descriptive scales
Neuropathic pain, which is variable in intensity, may be assessed by a visual analogue 
scale, which results have been shown to correlate with other measures of pain (Scott and 
Husklsson 1976). The patient is asked to indicate pain intensity on a line numbered from 0 to 
100. A verbal descriptive scale may also be employed, the patient being asked to describe 
pain intensity in accordance with a series of descriptive statements (e.g., absent, slight, 
intense, very intense, etc). An inherent assumption of both devices is that equal intervals 
along the scales denote equal degrees of pain; the use of the two scales together may 
increase confidence in the observed changes.
Questionnaires for pain
Various questionnaires are being proposed for neuropathic pain, however there is no 
general agreement on which one should be used in diabetes:
• Neuropathy Total Symptom Score-6 (Bastyr, Price et al. 2005) is an instrument that 
assesses symptoms rather than pain per se. A symptom score for frequency times is 
estimated separately for each of deep aching, superficial burning, prickling, and 
lancinating pains, as well as for numbness and allodynia. "Tight", "compression", 
"boring", "squeezing" descriptions of pain are to be included with deep-aching pain. 
Each symptom is graded on intensity (mild, moderate, or severe) and on frequency 
(never or occasional, occasional but abnormal [<33% of the time], often [>33% - 
>66%] or most continous [>66%]). The total score possible for each symptom is 3.66.
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• The Neuropathy Pain Scale (Galer and Jensen 1997) includes 10 items: intensity, 
sharp, hot, dull, cold, sensitive, itchy, unpleasant, deep, superficial. Patients are 
asked to answer on a 0 to 10 scale; according to the intensity of the category of pain 
they are experiencing. A score can then be calculated for each item.
• The LANSS (Leeds Assessment of Neuropathic Symptoms and Signs) pain scale 
includes a short questionnaire and a brief clinical examination. This assessment 
investigates the nature of pain. The higher the LANSS index, the more likely is the 
pathological the nature of the pain experienced. It may be used to distinguish 
neuropathic from nociceptive and psychogenic pain (Bennett 2001).
• The McGill Pain Questionnaire takes into account the quality and emotional aspects 
of pain. It consists of four classes of words describing pain, listed within each 
subclass in order of increasing intensity. The subclasses are grouped into four major 
categories: sensory (i.e., words that describe pain in terms of temporal, spatial, 
pressure, and other properties: subclasses 1-10), affective (i.e., words that describe 
pain in terms of tension, fear and autonomic symptoms: subclasses 11-15), 
evaluative (i.e., describing the overall intensity of the experience of pain: subgroup 
16), and miscellaneous (subgroups 17-20). A score can be calculated for each 
category. The questionnaire also asks for additional information such as 
exacerbating or relieving factors, and anatomical location. Patients are asked to 
choose one word from each group, or to omit the group entirely. Responses are 
scored using the rank values of words chosen (Melzack 1975). The McGill Pain 
questionnaire is a quick and simple tool and is very helpful in the global evaluation of 
chronic pain syndromes. It may be potentially useful to adapt it to address the 
specific problem of differential diagnosis of the neuropathic leg (Masson, Hunt et al. 
1989).
• Quantifying pain in diabetic neuropathy
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• Attempts to quantify this very patientive entity have led to the development of 
numerous questionnaires (Table A3.1). These employ verbal rating scales, self 
completed forms and visual analogue scales. It is also beneficial to use a quality of 
life assessment tool as quality of life is often affected in chronic pain states. Some of 
the more commonly used questionnaires are shown in the box below. They are most 
frequently used in pain clinics and in clinical trials setting.
Table A3.1: Questionnaires used to quantify and assess pain in diabetic 
neuropathy.
Pain generic
McGill Pain Questionnaire (Melzack 1975)
Neuropathic Pain Scale (Galer and Jensen 1997)
Quality of life generic
EuroQOL Questionnaire (The EuroQol group 1990)
Modified SF-36 (Jenkinson, Coulter etal. 1993)
Nottingham QOL questionnaire (Keinanen-Kiukaanniemi, Ohinmaa et al. 1996) 
Quality of life diabetes specific
Norfolk QOL questionnaire (Vinik, Hayes et al. 2005)
ADDQOL questionnaire (Bradley, Todd et al. 1999)
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Quality of Life assessment
Although diagnosis can readily be made on clinical examination, measuring the full impact of 
painful neuropathy is more difficult. Chronic pain affects many aspects of the sufferer's life. It 
is important to appreciate that there is little relationship between symptoms and signs. Some 
patients may experience severe symptoms with relatively normal examination and vice- 
versa. Thus, symptoms should not be dismissed, simply because there are no abnormal 
signs. Clinical assessment must also include examination of the mental state of the patient. 
An empathic approach to history taking is recommended, especially with regard to positive 
symptoms, as patients are often worried and distressed. Some patients with painful 
neuropathy are very anxious, as they mistakenly believe that their condition will inevitably 
result in amputation. Clearly, such unwarranted fears need to be dismissed by health care 
professionals. Others may feel guilty, as they perceive that a period of poor compliance with 
their diabetes control may have lead to their predicament. Some may be intensely angry, as 
they have to cope with yet another diabetic complication.
Unfortunately, there are few instruments specifically designed to assess quality of life 
in diabetic neuropathy. Clearly, any such instrument must take into account the presence 
and impact of other diabetic complications too, as these may influence overall well-being. 
Specifically developed questionnaires may allow patients to describe their experience in a 
more standardised manner, and this is particularly important in monitoring response to 
therapy. A number of questionnaires have been developed, in order to assess quality of life.
Health-related quality of life can be measured either with generic measures, such as 
the Nottingham Health Profile or the Medical Outcomes Study Short Form 36 (SF-36) (Hunt, 
McKenna et al. 1981; Jenkinson, Coulter et al. 1993) or with specific instruments for pain. 
Recently, a theoretically based, clinical relevant neuropathy-specific quality of life scale has 
been developed and validated. This instrument, called Neuropathy Quality of Life 
(NeuroQoL), includes a neuropathy symptoms checklist and psychosocial domains. Such an
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approach, being patient-centred, should increase physician’s understanding as to how 
diabetic patients experience and deal with their neuropathy (Vileikyte, Peyrot et al. 2003).
Severity of neuropathy
Although attention should be paid to symptoms, these per se are not a good measure of 
severity, since they tend to come and go and do not correlate well with severity of 
impairments (Dyck and Thomas 1999). Overall severity is rather the sum of all sensory, 
autonomic and motor symptoms and impairments caused by DPN. To help categorising 
patients more accurately within the context of a progressive disease, it is recommended 
(Grant et al., 1999) to take into account abnormalities in the following:
• Neuropathic symptoms: positive and negative symptoms, symptoms of weakness 
and autonomic symptoms.
• Neurological examination: sensory and motor examination
• Quantitative motor, sensory or autonomic examination: measurement of vibration, 
warmth and cool detection thresholds, heat as pain threshold, cardiac autonomic 
function tests etc.
• Nerve conduction: abnormality of nerve conduction of one or more attributes 
(amplitude, velocity or distal latency of motor nerves) in two or more nerves.
Staging of neuropathy has been developed by (Dyck and Thomas 1999). This staging 
depends upon the severity of neuropathic symptoms and great emphasis is given to 
neuropathic pain. Stages range from 0 (no neuropathy) to 3 (disabling neuropathy). Provided 
that minimal criteria for diabetic polyneuropathy are met, the presence of pain places a 
patient in stages 2 or 3. More precisely, pain is graded as being "disabling" (stage 3) when 
the patient has previously attended a physician for pain relief; work and recreational 
activities have been curtailed by at least 25% because of pain; and medication for pain relief
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has been taken on a continuing basis (>50% of days) for at least 6 weeks. When this is not 
the case, then a patient would be placed in stage 2 (pain of a lesser severity).
Clinical neuropathy assessment
Objective
To grade, score and report neuropathic dysfunction, impairment and symptoms using 
standard and reproducible approaches so that results are quantitative and useful for 
subdividing patients into different stages of diabetic neuropathy (DPN).
Key points
• Assessments were performed by investigator:
• Who is experienced in neurological examination.
• Uses the same basis for grading abnormality over time.
• Assume that the basis of abnormality is the 5th or 95th percentile (whichever applies) 
based on study of healthy patients (without neurologic disease, systemic disease or 
other exposure or deficiency predisposing patients to neurologic disease) taking into 
account age, sex, anthropomorphic factors (height, weight, body mass index) and 
physical fitness.
• Who washed his hands before and after examining patients and never re-used pins.
• Clinical assessments were performed in the following order: Neuropathy Symptom 
Score, Neuropathy Symptom Change questionnaire and upper and lower limb 
neurological examination (Neuropathy Impairment Score).
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Neuropathy Symptom s Score (NSS)
NSS is a standard tally of neuropathic symptoms abstracted from a neurologic history that 
inquires about neuropathic symptoms. Recorded symptoms related to DPN, not from cranial, 
plexus, mononeuropathies, arthritis, carpal tunnel, aches and pains of living etc. Investigator 
decided whether it is from DPN. The Investigator decides whether a symptom is beyond 
(abnormal) from what occurs in healthy people of the age and sex of that patient. It is graded 
towards specificity not sensitivity. A general approach used was to ask direct questions such 
as “ Do you have ...."
if the answer is “yes" and consistent with DPN, scored 1 recorded 
if the answer is “no”, scored 0 recorded 
Neuropathy Symptom Change (NSC)
The NSC is a standard true and false questionnaire of neuropathic symptoms based on an 
interview of patients by a trained clinician.
Clinical neurological examination
Lower lim b function
Standard proforma was completed. Ability to arise from kneeling and walk on toes and heels 
is quite a good indicator that major muscles of the lower limb are strong.
Neuropathy impairment score (NIS)
Cranial nerve involvement is atypical for DPN.
Muscle weakness (weakness graded was from DPN) 
the muscle groups tested are listed
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scored for age, sex, physical build, fitness and anthropomorphic features 
graded using percentile, plus:
0 = normal; 1 = 25%; 2 = 50% and 3 = 75% weak; 3.25 = just able to move joint against 
gravity; 3.5 = able to move at joint with gravity eliminated; 3.75 = muscle flicker only; and 4 = 
paralysed
Reflexes (abnormality graded due to DPN).
scored for age, sex, physical attributes (build, fitness and anthropomorphic features)
grade as 0 = normal, 1 = decreased, 2 = absent
hyperreflexia not graded
limbs repositioned as needed
if all reflexes were sluggish, graded as normal
decreased ankle reflexes were taken in context of age
used reinforcement where appropriate (i.e. clasped hands or clenched teeth)
Sensation
tested on terminal phalanx of index finger and great toes (other sites tested to help decide 
abnormality at sites recorded)
assessed were touch-pressure, joint position and motion, vibration and pin-prick
used cotton wool balls, neurotip pins, 10g monofilament and 257mHz tuning fork (Figure 
A7.2)
scoring was performed in the context of age, height and skin condition
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g ra d e d  fo r  sp e c ific ity , no t se n s itiv ity .
Figure A7.2: Tools for Clinical Examination 
Recognition of concomitant neuropathy
Oculomotor neuropathy, median neuropathy at the wrist (from carpal tunnel syndrome) and 
ulnar neuropathy at the elbow (from compression neuropathy) are common in diabetes. 
Radiculoplexus neuropathies (cervical, thoracic or lumbosacral [proximal, amyotrophy]) may 
occur or multiple mononeuropathy may also occur in diabetic patients. For this study, 
impairments or symptoms from these associated neuropathies were not included
Cardiovascular autonom ic fu n c tio n  tests
Background information
This is probably the most important and reliable index of cardiovagal integrity. The afferent 
and efferent pathways are vagal. That vagal efferents are important have been 
experimentally demonstrated in both experimental animals and in humans. In the cat, heart 
rate variations are predictable on basis of recorded vagal efferent activity (Egbert and 
Katona 1980) and its variation is blocked by atropine or by freezing (Anrep and Segall 1926;
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Koepchen, Klussendorf et al. 1981). In the human, atropine (a muscarinic antagonist) will 
totally abolish sinus arrhythmia (heart rate variation) (Wheeler and Watkins 1973).
The main origin of respiratory sinus arrhythmia has been suggested as being the 
medullary connection from the respiratory and cardioinhibitory centres. Evidence includes 
the preservation of heart rate variation with active but not passive breathing (Joels and 
Samueloff 1956; Katona and Jih 1975; Ott, Tarhan et al. 1975) and the loss of heart rate 
variation with brain stem infarction (Persson and Solders 1983).
Heart rate variation is greatly modulated by a number of peripheral inputs. These include:
1. Hering-Breuer respiratory reflex
When the lungs are stretched during inspiration pulmonary stretch receptors are activated 
and impulses travel up the vagus to cause inhibition of the respiratory centre.
2. Venoatrial mechanoreceptor sympathetic reflex
During inspiration there is increased filling and this reflex result in compensatory increased in 
heart rate (Brooks, Lu et al. 1966; Koizumi, Ishikawa et al. 1975)
3. Bainbridge reflex
Inspiration results in increased venous return and an increase in pressure in the right atrium 
and great veins which in turn stimulate an increase in heart rate. The pathway is likely right 
atrium -  vagus nerve -  nucleus of tractus solitarius -  vagus -  sinoatrial node. The normal 
function of this reflex is probably a way of handling the increased venous return. This reflex 
is assessed by the valsalva manoeuvre, which results in an increase in venous return 
(Bainbridge 1915; Bainbridge 1920).
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4. Baroreceptors
Blood pressure (pulse pressure) changes occur during respiration. It has been suggested 
that breathing mechanically influences the left ventricle output activating arterial baroreflexes 
(Manzotti 1958; Davies and Neilson 1967). Also during inspiration there is an increase in 
negative intra thoracic pressure resulting in an increase in venous return -  increase atrial 
filling -  increase stroke volume and cardiac output (since CO = SV x HR) and blood 
pressure (since BP = CO x PR). The increase in blood pressure activates the baroreceptors 
and reflex variations of heart rate occur. Melcher suggested that sinus arrhythmia was due to 
a cardio-cardiac reflex with central resetting of the baroreflex (Melcher 1976). Standing 
produces venous pooling due to a gravitational effect, and hence a fall in venous return. 
Under normal circumstances, reflex activation of an intact sympathetic nervous system 
occurs, resulting in an increase in the force and rate of cardiac contraction, and peripheral 
vasoconstriction.
In conclusion, the efferent pathway is clearly vagal, since efferent blockade will 
abolish the reflex. However, the afferent and central mechanisms are problematical in 
humans. Based on present information, distension of the right atrium appears to be 
important. However, all of the above mentioned pathways could be important under different 
circumstances.
Factors that affect heart rate variation in autonomic function tests
1. Position
Heart rate variation varies with the position of the patient. The response is larger supine than 
sitting or erect (standing; (Davies and Neilson 1967; Bennett, Fentem et al. 1977; Mackay, 
Page et al. 1980). For this reason the patient is supine for assessments.
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2. Depth of breathing
A standardised tidal volume was used since depth of breathing above about two litres 
causes insignificant changes in heart rate variation (Freyschuss and Melcher 1975). Bennet 
et al and Eckberg found little or no difference in heart rate variation for different depths of 
respiration (Bennett, Farquhar et al. 1978; Eckberg 1983).
3. Rate of breathing
Maximum heart rate variation with deep breathing occurs at a breathing frequency of 5-6 
rpm (Angelone and Coulter 1964; Bennett, Farquhar et al. 1978; Mackay, Page et al. 1980; 
Pfeifer, Cook et al. 1982) in normal patients and this observation forms the basis for the 
standard test for deep breathing (Wheeler and Watkins 1973). Each patient breathes at six 
breaths per minute (five seconds in / five seconds out).
4. Effect of age
All studies to date have found a progressive reduction in the response with increasing age. 
Results were compared with age related normal ranges
5. Effect of sex of the patient
No sex difference have been observed (Hilsted and Jensen 1979)
6. Amount of rest
It has been demonstrated that following five minutes of rest, another 25 minutes of supine 
rest does not alter the heart rate variation (Hilsted and Jensen 1979). For this reason 
patients were asked to rest supine for five minutes before starting the test.
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7. Influence of sympathetic activity
There is a sympathetic modulation of heart rate variation being inhibited by stress and 
sympathetic activation (Coker, Koziell et al. 1984) and during severe tachycardia (Pfeifer, 
Cook et al. 1982). For this reason patients were relaxed and comfortable during the duration 
of the study.
8. Time of day
No significant difference has been found in heart rate variation performed in the same 
patients in the morning and afternoon (Bennett, Farquhar et al. 1978).
9. Hypocapnia
One indirect effect of prolonged hyperventilation is the reduction of pC02 resulting in a 
depression in heart rate variation (Borgdorff 1975). For this reason patients were asked to 
breathe deeply for eight breaths only.
Autonom ic Function Tests procedures
A standard battery of cardiac autonomic function tests was used, with age related reference 
ranges (O'Brien, O'Hare et al. 1986). These tests consisted of:
i) Resting heart rate
Basal heart rate was obtained from the mean of three consecutive R-R intervals obtained 
from a 12 -  lead ECG recorded after the patient had rested supine for five minutes (Burdick 
Eclipse LE Electrocardiograph, Burdick Inc., Milton, Wisconsin USA). A value of 100bpm or 
higher was taken as abnormal.
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ii) Heart rate response to the valsalva manoeuvre
A forced expiration against a closed glottis was performed. At the onset of straining 
arterial pressure rises due to an increased intrathoracic pressure. Since high intrathoraclc 
pressure results in venous compression, there is a decrease in venous return and hence 
cardiac output. A resulting fall in arterial pressure inhibits baroceptor firing, leading to a reflex 
tachycardia and a rise in peripheral resistance. When the glottis is opened, on relaxation, 
intrathoracic pressure normalises and cardiac output is restored. However, residual 
peripheral vasoconstriction produces a blood pressure ‘overshoot’. Arterial baroceptor 
stimulation then leads to a fall in heart rate and blood pressure returns to basal levels.
Participants were asked to exhale into a tube connected to a mercury 
sphygmomanometer and maintain a pressure of 40mmHg for 15 seconds. On relaxation 
ECG recording continued for a further 45 seconds. The valsalva ratio was calculated as the 
ratio of the highest heart rate achieved during the manoeuvre to the lowest heart rate during 
the relaxation period (i.e. the ratio of the longest R-R interval after the manoeuvre to the 
shortest R-R interval during it) (Ewing and Clarke 1982).
iii) Heart rate response to deep breathing
The rhythmic fluctuations in heart rate in response to inspiration (rise) and expiration (fall) 
can be expressed as the E:l ratio (ratio of R-R interval during maximal expiration to R-R 
interval during maximal inspiration). Patients were asked to take slow deep breaths at a rate 
of six cycles/min. Results were expressed as the ratio of the peak inspiratory heart rate to 
the lowest expiratory heart rate during a single cycle (O'Brien, O'Hare et al. 1986).
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iv) Systolic blood pressure response to standing
Blood pressure was measured using a mercury sphygmomanometer 60 seconds after 
standing. A defect in this reflex arc is conventionally defined as a fall in systolic blood 
pressure of at least 30mmHg (Ewing and Clarke 1982), age-related adjustment is generally 
regarded as unnecessary (Ziegler, Laux et al. 1992).
v) Lying -  standing heart rate response (30:15 ratio)
This index is based on the physiological mechanisms discussed above. The peak heart rate 
(due to sympathetic activation) occurs at approximately the 15th beat after standing; as 
vasoconstriction occurs and blood pressure rises towards baseline, heart rate falls, reaching 
a nadir at approximately the 30th beat (Ewing and Clarke 1982).
The maximum/minimum R-R (30:15) ratio is calculated as the ratio of the longest R-R 
interval on standing (usually around the 30th beat) to the shortest R-R interval after the 
change from the recumbent position (usually at about the 15th beat) (Ewing and Clarke 
1982). It has been shown that the shortest R-R interval can occur between beats 6-24 and 
the longest R-R interval between beats 20-40 (Ziegler, Laux et al. 1992). Therefore, in these 
studies the max/min R-R ratio is defined as the longest R-R interval during beats 20-40 
divided by the shortest R-R interval during beats 5-25.
For tests (ii) to (iv) heart rate was measured using a three lead surface ECG monitor 
connected to an ATARI 360S microprocessor (Royal Hallamshire Hospital) on an IBM 286 
personal computer. Both were equipped with analogue to digital signal converters and QRS 
algorithm recognition software sampling at 600Hz.
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Q uantitative Sensory Testing Procedures
Quantitative sensory thresholds were assessed using the Computer Assisted Sensory 
Evaluation IV (CASE IV, Minnesota, USA, Figure A7.3). Figure A7.3 represents the 
apparatus through which a standard predicted vibratory stimulus could be applied by the 
computer to the part of the body being studied. The CASE IV system was also used to 
measure Cooling Detection (CDT) and Heat-Pain Detection Thresholds, by securing a 
porcelain block device, though, which predetermined temperature stimuli were applied, to 
the foot (Figure A7.3). This method eliminated the touch pressure artefact.
In my studies, quatitative sensory thresholds were only assessed in the lower limb. 
Values were expressed as percentiles, where >99m was considered to be abnormal. The 
CASE IV system uses 25 stimulation levels for patient testing. These 25 levels are termed 
‘just noticeable differences’ or ‘JNDs. Differences of less than one JND are difficult to 
distinguish, so that one JND step is the smallest difference that is presented to patients. The 
JNDs allow the minimum number of stimulus trials to be used. The test is started at a 
baseline level: for vibration stimuli, the baseline is 0 micrometers of displacement; for cooling 
stimuli, the baseline is set to 30°C; for heat-pain the baseline is set to 34°C. The thermal 
stimulator uses a 4-degrees-per second ramp up and down. For warming stimuli, the 
maximum temperature is limited to 50°C. For cooling stimuli, the minimum temperature is 
8°C. With the CASE IV system, a statistically validated set of age adjusted normative data is 
provided.
One time period with 4,2,1 stepping is an algorithm for quick assessment of vibration 
and cooling detection thresholds. This is also the most used in practise (Figure A7.3). The 
testing is begun at a middle JND level (Dyck, O'Brien et al. 1993). The system increases 
the next stimuli level if the patient cannot feel the stimulus. As the test progresses, the 
number of steps that the stimulus level increases or decreases changes, beginning with a 
JND value of 4, decreasing to 2, and finally to a step value of 1, until the threshold is defined.
202
During the test, a number of null stimuli are placed randomly among the others to prevent 
false results.
Several factors affect the length of testing: the time required to explain the test to the 
patient, the speed in which the patient makes decisions, the alertness of the patient and the 
number of stimuli needed to find the threshold. For thermal testing the time also depends on 
the level of sensitivity because larger stimulus magnitudes (longer times) are needed for 
insensitive patients. For one time period testing with 4, 2, 1 stepping, vibration and cooling 
tests take approximately ten minutes each. Heat pain Non-Repeating Ascending with Null 
stimuli only requires five minutes but should not be repeated on the same day is the patient 
fails to recognise any of the null stimuli.
Figure A7.3: The CASE IV
Nerve C onduction Study Procedures
Nerve conduction studies (NCS) have long been the mainstay of measurement of DPN in 
clinical trials. NCS correlate well with the morphological changes seen in nerve biopsies 
(Veves, Malik et al. 1991) and with clinical testing and examination (Redmond, McKenna et 
al. 1992; Feki and Lefaucheur 2001). Conventional NCS, have a specificity of 58% and a 
sensitivity of 93% for the detection of DPN; with a specificity of 91% and a sensitivity of 81% 
for clinical worsening of DPN. This test is, therefore, ideally suited to clinical trials. However
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NCS measure sensory and motor nerve function transmitted by impulses from large 
(myelinated) fibres that make up only 25% of the total nerve fibre population. 
Electrophysiological tests are therefore not sensitive to small fibre damage (Dyck, Litchy et 
al. 2003). Thus despite their reliability and high reproducibility, NCS cannot be used as the 
sole tests in the investigation of DPN (Valk, Grootenhuis et al. 2000).
In NCS, peripheral nerve conduction velocity (NCV), summated amplitude, 
conduction latency and motor nerve F-Wave latency are the parameters that are most 
commonly assessed. The median and ulnar (sensory and motor) nerves in the upper limb, 
are commonly tested. A reduction in peripheral nerve summated amplitudes is a measure of 
nerve fibre loss, whilst decreased latency and NCV are measures of the degree of nerve 
fibre demyelination. Reproducibility is poor for amplitudes but is satisfactory for all other 
parameters, and is particularly good for NCV measurement. For most of the parameters, 
total variance is mainly related to inter-examiner variability (Chaudhry, Corse et al. 1994). In 
trials involving several operators, sites of recording electrode placement must be strictly 
defined and the same standardised methodology strictly adhered to, to avoid inter-examiner 
variability in data collection. Table A7.2 highlights expected reasons for differences in NCS 
results.
Table A7.2: Factors a ffecting  nerve conduction  m easurem ents
Factors attributable to the patient
Age, Height, Body mass index, Gender, The degree of DPN 
Physiological factors
Skin temperature, hyperglycaemia
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Operator dependant factors
Placement of recording and stimulating electrodes, Distance measurements 
Failure to achieve supramaximal stimulation, Placement of cursors on the screen
The investigator (DS) performed all the nerve conduction studies attended formal and 
informal training sessions. Informal training sessions was a three week attachment with a 
clinical consultant neurophysiologist (Dr Jarrett) at the Royal Hallamshire hospital. A formal 
training session for technicians conducting a phase 2 clinical trial organised by Lily Research 
Laboratories was attended. Competency was established prior to assessing study patients 
by performing repeat nerve conduction measurements on 20 normal controls (medical 
students and willing members of staff) on two separate occasions to ensure reproducibility of 
methods precision of results and minimise intra examiner variability had been achieved.
Nerve conduction equipment
N e rv e  c o n d u c t io n  m a c h in e : Medelec, Synergy Oxford Instruments, Oxford, UK
R e c o rd in g  e le c tro d e s : Standard commercially available electrodes was used for all nerve 
conductions studies.
G ro u n d  e le c tro d e s : Standard commercially available lead plate electrodes was used for this 
study.
S t im u la t in g  e le c tro d e s : Standard surface stimulating electrodes was used for this study.
T e m p e ra tu re  c o n tro l: A warming bath was used to raise limb temperature, which was 
maintained with a radiant heat lamp.
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Temperature m easurem ent
The temperature was measured continually during the nerve conduction study. The 
temperature at the time of collection of each waveform was automatically be entered into 
nerve conduction table. For the lower limb temperature measurements the thermistor was 
placed on the dorsum of the foot 2.0cm proximal to the first web space. The temperature of 
the lower limb was maintained to at least 31 + 1°C during the entire nerve conduction study. 
If the temperature fell below the required temperature before the beginning of the study, the 
limb was rewarmed in a warming bath. Room temperature of 24 + 2oC.
Skin preparation
Skin preparation was performed before starting nerve conduction studies to minimise shock 
artefact, improve the quality of the study, and reduce the time taken to complete the study. 
Skin preparation procedure included cleaning the skin with alcohol and then abrading the 
skin with a mild dry abrasive material.
Ground electrode
The ground electrode will be placed between the active recording electrode and the 
stimulating electrode.
Nerve stim ulation technique
All nerves were stimulated with an electrical stimulator. A constant current stimulator was 
used. The strength of the stimulus was increased in steps until a maximum response was 
obtained. When maximum response was obtained the stimulator was increased by 5-10% 
more to make sure the response was supramaximal. Sensory responses were averaged at 
least three times but no more that ten times. Motor responses were not averaged.
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Measurements
All distances were measured to the nearest 1.0mm. Extreme care was taken to use the 
same distance for each subsequent test.
Waveform measurement
All waveform measurements were made at the sweep speed and display sensitivity at which 
the waveform was acquired.
Amplitude measurement
The motor amplitude was measured from the baseline to the negative peak. The amplitude 
was reported to the nearest 0.1 mV. The amplitude of the sensory action potential was 
measured from the baseline to the negative peak. When there was a positivity preceding the 
negative component of the potential, the amplitude was measured from the base of the 
positive peak to the top of the negative peak. Sensory action potential was reported to the 
nearest whole number.
Latency measurement
The only latency measured for motor nerve conduction studies was the onset latency. The 
onset latency was measured at the take off of the negative component of the M-wave from 
the baseline. The latency was measured at the display sensitivity at which the waveform was 
acquired. Onset and peak latencies were measured for the sensory potentials. The onset 
latency was measured from the take off of the negative component of the sensory action 
potential from the baseline. If a positivity precedes the negative component the onset latency 
will be measured from the base of the positivity. The peak latency was measured at the peak 
of the negative component of the action potential.
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Velocity measurement
The nerve conduction velocities were calculated using onset latencies. The distance used for 
calculation of conduction velocities were from ‘long segment’ distances. A long segment 
distance is the distance between the site of stimulation and the most distal stimulation site.
The composite score of NIS(LL) + 7 tests will be used to evaluate the severity and monitor 
neuropathic impairment in this study.
Sural Nerve Sensory Nerve Conduction Study
Anatomy
The sural nerve contributes to the sensory innervation of the leg and foot. This nerve, 
formed by the junction of the medial sural cutaneous with the peroneal anastomotic branch, 
passes downward near the lateral margin of the tendocalcaneus, lying close to the small 
saphenous vein, to the interval between the lateral malleolus and the calcaneus. The sural 
nerve runs forward below the lateral malleolus, and is continued as the lateral dorsal 
cutaneous nerve along the lateral side of the foot and little toe, supplying this potion of the 
foot with somatic sensation (Gray and Standring 2005).
The right sural nerve was examined first. If no response is obtainable then the left sural 
nerve will be evaluated.
Recording electrode
Disposable xbar electrodes were used
Active electrode: The active electrode was placed immediately behind the lateral malleolus. 
The electrode was placed over the sural nerve on a line that goes from the triceps sural 
tendon to the prominence of the lateral malleolus perpendicular to the sural nerve.
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Reference Electrode: The reference electrode wass placed 4.0cm distal to the active 
electrode, distal to the lateral malleolus along the course of the nerve.
Stimulating electrode
Bipolar, surface stimulating electrode
The sural nerve was stimulated 14.0cm from the active recording electrode. The nerve is 
located about 3.0cm lateral to the posterior midline.
Filter settings
30Hz LLF, 3.0 kHz HLF
Sweep speed
The sweep speed was set at 1.0ms/division. It was occasionally necessary to use longer 
sweep speeds to ensure that the entire waveform is recorded.
Amplifier gain
The amplifier gain/display sensitivity was set at 10 uV/division. It was occasionally 
necessary to use a different sensitivity to ensure that the response is a minimum of two 
divisions.
Procedure
The nerve was stimulated at a point 14.0cm proximal to the active recording electrode
When a supramaximal response was obtained, an average at least three but not more then 
ten responses was performed
Responses were marked with the cursors. If the instrument automatically marked the 
responses, I made sure they are marked correctly and changed the cursors if necessary
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The distance between the active electrode and the site of the cathode stimulating electrode 
were measured and recorded
The skin temperature was recorded before and after nerve conduction was completed
Peroneal M otor Nerve conduction Study
Anatomy
The deep peroneal nerve begins at the bifurcation of the common peroneal nerve, between 
the fibula and upper part of the peroneus longus, passes obliquely forward beneath the 
extensor digitorum longus and comes into relation with the anterior tibial artery above the 
middle of the leg; it then descends with the artery to the front of the ankle joint, where it 
divides into a lateral and a medial terminal branch. It lies at first on the lateral side of the 
anterior tibial artery, then in front of it and again on its lateral side at the ankle joint. In the 
leg, the deep peroneal nerve supplies muscular branches to the tibialis anterior (ankle 
dorsiflexion), extensor digitorum longus (2nd and 5th toe extension), peroneus tertius and 
extensor hallucis propius (big toe extension), and an articular branch to the ankle joint. The 
lateral terminal branch supplies the extensor digitorum brevis (2nd and 5th toe extension) and 
the tarsal joints, as well as the metatarsophalangeal joints of the second, third and fourth 
toes. The medical terminal branch divides into two sensory nerves that supply the adjacent 
sides of the great and second toes with sensation (Gray and Standring 2005).
Recording electrode
Disposable xbar electrodes were used
Active electrode: The active electrode was placed over the centre of the palpable portion of 
the extensor digitorum brevis muscle on the lateral aspect of the dorsum of the foot, 1.0cm 
distal to the calcaneous bone (bony prominence from which the muscle takes its origin)
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Reference electrode: The reference electrode was placed over the fifth metatarsal- 
phalangeal joint on the lateral portion of the foot. It was placed lateral to the long extensor 
tendons of the small toe.
Stimulating electrode
Bipolar surface stimulating electrode
Distal stimulation site (ankle)
The cathode was placed on the anterior aspect of the ankle 2-5cm lateral to the tendon of 
the tibialis anterior muscle, approximately 5.0cm proximal to the lateral malleolus, and 8.5cm 
from the active electrode.
Proximal stimulation site (fibular head)
The cathode was placed over the nerve where it runs immediately below the fibula and 
enters the anterior compartment
Proximal stimulation site (knee)
The cathode was placed over the nerve in the popliteal fossa approximately 10.0cm proximal 
to the head of the fibula. The cathode was placed just medial to the tendon of the long head 
of the biceps femoris muscle.
Filter settings
2.0Hz LLF, 10.0 kHz HLF
Sweep speed
The sweep speed was set at 2.0ms/division. Occasionally it was necessary to use other 
sweep speeds (e.g. to 5.0 ms/division) to ensure that the entire waveform is recorded.
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Amplifier gain
The amplifier gain/display sensitivity was set at 2.0mV/division. It was occasionally 
necessary to use a different sensitivity to ensure that the response is a minimum of two 
divisions.
Procedure
The nerve was stimulated at the ankle, fibula head and the knee.
When a supramaximal response was obtained, the response was recorded.
Responses were marked with cursors. If the instrument automatically marked the responses,
I made sure they were marked correctly and changed the cursors if necessary
The appropriate distances were measured and recorded. The distance between the active 
recording electrode and the cathode of the stimulator was measured. The distance between 
the active electrode at the ankle and the site of the stimulating cathode electrode was 
measured. The distance between the ankle and fibula head was also measured. The 
distance between the ankle and the knee was measured.
The temperature was recorded before and after the nerve conduction is completed
Tibial m otor nerve conduction study
Anatomy
The tibial nerve is the larger of the two divisions that form the sciatic nerve. It originates 
from L4 through S3 roots and travels as part of the sciatic through the posterior thigh under 
the long head of the bicep femoris. By the popliteal fossa, it has separated from the sciatic 
nerve.
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It supplies the motor innervation of the posterior compartment of the leg and all foot muscles 
(except the extensor digitorum brevis). Its motor distribution in the leg includes the 
gastrocnemius, plantaris, soleus, popliteus, tibialis posterior, flexor digitorum langus and 
flexor hallucis longus.
The nerve is superficial as it passes vertically down the middle of the popliteal fossa. It lies 
lateral then crosses superficially to lie medial to the popliteal artery. As it leaves the fossa, it 
gives off the sural nerve supplying the posterior leg. Its course then becomes deep as it 
passes between the gastrocnemius and soleus muscles, under the tendinous arch formed 
by the soleus, lying on the posterior surface of the tibialis posterior muscle and then on the 
tibia. It again becomes superficial at the upper end of the medial malleolus where it passes 
behind it and in front of the calcaneous tendon. Its terminal course takes it under the flexor 
retinaculum (posterior tarsal tunnel). The medial calcaneous branches perforate the flexor 
retinaculum and supply the skin of the heel and medial side of the sole of the foot. Under 
the retinaculum the nerve divides into medial and lateral plantar branches and innervates the 
plantar aspect of the foot (Gray and Standring 2005).
Recording electrode
Disposable xbar electrodes were used
Active electrode: The active electrode was placed over the centre of the abductor hallucis 
muscle 1.0cm below and 1.0cm behind the prominence of the navicular bone
Reference electrode: The reference electrode was placed over the first metatarsal- 
phalangeal joint on the medial surface of the big toe
Stimulating electrode
Bipolar surface stimulating electrode
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Distal stimulation site (ankle)
The cathode was placed on the tibial nerve on the medial aspect of the ankle 8.0cm proximal 
to the active recording electrode.
Proximal stimulation site (fibular head)
The cathode was placed over the nerve in the middle of the popliteal fossa.
Filter settings
3.0Hz LLF, 10.0 kHz HLF
Sweep speed
The sweep speed was set at 2.0ms/division. It was occasionally necessary to use other 
sweep speeds (e.g. to 5.0 ms/division) to ensure that the entire waveform was recorded.
Amplifier gain
The amplifier gain/display sensitivity was set at 5.0mV/division. It was occasionally 
necessary to use a different sensitivity to ensure that the response was a minimum of two 
divisions high.
Procedure
The nerve was stimulated at the ankle then at the knee.
When a supramaximal response was obtained, response was recorded.
Responses were marked with cursors. If the instrument automatically marked the 
responses, I made sure they were marked correctly and changed the cursors if necessary
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The appropriate distances were measured and recorded. The distance between the active 
recording electrode at the ankle and the site of the stimulating electrode were measured. 
The distance between the ankle and the knee were also measured
The temperature was recorded before and after the nerve conduction was completed
Measurement o f DPN
The neuropathy staging tool used in these studies was defined by P.J.Dyck and developed 
from the Rochester Diabetic Neuropathy Study (RDNS) (Dyck, Karnes et al. 1992). It takes 
into account results obtained from five neuropathy measures to calculate a composite score 
used detect and measure severity of neuropathy. The Neuropathy Impairment Score for the 
Lower Limbs plus Seven Tests or NIS(LL)+7 is considered by many to be the gold standard 
for the detection of DPN and change of DPN (following intervention) in clinical trials (Table 
A7.3, (Dyck and Thomas 1999). It includes measures of muscle weakness, reflex loss, 
sensory loss and nerve conduction abnormalities in the lower limbs, plus autonomic heart 
rate abnormalities during deep breathing.
Calculating the NIS(LL) + 7 tests score:
Sum of individual scores of the NIS for the lower limbs, NIS(LL). Items 17-24,28-29 and 34- 
37.
In NIS (LL), substitute transformed points for percentile abnormality * of VDT for each great 
toe (obtained with CASE IV) for the clinical vibration sensation point score of the great toes.
Add transformed points for percentile abnormality * of HB DB (one time only).
Summate transformed points for percentile abnormality * of the five attributes of nerve 
conduction of lower limb (peroneal nerve (CMAP, MNCV and MNDL), tibial nerve (MNDL) 
and sural nerve (SNAP), divided by the number of attributes with obtainable values **, 
Multiply by 5 (the number of attributes), and add this number to the global score.
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* < 95th = 0; >95th -  99th =1 ; >99th -  99.9th = 2; ^99.9,h = 3 
** MNCV and MNDL cannot be estimated when CMAP is 0
This composite score was found to be both highly sensitive and specific for the detection of 
DPN, as well as, for neurological progression. Based on this composite score, patients were 
divided into three groups based on the severity of neuropathy (Table A7.3):
No DPN -  NO
Subclinical DPN -  N1a and N1b
Established (Painless DPN) -  N2 and N3 with negative symptoms
Established (Painful DPN) -  N2 and N3 with symptoms of painful DPN for at least six 
months
216
Table A7.3: Dyck’s staging of Diabetic Peripheral Neuropathy (Dyck 1988)
NO
No polyneuropathy. Less than N1a 
N1
N1a: Asymptomatic polyneuropathy as recognised by nerve conduction abnormality 
in at least two nerves or heartbeat deep breathing abnormality, caused by DPN.
N1b: N1a criteria plus neurologic examination abnormality or abnormality on 
quantitative sensory testing of vibration detection threshold or cooling detection 
threshold.
N2
N2a: Symptomatic mild DPN. Sensory autonomic or motor symptoms caused by 
DPN. Neuropathic impairment is the same or more than N1a. Patients has less than 
50% weakness of ankle dorsiflexor muscles (able to walk on heels)
N2b: Symptomatic severe DPN. Neuropathic impairment is the same or more than 
N1a. Patient has 50% or greater weakness of ankle dorsiflexor muscles (unable to 
walk on heels).
N3
Disabling DPN
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9 RESEARCH OUTPUT
At the time of writing, the following publications/presentations have resulted from data 
accumulated during the course of this work.
1. Peer reviewed first author papers
- Selvarajah D, Wilkinson ID, Emery CJ, Harris ND, Shaw PJ, Witte DR, Griffiths PD,
Tesfaye S. Early involvement of the spinal cord in diabetic peripheral neuropathy. Diabetes 
Care. 2006 Dec;29(12):2664-9.*
- Selvarajah D, Wilkinson ID, Emery CJ, Griffiths PD, Gandhi R, Tesfaye S. Thalamic 
neuronal involvement In type 1 diabetes mellitus. Diabetologia 51(11): 2088-92.
- Selvarajah D, Tesfaye S. Central nervous system involvement in diabetes mellitus. Curr 
Diab Rep. 2006;6:431-8.
2. Peer review papers in preparation
-Selvarajah D et al A Randomised Controlled Double Blind Controlled Trial of Cannabis 
Based Medicinal Product (Sativex) in Painful Diabetic Neuropathy: Is Depression a Major 
Confounding Factor?
3. Books Chapters
-Selvarajah D, Tesfaye S. Diabetic Peripheral Neuropathy. Diabetes in the Arab World. Ed. 
G Gill.
- Selvarajah D, Wilkinson ID, Gandhi R, Tesfaye S. Central Nervous System Involvement in 
Diabetic Neuropathy.
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4. Selected firs t author oral and poster presentations
-Selvarajah D, Gandhi R, Griffiths PD, Emery CJ, Wilkinson ID, Tesfaye S. Thalamic 
Sensory Neuronal Involvement in Diabetic Neuropathy. American Diabetes Association 67th 
Scientific Sessions 2007, Diabetes UK APC 2006, ISMRM 2004 (Poster) and University of 
Sheffield Research Open Day 2007 (Prize for best research poster).
-Selvarajah D, Wilkinson ID, Emery CJ, Harris ND, Shaw PJ, Witte DR, Griffiths PD, 
Tesfaye S. Early Involvement of the Spinal Cord in Diabetic Peripheral Neuropathy. 
International Diabetes Federation 18th World Diabetes Congress, Paris 2003 (Kuusisto, 
Mykkanen et al.), Diabetes UK Annual Professional Conference 2003 (Kuusisto, Mykkanen 
et al.), American Society of Neuroradiologists 2004 (Oral).
-Selvarajah D, Gandhi R, Emery CJ, Bowler H, Tesfaye S. Depression is a major 
confounder in clinical trials of painful diabetes neuropathy. 43rd Annual Meeting of the 
European Association for the Study of Diabetes 2007 (Poster).
-Selvarajah D, Wilkinson ID, Emery CJ, Gandhi R, Griffiths PD, Tesfaye S. Unique thalamic 
perfusion abnormalities in painful but not painless diabetic neuropathy. Diabetes UK Annual 
Professional Conference 2009. (Eli Lily Poster Award -  Clinical Science).
-Selvarajah D. Diabetic Neuropathy. Diabetes UK Local Patient Support Group, Barnsley 
2002 (Invited lecture).
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